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The modification of proteins by reducing sugars is a process that occurs naturally
in the body. This process, which is known as glycation, has been linked to many of the
chronic complications encountered during diabetes. Glycation has also been linked to
changes in the binding of human serum albumin (HSA) to several drugs and small solutes
in the body. While these effects are known, there is little information that explains why
these changes in binding occur. The goal of this project was to obtain qualitative and
quantitative information about glycation that occurs on HSA.
The first section of this dissertation examined methods that could be used to
quantify and identify glycation that occurs on HSA. The extent of glycation that occurred
on HSA was quantified using

18

O-labeling mass spectrometry and the glycation sites

were identified by observing the mass-to-charge (m/z) shifts that occurred in glycated
HSA. This initial investigation revealed that

18

O-labeling based quantitation can be

improved over previous methods if a relative comparison is done with

18

O-labeled

peptides in a control HSA sample. Similarly, the process of making m/z shift-based

assignments could be improved if only the peptides that were unique to the glycated HSA
samples were used with internal calibration.
These techniques were used in subsequent chapters for the assignment of early
and late-stage glycation products on HSA. The regions on HSA that contained the highest
amount of modification were identified, quantified, and ranked in order of their relative
abundance. Of the commonly reported glycation sites, the N-terminus was found to have
the highest extent of modification, followed by lysines 525, 199, and 439. The relative
amount of modification on lysine 281, with respect to the aforementioned residues, varied
with different degrees of glycation. The

18

O approach used for this analysis was novel

because it allowed for the simultaneous quantification of all glycation-related
modifications that were occurring on HSA. As such, several arginine residues were also
found to have high amounts of modification on glycated HSA.
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CHAPTER 1

GENERAL INTRODUCTION

1.A. EFFECTS OF DIABETES AND PROTEIN GLYCATION

1.A.1. Classification and Effects of Diabetes in vivo. Diabetes is a disease state which
is characterized by abnormally high blood sugar concentrations. The American Diabetes
Association estimates that there are at least 24 million Americans that are currently living
with diabetes (1). Of these 24 million people, older populations (i.e., above 60 years of
age) and individuals of ethnic origin represent a large percent of the diabetic population.
In healthy individuals, the blood glucose concentration is tightly regulated by insulin (2).
After food ingestion, glucose is transported to the β-cells of the pancreas, initiating a
reaction cascade that causes insulin to be released into the bloodstream. Insulin is
subsequently able to interact with fat, liver, and muscle tissue to facilitate the storage of
blood glucose as glycogen and triacylglycerides for later use. The high blood sugar
concentration that is found during diabetes is related to either insufficient insulin
production (i.e., type 1 diabetes) or resistance to insulin (i.e., type 2 diabetes) (3, 4).
This increased blood glucose concentration has a number of effects in the body,
which include an increased risk of heart disease (5), stroke (6), kidney disease (7),
blindness (8), and amputations (9). Many of these complications are due to protein
glycation and the formation of advanced glycation endproducts (AGEs) from blood
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sugars (10). AGE-related complications in the body can be classified into two different
areas. In one case, the interaction of AGEs with the receptor protein for AGEs (RAGE) is
responsible for a wide range of inflammatory responses which eventually lead to tissue
damage (11, 12). The second case involves direct modification of proteins by AGEs,
leading to a loss of protein function (13) or tissue damage that results from protein
crosslinking (14, 15).
1.A.2. Glycation and Advanced Glycation End Products. Glycation is a process that
involves the non-enzymatic addition of reducing sugars to proteins. This reaction was
first identified by Louis-Camille Maillard in 1911, who noticed a characteristic yellowing
that occurred when a solution containing glycine was incubated with D-glucose (16). It
was later determined that this characteristic coloring was due to complex reactions that
eventually led to the formation of two different classes of compounds, reductones (i.e.,
dehydrated forms of sugars that are condensed on proteins) and melanoidins

(i.e.,

nitrogen containing polymers initiated by late-stage glycation) (17). This process, which
is now known as the Maillard reaction, was further organized into different stages by
John E. Hodge in 1953 (18). The initial stage of glycation (i.e., early-stage glycation)
involves the addition of reducing sugars to free primary amine groups that are present on
a protein (see Figure 1.1) (19, 20). The predominant amino acids involved in glycation
are therefore lysine residues and the N-terminus of a given protein. This initial step of
this reaction results in the formation of a Schiff base. This reaction occurs fairly rapidly
with the open chain form of a reducing sugar, where the equilibrium that is established
favors the formation of a Schiff base under physiological conditions (21). The Schiff
base, however, is unstable and subsequently rearranges over the course of about two
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Figure 1.1

Diagram showing the initial steps of glycation. Reducing sugars
condense on the primary amine groups (i.e., as present on lysine or
the N-terminus) of proteins. This results in the formation of a Schiff
base, which subsequently rearranges to form the more stable
Amadori product. The α-oxaloaldehydes that result from prolonged
glucose incubation are also shown.
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5
days to form a more stable class of compounds known as Amadori products (17, 22, 23).
While early glycation reactions in its own right is able to modify the function of
many proteins, a more complex scenario unfolds when a protein is incubated with
reducing sugars over extensive periods of time. This represents the intermediate-stage of
the Maillard reaction, which is characterized by the formation of reactive dicarbonyl
compounds (i.e., α-oxaloaldehydes) from either free sugars in solution (24-26). The rate
of formation of these compounds varies with reaction conditions such as the temperature,
pH, and the presence of buffers in the solution (10). While several α-oxaloaldehydes are
involved in protein damage, the most significant and commonly cited compounds that
result in protein damage in vivo are glyoxal, methylglyoxal, and 3-deoxyglucosone (see
Figure 1.1) (27, 27, 28). Previous studies which looked at the formation of αoxaloaldehydes during incubations of free glucose (Note: no proteins were added) over a
three week period showed that the glyoxal was present at the highest concentrations,
followed by 3-deoxyglucosone and methylglyoxal (10). These compounds are highly
reactive and are able to bind with lysine, arginine, or the N-terminal regions of proteins,
forming AGEs.
The study of AGEs is important because the loss of protein function and tissue
damage that can occur in vivo is directly related to the formation of AGEs. This effect is
fairly well studied for long lived proteins such as collagen (29-32) and lens crystallin (8,
14, 15), as well as some short lived proteins such as hemoglobin (33-35). However, there
is little information that is available for the major serum transport protein, human serum
albumin (HSA) (21). The research presented in this dissertation focuses on products that
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result from the interaction of HSA with these reactive dicarbonyl compounds and Dglucose.
1.A.3. Early and Late-Stage Glycation of HSA. HSA is the most abundant protein in
human serum, with concentrations that range anywhere from 30 – 50 g/L, representing
approximately 50% of the total serum protein concentration (36, 37). As such, HSA
exhibits large effects on a number of physiological processes, including the regulation of
oncotic pressure (38) and blood pH (39), as well as the transport of fatty acids (40), drugs
(41), and small solutes (42) in the body. HSA has 585 amino acids (43), which includes
59 lysines and 24 arginines that could potentially be modified to form glycation products.
A crystal structure of HSA that shows the major drug binding sites on HSA is given in
Figure 1.2. From this crystal structure, it can be seen that HSA has high helical content
(43). There are also a number of drug interaction sites located in subdomains IIA
(Sudlow site 1) and IIIA (Sudlow site 2) (44).
There are several reports suggesting that the glycation of HSA that occurs during
diabetes may affect its drug-binding properties in vivo (41, 42, 45, 46). Additionally, the
clearance of albumin from serum has been shown to be accelerated by approximately 2
fold in diabetes (47), which is thought to be due to interaction with RAGE receptors in
the liver and kidney. While these effects are known to occur, the specific regions of HSA
which are being modified by early or late-stage glycation products, which leads to these
effects, have not yet been fully elucidated.
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Figure 1.2

Crystal structure of HSA (48) that was developed using visual
molecular dynamics (49). The majority of the structure of HSA
(approximately 67%) is helical. Subdomains containing Sudlow sites
1 and 2, are shown in red and the amino acids that play a significant
role in drug interactions at these sites are given in blue. The three
main domains of HSA are also shown.
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1.B. APPROACHES FOR THE ANALYSIS OF GLYCATED HSA
1.B.1. Prior Attempts at Determining HSA Glycation. Past studies of HSA glycation
have involved total glycation analysis using spectroscopic techniques (50, 51) or the
measurement of specific-glycation induced properties such as fluorescence (30) and
interaction with affinity supports (52-54). The information obtained using these methods,
however, provided no structural information. Studies using isotopically-labeled reducing
sugars have also been used to quantify glycation sites and identify the location of these
glycation sites (55, 56). These methods, however, have not given information about
AGE-formation that occurs on HSA.
In an attempt to clarify the regions on HSA that are being modified during
glycation, mass spectrometry offers the potential advantage of providing both structural
and quantitative information. Mass spectrometry has an additional advantage, of being
capable of global identification and quantification of modifications, when 18O-labeling is
employed (57). The majority of reports describing the identification of modification sites
on HSA have used peptide mapping for glycation product identification (19, 58-61). In
peptide mapping, a protein is digested followed by mass spectrometry analysis, where
shifts in the mass-to-charge (m/z) ratio can be matched to glycated peptides (see Figure
1.3). Typically, complex modification pattern can occur on HSA as a result of to
glycation (see Table 1.1). This complexity, combined with the possibility that multiple
lysine or arginine residues are present within a given peptide, often makes it difficult to
pinpoint the exact location of modified residues on HSA.

10

Figure 1.3. Diagram showing the procedure that was used in this dissertation to identify
glycation-related modification sites on HSA. HSA was first digested and the
glycation sites were assigned based on the detected m/z shifts. The m/z shift
depended on the mass of the glycation product and the number of glycation
products that were present on any given peptide.

Step 1: Digestion of glycated HSA containing a mixture
of modified and non-modified protein.

Step 2: Mass spectra are obtained, where the glycation
sites are identified based on m/z shifts.
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Table 1.1. Glycation products involving lysine and arginine residues
Glycation adducts involving lysine

Abbreviation

∆M (Da)

Fructosyl-lysine

FL

162.0528

Fructosyl-lysine-1H2O

FL-1H2O

144.0423

Fructosyl-lysine-2H2O

FL-2H2O

126.0317

Nε-Carboxyethyl-lysine

CEL

72.0211

Nε-Carboxymethyl-lysine

CML

58.0055

Pyrraline

Pyr

108.0211

Glycation adducts involving arginine

Abbreviation

∆M (Da)

Nε-[5-(2,3,4-Trihydroxybutyl)-5-hydro-4-imidazolon-2-yl]ornithine

3-DG-H1

144.0423

Tetrahydropyrimidine

THP

144.0423

Imidazolone B

IB

142.0266

Argpyrimidine

ArgP

80.0262

Nε-(5-Hydro-5-methyl-4-imidazolon-2-yl)ornithine

MG-H1

54.0106

Nε-(5-Hydro-4-imidazolon-2-yl)ornithine

G-H1

39.9949

Glycation adducts involving lysine or arginine

Abbreviation

∆M (Da)

1-Alkyl-2-formyl-3,4-glycosyl-pyrrole

AFGP

270.0740
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In recent publications, some authors have tried to circumvent this issue by using
tandem mass spectrometry and collision-induced dissociation (CID). While this method
can provide useful information, a limitation of this method is that the Amadori Product
cannot be detected because water loss on the condensed sugar is favored over the
cleavage of amide bonds during CID (19, 62). A common method for assigning the most
likely regions of glycation, using mass spectrometry is to use known information about
peptide chemistry such as the pKa, fractional accessible surface area (FAS) (63, 64), and
the location of certain residues that enhance glycation (56), to identify the most likely
regions where modification could occur. The research presented in this dissertation uses
this information as well as quantitative

18

O-labeling data to identify which residues on

HSA are most prone to glycation related modifications.
1.B.2. Analysis of Glycated HSA using MALDI-TOF MS and 18O-Labeling. Matrixdesorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) was the
method used for obtaining the mass spectra that were used in this dissertation.

For

this analysis, a positive-ionization mode combined with delayed extraction and the use of
a reflector were employed to enhance the mass resolution and signal quality that was
obtained for a given spectra. The first step under this approach, involved the envelopment
of a mixture of peptides in an acidic matrix that absorbs ultraviolet (UV) energy. The
resulting sample was then crystallized on a MALDI plate. A pulsed UV laser was used to
irradiate the sample, where the energy absorbed was used to both vaporize the
protein/matrix mixture, and facilitate ionization of the peptides (65, 66). An acceleration
voltage was then applied to the ionized sample after a preset delay time, causing these
ions to drift to the detector at a velocity dependent on the mass of the peptide (67). The
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m/z of a peptide was then be determined from the time it took the peptide to reach the
detector. The advantages of using MALDI-TOF MS for this analysis were that spectral
interpretation was simple because of the low abundance of multiply charged species.
MALDI-TOF MS also uses a soft ionization technique (66). This technique was also
good for use with 18O-labeling, because interaction of 18O-labeled peptides with 16O was
reduced in comparison to techniques based on electrospray ionization (68).
The 18O-labeling approach that was used for quantifying modification sites in this
dissertation is shown in Figure 1.4. Under this scheme, HSA and glycated HSA were
digested in 16O and 18O-labeled water, respectively. These samples were then mixed in a
1:1 (v/v) ratio, and the

16

O/18O ratios were obtained. Under this scheme, peptides that

contained a large amount of glycation should exhibit large

16

O/18O ratios. In this

technique, all of the peptides that result from an enzymatic digest can be labeled using in
a single step (68, 69). This is an important feature for the quantification of modification
sites, because of the sheer number of samples that were examined in this report.
1.B.3. Topics Covered in this Dissertation.

The first section of this dissertation

examined methods that could be used for glycation site identification and quantification.
More specifically, Chapter 2 of this dissertation described the use of

18

O-labeling for

quantifying the relative extent of modification that occurred on specific regions of HSA.
The quantitative information obtained using this approach was compared to previous data
that was obtained for the same type of HSA (63). Chapter 3 examined techniques that
were used to improve the assignment of modification sites on HSA. This was done by
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Figure 1.4. General procedure for obtaining quantitative estimates of glycation
based on 18O-labeling MALDI-TOF MS. The non-modified peptides
from HSA are represented by a-c, while a*-c* represent modified
peptides from the same regions of glycated HSA.

HSA

Glycated HSA

Step 1: HSA is digested in
water and glycated HSA is
digested in18O-labeled water

a*

b

b*

c

c*

a

b

b*

Intensity

Step 2: The HSA and glycated
HSA digests are mixed in a 1:1
ratio; the 16O/18O ratios of the
detected peptides are
determined by mass
spectrometry

a

c

c*

a*

16

Mass (Da)
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performing HSA glycation in vitro and examining the effects of glycation-product
heterogeneity, mass accuracy, and the level of selectivity on the identification of glycated
peptides. In Chapters 4 and 5, the location and type of modifications that occurred on
glycated HSA were examined. Chapter 4 focused on the identification of early-stage
glycation products and Chapter 5 focused on the identification of AGEs in glycated HSA.
The HSA that was used in both cases was glycated in vitro. The glycation products
present at three stages of glycation were examined using the techniques that were
optimized in Chapter 3.
Chapter 6 of the dissertation examined the use of 18O-labeling mass spectrometry
for the quantification of glycation sites on HSA. Several improvements to the methods
described in Chapter 2 were used here, such as the use of control HSA to obtain a set of
reference 16O/18O ratios. These reference ratios were directly compared to ratios that were
obtained for the control and glycated HSA samples. Comparisons were made with the
data obtained using commercially glycated HSA. The quantitative results were used to
determine the most likely modification sites on glycated HSA from the data presented in
Chapters 4 and 5.
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CHAPTER 2
QUANTITATIVE ANALYSIS OF GLYCATION SITES ON
COMMERCIALLY GLYCATED HUMAN SERUM
ALBUMIN
2.A. INTRODUCTION
This chapter evaluates the use of 18O-labeling quantitative proteomics as a means
of quantifying modifications that occur on commercially glycated human serum albumin
(HSA). The glycation of HSA has been shown to affect its drug binding kinetics (1-3) as
well as its structure (4). These functional effects have not yet been fully characterized and
better information regarding the glycation pattern that occurs on HSA, the extent of
modification that occurs on various parts of HSA, and whether the modifications are
consistent in both in vitro and in vivo glycated HSA are needed to get a better
understanding of why these functional changes are occurring. Some information about
the glycation pattern that occurs on HSA has previously been obtained (5-8); however,
quantitative information about the degree of modification that occurs on different regions
of HSA is an area where little work has been done (9-11). Similar trends have been noted
in other proteins where qualitative data is available (12-14), however very little
quantitative information is available.
In this study, isotopic labeling and matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS) will be employed as tools for
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quantitative studies by comparing HSA and minimally glycated HSA that have been
digested in the presence of

16

O- or

18

O-enriched water (see general approach in Figure

1.4) (15-21). The resulting digests will be mixed in a fixed ratio, and the 16O/18O ratios
of peptides found in this mixed digest will be determined by using mass spectrometry
(17, 22). If a modification takes place in a given region of HSA due to glycation, an
increase in the mass of peptides from this region should occur resulting in a reduced
concentration of non-modified peptide in the glycated sample. This reduction in
concentration would cause the 16O/18O ratio to increase above the expected 16O/18O ratio
when no modification is present. In addition, the size of the 16O/18O ratio should make it
possible to compare the relative extent of glycation-related modifications on different
regions of HSA.
These experiments will be conducted by using these tools from quantitative
proteomics to examine minimally glycated HSA that has been prepared in vitro by Sigma
Aldrich (St Louis, MO). A similar type of HSA has been used previously to identify
possible modifications in glycated HSA (5). This previous research will be expanded
upon in this current study by using

16

O/18O-labeling and MALDI-TOF MS to rank the

degree of modification that is occurring at such sites in HSA.
The theory behind the determination of

16

O/18O ratios when using

16

O- and 18O-

labeling has been described previously (15, 23). Two different methods for calculating
16

O/18O ratios were used in this report. The first method employed mass spectra for a 18O

and 16O mixed digest along with the expected relative intensities for unmodified peptides,
as predicted by using MSIsotope (24). The

16

O/18O ratio for a peptide in this case was
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determined by using the following equation, which was derived from a set of equations
that are described in the published literature (23).
16
18

O
I0
=
O 
M  
M 
M M 
 I 2 − I0 2  +  I 4 − I0 4 −  I 2 − I0 2  2 
M 0  
M0 
M 0  M 0 


(1)

In this equation, the terms I0 through I5 represent the relative intensities for the M+0 to
M+5 peaks in an isotope cluster, where M0 through M5 represent the expected relative
intensities for a digest in which no isotopic label is present. The terms in the first
parentheses on the left side of the denominator represent the
peptide with one

18

18

O contribution for a

O label. The terms in the second parentheses represent the

contribution for a peptide with two

18

O labels. This approach for determining

16

18

O

O/18O

ratios will be referred to as “Method 1” throughout this chapter.
The second method employed an internal standard by using the mass spectra
obtained by digesting HSA in 16O-enriched water instead of using the theoretical digest.
For this method, the relative intensities of both the
estimate the contribution of

16

O or

16

O and

18

O digest were used to

18

O-labeled peptides to the corresponding mixed

peptides. This is method is previously described in the literature (15, 19). A summary of
the equation that was used to determine the 16O/18O ratio is shown below.
16

O
I'0
=
18
O (I"0 + I"2 ( c ) + I"4 ( c ) )

(2)

In this equation, I’0 represents the contribution of the 16O-labeled digest to the I0
peak in the mixed digest. Similarly, I”0, I”2(c), and I”4(c) represents the corrected

18

O-
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labeled digest contribution to the I0, I2, and I4 peaks respectively, in the mixed digest. The
advantage of using this method is that it allows corrections to be made for variations in
the actual extent of

18

O incorporation and the type of instrumentation being employed.

The disadvantage of this method is that peptides have to be detected in all three digests
for the

18

O/16O ratio to be determined. The use of this approach to determine

ratios will be referred to as “Method 2” in the remainder of this chapter.

16

O/18O
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2.B. EXPERIMENTAL
2.B.1. Materials.

The following chemicals were purchased for Sigma-Aldrich (St.

Louis, MO): Des-Arg-bradykinin (97% pure), glu-fibrinopeptide (97%), angiotensin I
(97%; acetate salt), HSA (99%, essentially fatty acid and globulin free), glycated HSA
(95%; lot number 013K9166, containing 8 mol hexose/mol HSA), sequencing grade
trypsin, sequencing grade Glu-C, sequencing grade Lys-C, guanidine HCl (99%), D/L
dithiothreitol (99%), iodoacetamide (99%), formic acid (96%), 2,5-dihydroxybenzoic
acid (98%), α-cyano-4-hydroxycinnamic acid (99%),

18

O-enriched water (97%),

16

O-

enriched water (99.99%), tris-HCl (99%) and ammonium bicarbonate (99%). All of the
chemicals that were used were reagent grade or better.
experiments (other than that utilized for

18

The water used for these

O-labeling) was obtained from a Nanopure

water system (Barnstead, Dubuque, IA, USA)
2.B.2. Apparatus. The following items were purchased from Thermo Fisher Scientific
(Rockford, IL): Slide-A-Lyzer dialysis cassettes (7000 Da MW cutoff, 0.1 – 0.5 mL
capacity) and a 0.5 – 10 µL digital pipette. Micro-C18 ZipTip pipette tips with 5.0 µg of
bed material were obtained from Millipore (Billerica, MA). Plastic sheets were used to
mix the sample and matrix mixing prior to MALDI-TOF MS. These sheets were
purchased from C-Line Products (Des Plaines, IL). Mass spectra were acquired on a
Voyager 6148 MALDI-TOF-MS system (Applied Biosystems, CA). The instrument
settings were as follows: positive-ion delayed extraction reflection mode; delay time, 100
ns; accelerating voltage, 20 kV; guide wire voltage, 0.008% of accelerating voltage; grid
voltage, 76% of accelerating voltage. The MSIsotope software was obtained from the
UCSF Protein Prospector webpage (24).
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2.B.3. Sample Pretreatment, Digestions & Peptide Fractionation. The HSA samples
were pretreated as described previously in work with immobilized HSA supports (15),
but with the following modifications being made for this study. A 5 mg/mL HSA
solution prepared in denaturing buffer was used as described in the previous study,
however, the solution volume was now reduced from 1 mL to 300 µL to reduce the
amount of HSA that was used. The ratio of HSA to dithiothreitol and iodoacetamide was
kept the same as in Ref. (15) while the solution volumes were adjusted accordingly to
compensate for the change in the volume of the HSA solution. Digestion was carried out
with normal HSA being placed into 16O-labeled water and glycated HSA being digested
in

18

O-labeled water. Zip-tip fractionation was performed as described previously by

using aqueous mixtures of 5, 10, 20, 30 and 50% acetonitrile for elution in a series of step
gradients (15).
2.B.4. Mass Spectrometry & Data Acquisition. The details regarding the preparation
of mass calibrants and matrix solutions are described elsewhere (15).

The mass

spectrometer was externally calibrated using a mixture containing des-Arg-bradykinin
(25 pmol/µL), glu-fibrinopeptide (32.5 pmol/µL), and angiotensin I (32.5 pmol/µL). A 4
µL portion of this solution was mixed with 96 µL of α-cyano-4-hydroxycinnamic acid
and 2,5-dihydroxybenzoic acid mixed matrix solution (i.e., giving a final concentration of
0.1–5 pmol/µL for the final calibration mixture), and the resulting mixture was spotted
adjacent to each sample well on a MALDI plate. A mass spectrum was obtained for the
calibration mixture using Voyager Control Panel software (Applied Biosystems, Foster
City, CA, USA) and the file was exported to the Data Explorer software (also from
Applied Biosystems). Using Data Explorer, the monoisotopic M+0 peaks for des-Arg-
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bradykinin, glu-fibrinopeptide, and angiotensin I were calibrated to masses of 904.4681
Da, 1570.6774 Da, and 1296.6853 Da, respectively. The calibration constants obtained
were then saved and imported to the Voyager software. The mass spectrum for the
sample was then obtained. The calibration process was repeated for every sample spot on
the MALDI plate. The mass accuracy obtained when this method was used was typically
<50 ppm.
2.B.5. Peak Selection Criteria and Data Sorting. The masses of the peptides detected
in the HSA or glycated HSA digests were compared to the masses predicted for a
theoretical digest by using PEPTIDEMASS software (25, 26). When generating the
theoretical digest, the following considerations were made: the maximum amount of
missed cleavages was 2; all cysteine residues were assumed to be treated with
iodoacetamide; variable oxidation of methionine residues was allowed; and only
monoisotopic masses were selected. All peptides that could be matched within 50 ppm
of the theoretical digest were selected for further analysis (22). For all digests, only
peptides having a signal-to-noise ratio >5 were used for further quantitative studies. In
the

18

O digests, the M+4 peak was used to determine the signal-to-noise ratio for the

resultant peptides, while the M+0 peak was used to determine the signal-to-noise ratio for
the

16

O digests. Information about the pKa and the fractional accessible surface area

(FAS) was used to predict the reactivity of a given amino acid residue in forming
glycation products; the methods used for calculating these pKa and FAS values have been
described previously in the literature (5, 27, 28).
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2.C. RESULTS
2.C.1. Sequence Coverage. The usable sequence coverage (i.e., the sequence coverage
representing the residues on HSA corresponding to calculated

16

O/18O ratios) for both

methods are summarized in Figure 2.1. Prior to looking at the relative extent of glycation
at various regions on HSA, the sequence coverage for this protein was examined under
the analysis conditions used in this study. When using only qualitative data and looking
for m/z values that could be linked to specific peptides, the coverage obtained for the
trypsin, Lys-C and Glu-C digests of HSA were found to be 83.6%, 61.0% and 54.0%
respectively. The total coverage obtained when all three digests were considered was
92.3%, which is close to a previously reported value of 97.4% under similar pretreatment
and analysis conditions for samples of soluble or immobilized HSA that were not
glycated (15).
When Method 1 was used to obtain 16O/18O ratios, the usable sequence coverage
in these quantitative studies was lowered to 51.5%, 53.9%, and 51.5% for the trypsin,
Lys-C, and Glu-C digests respectively, which gave a total usable sequence coverage for
HSA of 83.6% (see Figure 2.1). Similarly, when Method 2 was employed, the usable
sequence coverage was 33.5%, 21.9%, and 42.1% for the trypsin, Lys-C, and Glu-C
digests, respectively, which gave an overall usable sequence coverage of 66.3% for HSA.
This reduction in usable sequence coverage in going from the qualitative to quantitative
experiments was expected because several of the peptides that were detected in the
qualitative studies did not have a high enough intensity to be used in the quantitative
studies. This same type of reduction in sequence coverage has been observed in previous
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Figure 2.1. Primary sequence of HSA and sequence coverage for modified
residues obtained for Method 1 (bold) and Method 2 (underlined).
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1-

DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV

41-

KLVNEVTEFA KTCVADEsae NCDKSLHTLF GDKLCTVATL

81-

RETYGEMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV

121-

DVMCTAFHDN EETFLKKYLY EIARRHPYFY APELLFFAKR

161-

ykAAFTECCQ AADKAACLLP KLDELRDEGK assakqrlkc

201-

aslqkFGERA FKAWAVARLS QRFPKAEfae vskLVTDLTK

241-

VHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE

281-

KPLLEKSHCI AEVEndempa dlpslaadfv eskdvckNYA

321-

EAKDVFLGMF LYEYARRHPD YSVVLLLRLA KTYEttlekC

361-

CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE

401-

YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH

441-

PEAKRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES

481-

LVNRRPCFSA LEVDETYVPK EFNAETFTFH ADICTLSEKe

521-

rqikkQTALV ELVKhkpkat keQLKAVMDD FAAFVEKcck

561-

addketcfae egkklvaasq aalgl
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studies using quantitative proteomics for immobilized versus soluble HSA, where a total
usable sequence coverage of 78% was obtained when quantitative data was considered
(15).
When using both Methods 1 and 2 for the quantitative studies,

16

O/18O ratios

could be determined for peptides that encompassed 42 lysine and 21 arginine residues in
HSA. By using a qualitative comparison between the

16

O- and

18

O-labeled samples,

K525 (found in residues 525-534 in the tryptic digest obtained in this study), was also
found to have significant levels of modification. The remaining 16 lysine and 3 arginine
residues that were not included in these peptides are located within residues 58–61, 160–
163, 191–206, 295–317, 355–359, 520–524, 535–543 and 558–585.

None of these

residues, with the exception of K199 (a known site of major glycation), are thought to
undergo any significant amounts of modification during the glycation of HSA (11).
2.C.2. Measurements of

16

O/18O Ratios for Peptide Digests from Glycated HSA.

Peptides containing a 16O/18O ratio higher than a cutoff value of 2.00 were selected and
treated as potential modification sites in the digests of glycated HSA. This cutoff value
was determined using a cumulative sums plot (Figure 2.2), where it was determined that
6% of the detected peptide peaks had a

16

O/18O ratio greater 2.00. This cutoff value is

similar to an upper reference value for 16O/18O ratios of 2.0–3.0 (depending on the type of
digest being used) that has been previously reported for this digestion and labeling
approach with normal HSA (15). The

16

O/18O ratio range of 2.0–3.0 was previously

obtained by comparing two control samples of the same preparation of normal HSA (15).
When both Methods 1 and 2 were used for quantitative analysis, the 16O/18O ratios for 83
peptides were determined. Of these peptides, eight peptides containing four lysine

39

0

0.25

0.50

0.75

1.00

1.25

1.50

1.75

2.00

2.25

2.50

2.75

3.00

3.25

3.50

3.75

4.00

Range of 16O/18O ratios

40

41
residues and five arginine residues were identified as major sites of modification because
their

16

O/18O ratios were above the selected cutoff ratio of 2.0. Two peptides that

encompass residues 525–534 and 415-439 on HSA were found to have significant levels
of modification; however, the extent of modification was too large to be quantified by
this current approach.
There were two cases where the

16

O/18O ratio was calculated for peptides with

identical residues where one peptide had a cysteine that had been modified by
iodoacetamide to form carbamidomethyl-cysteine (CAM-cysteine) and the other peptide
remained unmodified.

These two peptides were detected in the Glu-C digest and

corresponded to residues 466–479 and residues 101–119. In this situation, a pair of
16

O/18O ratios was calculated for each residue, where one ratio corresponds to the CAM-

modified peptide and the other to the unmodified peptide. In both cases, the unmodified
peptides had a much higher

16

O/18O ratio (1.27–1.86) than their CAM-modified

counterparts (0.31–0.37). This anomaly may indicate that CAM-incorporation was not
consistent between the glycated HSA and the reference HSA samples. The 16O/18O ratio
for the CAM-modified peptide in this case was assumed to be the 16O/18O ratio that most
closely represented glycation because the formation of CAM cysteine should be highly
favored under the reactions conditions used for alkylation in this study.
The 16O/18O ratios obtained for the tryptic digest using Method 1 and 2 are given
in Tables 2.1 and 2.2, respectively. In the tryptic digest, five peptides were found to have
16

O/18O ratios greater than 2.00. A total of three peptides were also noted in the Lys-C

digest that had

16

O/18O ratios greater than 2.00, but the Glu-C digest gave no peptides

with 16O/18O ratios above this cutoff value (see Supplemental Information).

Table 2.1. Calculated 16O/18O ratios for the tryptic digest using Method 1

Residue
74-81
146-159
318-323
324-336
1-10/42-51
145-159
337-348
65-81
11-20
213-218
65-73
138-144
403-410
414-428
546-557

a

m/z
933.52
1742.89
695.34
1623.79
1149.62
1899.00
1467.84
1932.04
1226.61
673.38
1017.54
927.49
960.56
1639.94
1342.63

Observed peak ratios for each peptide at given %ACN in water
5% ACN
10% ACN
20% ACN
30% ACN
50% ACN
3.68
2.40
2.15
1.94
1.43
1.30
1.17
1.08
1.39
1.11
1.18
1.12
1.07
1.10
1.07
1.02
0.81
1.15
0.97
0.94
0.93
0.93
0.96
1.12
0.75
0.93

Average 16O/18O ratio a
3.68
2.40
2.15
1.94
1.43
1.23 (± 0.09)
1.17 (± 0.13)
1.09 (± 0.02)
1.07
1.02
0.98 (± 0.24)
0.95 (± 0.02)
0.94 (± 0.02)
0.94 (± 0.26)
0.93

– For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions.

During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This
method for determining the final standard deviation was determined using the method of error propagation).
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Table 2.1 (continued). Calculated 16O/18O ratios for the tryptic digest using Method 1
Observed peak ratios for each peptide at given %ACN in water
Residue
373-389
107-114
338-348
13-20
137-144
263-274
234-240
82-93
182-186
433-444
390-402
275-286
115-136
94-106
485-500
163-174
115-136
a

m/z
2045.10
940.45
1311.74
951.44
1055.59
1443.64
789.47
1434.53
645.36
1400.68
1657.75
1546.80
2778.36
1714.80
1910.93
1371.57
2650.26

5% ACN

10% ACN

20% ACN
0.85

30% ACN
0.95

0.87

0.8

50% ACN

0.89
0.83
0.68
0.7
0.51
0.36
0.34
0.34

0.78

0.32
0.26
0.21

0.2

0.12

0.13

0.17

0.39

0.12

0.1
0.1

Average 16O/18O ratio a
0.90 (± 0.07)
0.89
0.84 (± 0.05)
0.83
0.73 (± 0.07)
0.7
0.51
0.36
0.34
0.34
0.32
0.26
0.24 (± 0.13)
0.16 (± 0.06)
0.15 (± 0.03)
0.1
0.1

– For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions.

During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation(Note: This
method for determining the final standard deviation was determined using the method of error propagation).
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Table 2.2. Calculated 16O/18O ratios for the tryptic digest using Method 1
Observed peak ratios for each peptide at given %ACN in water
Residue
107-114
213-218
145-159
414-428
137-144
138-144
403-410
21-41
373-389
337-348
94-106
338-348
11-20
390-402
433-444
485-500
115-136
a

m/z
940.45
673.38
1899.00
1639.94
1055.59
927.49
960.56
2490.29
2045.10
1467.84
1714.80
1311.74
1226.61
1657.75
1400.68
1910.93
2778.36

5% ACN
3.77
3.48

10% ACN

20% ACN

30% ACN

50% ACN

1.8
1.35
1.25
1.25

1.41
1.28
1.27
1.27

1.8

0.94
0.9
0.81
0.43

0.87

0.43
0.41

0.39
0.36
0.35
0.23
0.14

0.19
0.12

Average 16O/18O ratio a
3.77
3.48
1.8
1.60 (± 0.28)
1.32 (± 0.05)
1.26 (± 0.14)
1.26 (± 0.14)
0.94
0.88 (± 0.02)
0.81
0.43 (± 0.00)
0.41
0.39
0.36
0.35
0.21 (± 0.03)
0.13 (± 0.01)

– For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions.

During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This
method for determining the final standard deviation was determined using the method of error propagation).
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Table 2.3. Peptides corresponding to the top 8 peak ratios (Using a cutoff ratio of 2.0) and their potential modifications are reporteda
Amino Acids
R114
R81
R218

pKa/FASb
12.29/0.80
12.50/0.76
9.64/0.20

Residue (digest, method)
107-114 (Trypsin, 2)
71-84 (Trypsin, 1)
213-218 (Trypsin, 2)

Peak ratio
3.77
3.68
3.48

Detectedc
This Study
This Study
[13]

Residue [13]c
n/a
n/a
200-218 (Try.)

Modification
none detected
none detected
AFGP

K413, R410

10.01/0.23, 12.46/0.33

403-413 (Lys-C, 2)

3.29 (± 0.89)

This Study

403-413

FL-2H2O

K432, R428

9.92/0.36, 11.29/0.18

415-432 (Lys-C, 2)

2.57 (± 1.48)

[13]

426-442 (Glu-C)

FL

″

″

″

″

This Study

415-432

FL-2H2O

K159

9.94/0.44

146-159 (Trypsin, 1)

2.40

[13]

145-160 (Try.)

PYR

K212, R209
″

10.43/0.40, 12.08/0.61
″

206-212 (Lys-C, 2)
″

2.32 (± 0.76)
″

[13]
″

200-218 (Try.)
206-225 (Lys-C)

AFGP
FL

K323

10.50/0.54

318-323 (Trypsin, 1)

2.15

This Study

n/a

none detected

K233
K436, K439
K525, K534

Significantly modified peptides as indicated by a qualitative comparison
10.29/0.43
226-233 (Lys-C, 1)
4.32d
This Study
n/a
9.67/0.51, 10.50/0.94
415-439 (Lys-C)
n/a
[13]
426-442 (Glu-C)
10.06/0.07, 11.11/0.12
525-534 (Trypsin)
n/a
[13]
520-525 (Lys-C)

none detected
FL
CEL

a

– The values in bold represent the most likely modification sites.

b

– This column shows the pKa and fractional accessible surface area for the protein calculated using PROPKA [33] and VADAR [34].

c

– This column shows whether a similar amino acid or peptide was detected previously [13]. The corresponding residue and

modification are also shown.
d

– The corresponding peptide in the mixed digest had a mass accuracy that was outside the 50 ppm threshold.
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Table 2.3 shows the ranking of the peptides that were found in the quantitative
studies to have major degrees of modification, as listed according to the order of their
16

O/18O ratios. These peptides contained amino acids R114, R81, R218, K413, K432,

K159, K212 and R209, and K323. Of these residues R218, K159 and R209 were found
to be modified to produce the AGEs 1-alkyl-2-formyl-3,4-glycoyl-pyrole (AFGP),
pyrraline (Pyr) and AFGP, respectively. Similarly, residues 212, 413 and 432 were
modified to form fructosyl-lysine (FL), FL-2H2O and FL-2H2O, respectively, all of
which are early stage glycation products.
There were two instances where the m/z values for a given peptide were clearly
observed in the 16O digest, but the same m/z values were not found in the 18O digests or
mixed labeled digest (see Table 2.3). The absence of these characteristic peptides in the
18

O digests is indicative of significant glycation, because the concentration of the

unmodified forms of these peptides were too low to be detected at the selected signal-tonoise threshold of 5 (i.e., only peaks with intensities below this threshold were noted in
the

18

O and mixed oxygen labeled digests). Low intensity m/z values corresponding to

residues 525–534 (1128.69 Da) in the tryptic digest and residues 415–439 (2629.42 Da)
in the Lys-C digest were found only in the

16

O-labeled digest. Interestingly, these

residues also correspond to lysines 439 and 525, which are amongst the most commonly
cited glycated lysine residues in HSA (11). This finding is consistent with our previous
work, where K525 was shown to be modified to form Nε–carboxyethyl-lysine (CEL) and
K439 was shown to be modified to form FL (5). In addition to these peptides, K233
which is found on residues 226–233 of HSA is also believed to have significant levels of
modification. A set of m/z values corresponding to this peptide (880.44 Da), were clearly

identified in the

16

O- and
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O-labeled digests; however, the corresponding m/z value in

18

the mixed digest seemed to shift to 881.29 Da. This shift would result in a value that falls
outside the assigned mass accuracy. Nevertheless, a 16O/18O ratio was calculated for this
peptide, giving a

16

O/18O ratio of 4.32, indicating that this peptide could potentially

contain high levels of glycation. Previous studies have indicated that K233, which is
found within residues 226-233 of HSA, may be glycated (11).
The 16O/18O ratios for other modifications that occurred on glycated HSA which
did not exceed the 2.00 cutoff value were also considered, based on possible
modifications that have been noted in the literature in qualitative studies with HSA (5). If
multiple 16O/18O ratios could be linked to a given lysine or arginine residue, the resulting
16

O/18O ratios that are modified to form CAM-cysteine and peptides that have a minimum

combination of lysine and/or arginine residues were used to assign the most likely
glycation sites. This filtering was done to provide the most realistic representation of the
16

O/18O ratio for a given amino acid, without the influence of CAM modified cysteine or

assigning 16O/18O ratios that result from multiple minor modifications to a single amino
acid. When CAM modification and lysine/arginine heterogeneity are factored in, the
range of 16O/18O ratios for lysines 12 and 51 (or the N-terminus) is 1.18–1.32 and 1.28–
1.78 respectively. These results indicate that K51 (or the N-terminus) contains the most
early glycation products, followed by K12. These amino acid residues have previously
been linked to the formation of early stage glycation products (i.e., FL-related
modifications).

Similarly, the range of

16

O/18O ratios for AGE-linked peptides (5)

containing K159, K286, K378, R472 and R222 is 1.80–2.40, 0.26–0.28, 0.45–1.29, 0.31–
0.50 and 1.62–1.86, respectively. When these residues are ranked in order of decreasing

16
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O/ O ratios, K159 appears to have the largest extent of modification followed by R222,
18

K378, R472 and K286. Lysines 159, 378, and 286 were linked to Pyr, CEL, and CML
respectively.

Similarly, arginines 222 and 472 were linked to G-H1 and ArgP

respectively.
The peptide with the highest detected

16

O/18O ratio of 3.77 was detected in the

trypsin digest and had a mass of 940.45 Da. This mass corresponds to residues 107–114
on HSA, which indicates that R114 is modified to form AGEs. The particular type of
modification could not be identified by m/z shifts in this study or in our previous study
(5); however, early glycation does not occur on arginine residues so it likely being
modified to form AGEs. Similarly, a peptide (933.52 Da) with a high

16

O/18O ratio of

3.68 was detected in the trypsin digest. This mass corresponds to residues 74–81 on HSA,
indicating that R81 may be involved in AGE formation. Several peptides were identified
in this analysis that had high

16

O/18O ratios with corresponding glycation related m/z

shifts as identified previously (5).

For example, a high

16

O/18O ratio peptide

corresponding to residues 213–218 (673.38 Da) on HSA has previously been shown to be
modified by AFGP.

Similar cases where high

16

O/18O ratios and glycation related

modifications can be linked are shown in Table 2.3.
2.C.3. Peptides with High

16

O/18O Ratios Representing Early or Advanced

Glycation Products. Some of the peptides containing

16

O/18O ratios above the cutoff

ratio had multiple sites for possible modification. As a result it was difficult to link an
increased 16O/18O ratio to a particular amino acid in the respective peptide. For peptides
with several possible modification sites, the detected mass shifts were used to help assign
the sites that were being modified. For instance, peptide 403–413 (1352.77 Da) detected
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in the Lys-C digest (See Appendix) had a O/ O ratio of 3.29 and contained both K413
16

18

and R410. A separate peptide was found from the same region (residues 403-413) that
had a mass shift of 126 Da. This mass shift corresponds to modification by FL-2H2O,
suggesting that K413 is being modified during glycation to form this type of adduct.
Similarly, lysines 432 and 212 were clearly identified as likely modification sites because
the m/z shift data that was obtained previously (5) show that these amino acids were
being modified by early glycation products.
There were some glycation-related mass shifts that were identified in this study
(Table 2.4) and linked to peptides with intermediate

16

O/18O ratios. The resulting mass

shifts were similar to the mass shifts that were obtained previously (5). For instance,
amino acids K106, K136, K240, K174, K466, and R336 are suspected to be modified to
produce CML, FL-2H2O, FL-1H2O, FL and CEL, CEL, and AFGP respectively. Of
these residues, lysines 136, 174, and 240 were previously shown to be modified by FL1H2O, CEL, and FL-1H2O, respectively (5). All of the other modifications that were
linked to intermediate

16

O/18O ratios are new to this current study. Of these residues,

K432 and K413 were linked to

16

O/18O ratios that were above the cutoff ratio of 2.00.

The number of m/z shifts that were linked to intermediate 16O/18O ratios in this study and
in our previous study (5) illustrates the heterogeneous nature of glycation-related
modifications and the need for improved characterization techniques.
2.C.4. Correlation of Modifications with Local pKa or FAS Values.

Additional

sources of information can be used to determine which lysine or arginine residues on
HSA might be prone to modifications by glycation.

This information includes the

Table 2.4. Glycation adducts (found in this study) that are linked to peptides with calculated 16O/18O ratios.
Mass Shift Modification

16

O/18O (Method 1)

16

O/18O (Method 2)

Amino Acids

Residue

Detected Digest

K413, R410
K106, R98
K174
K174

403-413
94-106
163-174
163-174

Lys-C
Lys-C
Lys-C
Lys-C

126.03
58.01
162.05
72.02

FL-2H2O
CML
FL
CEL

1.29 (± 0.19)
0.77 (± 0.08)
0.72 (± 0.06)
0.72 (± 0.06)

3.29 (± 0.89)
1.42 (± 0.13)
na
na

K432, R428
K106, R114, R117
K466, R472, K475

415-432
101-119
466-479

Lys-C
Glu-C
Glu-C

126.03
58.01
72.02

FL-2H2O
CML
CEL

1.37 (± 0.35)
1.27 (± 0.24), 0.37 (± 0.29)
1.86 (± 1.39), 0.31 (± 0.14)

2.57 (± 1.48)
0.47 (± 0.20)
1.19 (± 0.14)

K240
R336

234-240
324-336

Trypsin
Trypsin

144.04
270.07

FL-1H2O
AFGP

0.51
1.94

na
na

K136, R117

115-136

Trypsin

126.03

FL-2H2O

0.39, 0.10

0.13
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estimated pKa values for the individual amino acid side chains, the fractional accessible
surface are (FAS) for each of these residues, and the location (surface or buried) of the
amino acid residue. Lysine or arginine residues on HSA having low pKa values would be
expected to be more susceptible to glycation reactions because a larger portion of these
residues would exist in a non-protonated state, favoring nucleophilic addition or
substitution (5). Amino acid side chains with high FAS values and residues that occur on
the surface of HSA would be more reactive because they have greater access to reactants
compared to sites buried within the protein’s structure. Another factor to consider is that
HSA is a flexible protein (3) in which changes in confirmation may facilitate or hinder
glycation reactions. As a result, the aforementioned variables are not static, and residues
with low FAS values, high pKa values or that are normally buried within the protein may
become more reactive as glycation-induced conformational changes occur.
Of the various residues with high

16

O/18O ratios that were noted in this study

(Table 2.3), residues R218, R410, and R428 are all buried within the structure of HSA,
while the majority of the remaining residues are located on the surface of HSA. In
addition, lysines 233, 439, and 525, which are believed to have undergone significant
glycation based on a qualitative comparison of the digest, are all found on the surface of
HSA. This result makes sense because the majority of modification that occurs on HSA
is expected to occur with residues that are easily accessible to sugars in the surrounding
medium. When looking at the modifications which were identified by mass shifts (Table
2.4), six of these modifications occur on residues that are found on the surface of the
protein and five occur on residues that are more buried in the structure of HSA. The
location of AGEs or glycation products in the buried locations could be explained by
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changes in the structure of HSA when glycation occurs (29). This change would increase
the accessibility of the glycation-related reactants to lysine or arginine residues. Further
evidence of this was indicated previously, when K199 was identified as a prominent
glycation site. Even though the location of this residue is buried within the structure of
HSA, it has consistently been identified as a glycation site that occurs on HSA (5, 30).
Additional information, such as the calculated pKa and FAS values for these residues,
were next used to provide further insight into these modification processes.
The range of calculated pKa values for the lysine and arginine residues on HSA
are 6.23–11.11 and 7.56–16.02, respectively, where the lysine residues have an average
pKa value of 10.08 and the arginine residues have an average pKa of 12.34 (Note: details
on how these calculated results were obtained are provided in the literature (15)). The
peptides listed in Table 2.3 appear to follow a trend in which the most frequently
occurring modifications took place on residues that either have pKa values below the
average or have high FAS values. For instance, R114, R81, and R209 have FAS values
of 0.80, 0.76, and 0.61, respectively, which are on the high end of the range of FAS
values for arginine. These residues are also suspected modification sites based on their
16

O/18O ratio values. R218 has the highest FAS value of all arginines on HSA, a pKa

value which is lower than average, and the highest calculated 16O/18O ratio in this study.
All of these features provide strong evidence that this residue is a likely site for
modification due to glycation-related reactions. Similarly, lysines 413, 432, and 212
were assigned as glycation sites because of the corresponding low pKa values, lysine
specific modifications were identified on these peptides, and peptides corresponding to
these residues all had high 16O/18O ratios. Similar assignments were made for m/z shifts
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that were identified in this study that corresponded to early or late stage glycation adduct
formation (Table 2.4). Of the glycation sites that were identified through a qualitative
comparison of the digests, lysine 439 had a high FAS value of 0.94, which partially
explains the reactivity of this residue. The reactivity of K233 and K525, however, cannot
be explained based on the pKa or FAS values alone because these values are more typical
of those seen for other lysines on HSA. It is therefore likely that some other process such
as a conformational change upon glycation (29) or localized acid-base catalysis (11) may
increase the amount of modification that occurs on these residues.
2.C.5. Location of Modified Sites versus Major Drug Binding Sites on HSA. It has
been suggested that the extent of glycation of HSA may affect how tightly HSA binds
drugs and small solutes in the body (31, 32). The two major drug binding sites on HSA,
commonly referred to as the Sudlow sites 1 and 2, contain several amino acids which
facilitate the binding of these compounds to HSA (2). When the results from Tables 2.3
and 2.4 are compared to the location of these binding sites (3), many of the potential
glycation sites are at or near the same regions on HSA that facilitate drug and solute
binding. For instance, K212, K233, R209, and R218 (noted in Table 3 to be potentially
important sites for modifications due to glycation) occur in the same vicinity as the key
residues W214, Y211, and Y211 that are found in Sudlow site 1. Similarly, K413, K432,
K439, are located in the same region of HSA as R410 and Y411, which are important
residues taking part in drug interactions at Sudlow site 2. Of the major glycation adducts
that were noted in this study (Table 2.4), K240 and K432 occur in the same region of
HSA as L430 (Sudlow site 2) and L234/L238 (Sudlow site 1), respectively. These results
suggest that the glycation of HSA, even at the minimal levels examined in this report,

54
may have a potential effect on the binding of drugs and other small solutes at these sites
on HSA.
2.C.6. Comparisons of Methods 1 and 2 for

16

O/18O ratio Determination.

The

consistency of Methods 1 and 2, as used in this report for the quantitative studies, was
also examined. As was mentioned earlier, Method 1 consistently gave a larger sequence
coverage than Method 2. This result is expected, because the 16O/18O ratio calculations
using Method 1 only involved the use of a combined 16O and 18O digest, while method 2
required that a 16O, 18O, and combined digest all be employed. Ideally, in this scenario
all of the digests will behave similarly, but in practice not all peptides detected in the
combined digest are detected in the

16

O and/or

18

O digest. A consequence of using

Method 2, therefore, is that the sequence coverage of HSA will be reduced compared to
Method 1. The advantage of using Method 2 is that the changes in

16

O/18O ratios are

more sensitive to changes in the extent of glycation, because corrections for back
exchange are being made.
As shown in Figure 2.2, the distribution of

16

O/18O ratios for both methods is

similar. 94% of the detected peaks in both methods 1 and 2 had 16O/18O ratio less than
2.00, which was the rationale for choosing this value as a cutoff
looking at
16

16

16

O/18O ratio. When

O/18O ratios calculated using methods 1 and 2 one observation is that the

O/18O results were not particularly correlated. One explanation for the low correlation

is that the theoretical isotopic distribution is different than the actual distribution that was
obtained and used in Method 2. Such cases are more evident when looking at larger mass
peptides or peptides that overlap and have a similar mass at 50 ppm. It is expected that
using Method 2 would be advantageous in both of these cases because the actual isotopic
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distributions in the O and O digests can be factored in, hence the ratio obtained would
16

18

be a true value, and not an inferred result. Overall a larger number of high ratio peptides
were detected using Method 2, and a larger amount of the peptides found in Method 2
were linked to modifications which were previously identified [13].

Both of these

reasons indicate that Method 2 would be a better suited for quantitation, especially under
conditions where small amounts of modification are taking place.
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2.D. SUMMARY
Figure 2.3 shows an image of HSA (as created using the Visual Molecular
Dynamics software (33)) that summarizes the results found in this study. This figure
includes the major glycation/modification sites identified in this study and lists their
16

O/18O ratios. When ranked in order of decreasing

16

O/18O ratios, R114, R81, R218,

K413, K432, K159, K212, and K323 were found to give significant changes in their
16

O/18O ratios due to glycation or a reaction that produced AGEs. In addition to these

peptides, lysines 439, 525, and 233 are also believed to contain significant amounts of
modification based on this work. These possible modification sites were obtained by
combining information on the observed mass shifts for the affected peptides in the
digests, the 16O/18O ratios for these peptides, the location of the peptides in HSA, and the
corresponding pKa and FAS values that were calculated for the given residues.
The approach discussed in this report is novel because it allows for the
simultaneous quantification of glycation-related products that occur on lysine and
arginine residues in HSA.

It was clearly established in this work that significant

glycation and AGE-modification occur at or near the two major drug binding sites of
HSA, which explains the changes in binding affinity that have been noted for some drugs
with glycated HSA (4, 29, 32). The results in this chapter also complement and build on
previous work in the analysis of glycation related modifications (5, 34, 35), by providing
a relative ranking of the amount of glycation that is found in various portions of
minimally glycated HSA.
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Figure 2.3. Structure of HSA, showing the peptides with significant glycationrelated modifications that were found in minimally glycated HSA
and the corresponding arginine or lysine that was modified in this
region. The values of the measured indicated 16O/18O ratios are also
provided, where applicable. This image was generated using VMD
and a PDB file with accession number 1AO6 (36).

107-114 (R114, 3.77)
525-534 (K525 or K534)

403-413 (K413 or R410, 3.29)

415-432 (K432or R428, 2.57)
415-439 (K439)

146-159 (K159, 2.40)

206-212 (K212 or R209, 2.38)

213-218 (R218, 3.48)
226-233 (K233)

318-323 (K323, 2.15)
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While the results from this current analysis are promising, the lack of usable
sequence coverage for sites with the highest amount of glycation and the heterogeneity of
the glycation products are both areas where further examination is needed. In addition,
the range of

16

O/18O ratios for a reference HSA digest is approximately 0.5 – 3.0 (15).

This wide range, combined with the fact that the “high”

16

O/18O ratios were marginally

greater than the assigned cutoff value of 2.0 indicates that true quantitation is not being
obtained with this current approach. Issues related to glycation product heterogeneity,
lack of usable sequence coverage for sites with the highest amount of glycation, and
quantitation errors are examined more thoroughly in the remaining chapters using HSA
that was glycated in vitro.
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2.F. APPENDIX
One figure and five tables are given in this section. Figure 2.1a shows the distribution of
16

O/18O ratios that were obtained for Methods 1 and 2. The first four tables summarize

the 16O/18O ratios that were obtained for the Glu-C digests (Tables 2.1a and 2.2a) and the
Lys-C digests (Tables 2.3a and 2.4a) when using Methods 1 and 2.
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Table 2.1a. Calculated 16O/18O ratios for the Glu-C digest using Method 1
Observed peak ratios for each peptide at given %ACN in water
Residue

m/z

466-479
334-354

1566.76
2563.41

209-227
101-119b
133-141
543-556
7-17
426-442
142-153
443-450
496-505
369-376
120-132
502-518
377-393

2232.25
2291.17
1204.66
1583.78
1300.66
1955.99
1519.78
962.45
1197.58
1031.45
1566.62
1945.86
2086.06

b

a

5% ACN

10% ACN

20% ACN

30% ACN

50% ACN

Average 16O/18O ratio a

1.86

1.86
1.41

1.41

1.31
1.27
1.26
1.19
1.22
0.93
0.85
0.8
0.71
0.77

1.15
1.11
0.96

0.93

0.94

0.45

0.54
0.45

0.76
0.58
0.47

1.31
1.27
1.26
1.19
1.18 (± 0.05)
1.11
0.94 (± 0.02)
0.75
0.78 (± 0.03)
0.64 (± 0.09)
0.62 (± 0.21)
0.54
0.45 (± 0.01)

– For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions.

During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This
was determined using the method of error propagation).
b

– CAM-cysteine was also detected on this peptide. The higher mass peptides would correspond to this modification.
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Table 2.1a (continued). Calculated 16O/18O ratios for the Glu-C digest using Method 1
Observed peak ratios for each peptide at given %ACN in water
Residue
253-266
451-465
480-492
496-501
101-119b
61-82
466-479b
87-100
286-294
49-57

a

m/z
1699.74
1801.92
1548.8
736.39
2348.19
2578.28
1680.8
1737.7
1015.49
983.45

5% ACN

0.45
0.38

10% ACN
0.45

20% ACN

30% ACN

50% ACN

0.46

0.48

0.44

0.44
0.36

0.4

0.34

0.33
0.38

0.42
0.31

0.31
0.29
0.28
0.26

Average 16O/18O ratio
0.45
0.44
0.44 (± 0.05)
0.38
0.37 (± 0.04)
0.35 (± 0.05)
0.31
0.29
0.28
0.26

– For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions.

During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This
was determined using the method of error propagation).
b

– CAM-cysteine was also detected on this peptide. The higher mass peptides would correspond to this modification.
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Table 2.2a. Calculated 16O/18O ratios for the Glu-C digest using Method 2
Observed peak ratios for each peptide at given %ACN in water
Residue
443-450
7-17
466-479
209-227
142-153
502-518
334-354
49-57
369-376
480-492
377-393
451-465
120-132
61-82
87-100
466-479
101-119
a

m/z
1583.78
962.45
1300.66
1680.8
2232.25
1519.78
1945.86
2563.41
983.45
1031.45
1548.8
2086.06
1801.92
1566.62
2578.28
1737.7
1566.76
2348.19

5% ACN

10% ACN

20% ACN

30% ACN

50% ACN
1.83

1.73
1.32
1.19
1.09
1.00

1.05

0.9
0.98
0.89

0.89
0.87
0.83
0.57
0.58
0.51
0.53

0.82
0.91

0.85
0.75

0.77
0.77
0.64

0.49

0.46
0.39

0.45

0.49

0.53

0.46

0.57

Average 16O/18O ratioa
1.83
1.73
1.32
1.19
1.09
0.98 (± 0.08)
0.98
0.89
0.89
0.85 (± 0.03)
0.84 (± 0.06)
0.76 (± 0.01)
0.61 (± 0.05)
0.54 (± 0.06)
0.51 (± 0.03)
0.51
0.50 (± 0.05)
0.47 (± 0.08)

– For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions.

During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This
method for determining the final standard deviation was determined using the method of error propagation).
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Table 2.3a. Calculated 16O/18O ratios for the Lys-C digest using Method 1
Observed peak ratios for each peptide at given %ACN in water

a

Residue

m/z

5% ACN

10% ACN

20% ACN

30% ACN

213-225
546-557

1529.87
1342.63

1.75

1.51
1.7

1.59

2.64

13-20
21-41
138-159
415-432
42-51
65-73
7-12
414-432
403-413
373-389
526-534
373-378

951.44
2490.16
2807.39
1924.09
1149.62
1017.54
973.52
2052.18
1352.77
2045.1
1000.6
784.39

1.63
1.53
1.22
1.21
1.29
1.34
1.16
1.23

1.49
1.52
1.43
1.34
1.27

50% ACN

Average 16O/18O ratioa
1.87 (± 0.52)
1.7

1.48
1.22

1.42

1.38
1.29

1.06
1.07

1.17
1.16

1.63
1.48
1.38 (± 0.22)
1.37 (± 0.14)
1.36 (± 0.21)
1.36 (± 0.09)
1.34
1.25 (± 0.13)
1.24 (± 0.13)
1.18 (± 0.16)
1.17
1.16

– For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions.

During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This
method for determining the final standard deviation was determined using the method of error propagation).
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Table 2.3a (continued). Calculated 16O/18O ratios for the Lys-C digest using Method 1
Observed peak ratios for each peptide at given %ACN in water
Residue
206-212
403-414
263-274
94-106
175-190
163-174
501-519
445-466
241-262
74-93
360-372

a

m/z
854.45
1480.86
1443.64
1714.8
1827.96
1371.57
2260.02
2674.31
2585.12
2349.03
1552.6

5% ACN
1.4
0.88
0.82
0.77
0.75
0.72
0.57
0.35
0.36

10% ACN
1.45

20% ACN

0.74

0.78

0.34
0.3

0.27

30% ACN

50% ACN

0.54

0.51
0.35

Average 16O/18O ratioa
1.42 (± 0.04)
0.88
0.82
0.77
0.76 (± 0.02)
0.72
0.54 (± 0.04)
0.35 (± 0.10)
0.35 (± 0.01)
0.3
0.27

– For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions.

During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This
method for determining the final standard deviation was determined using the method of error propagation).
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Table 2.4a. Calculated 16O/18O ratios for the Lys-C digest using Method 2
Observed peak ratios for each peptide at given %ACN in water
Residue
403-413
415-432
206-212
213-225
7-12
65-73
42-51
414-432
94-106
94-106
175-190
241-262

m/z
1352.77
1924.09
854.45
1529.87
973.52
1017.54
1149.62
2052.18
1657.78
1714.8
1827.96
2585.12

5% ACN
3.41
2.46
2.32
2.11
1.84
1.78
1.77
1.47
1.29
1.07
0.47

10% ACN
2.96
2.60

20% ACN
3.50
2.64

1.66

1.80

1.79
1.42
1.42
1.05
1.19
0.46

30% ACNa

50% ACNa

Average 16O/18O ratiob
3.29 (± 0.29)
2.57 (± 0.09)
2.32
1.86 (± 0.23)
1.84
1.78
1.78 (± 0.01)
1.45 (± 0.03)
1.42
1.17 (± 0.17)
1.13 (± 0.08)
0.46 (± 0.01)

a

– Peptides in zip-tip fractions 30 % and 50 % are mislabeled. These values were not included in subsequent calculations.

b

– For consistency, the standard deviations shown were calculated using the 16O/18O ratios obtained in the different ACN fractions.

During data processing there are some instances where standard deviations were calculated for each Zip-tip fraction. In these
instances, the square root of the sum of the standard deviations squared was used to determine the final standard deviation (Note: This
method for determining the final standard deviation was determined using the method of error propagation).
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CHAPTER 3

IMPROVED TECHNIQUES FOR IDENTIFYING EARLY
AND ADVANCED GLYCATION ADDUCTS USING MASS
SPECTROMETRY

3.A. INTRODUCTION
During diabetes, the formation of early and advanced glycation products can be
enhanced due to the increased concentration of reducing sugars in the body. The process
by which proteins are modified by glycation products is known as the Maillard reaction
(1, 2). The extent of modification that occurs on a given protein depends on the amount
of time that the protein is incubated with a reducing sugar (3), the type of reducing sugar
that is present (4), and the environment (i.e. location in the body) where the Maillard
reaction is occurring (5). The identification of the types of modification that are occurring
on a given protein is often difficult because the sugars that modify serum proteins often
fragment, self-oxidize, and rearrange to form reactive dicarbonyl compounds that are also
capable of modifying proteins to form advanced glycation end products (AGEs) (6-9).
There have been many reports indicating that many of the advanced glycation products
that are found in vivo are linked to the production of reactive dicarbonyl compounds,
namely glyoxal, methylglyoxal, or 3-deoxyglucosone (8). The end result of these of
reactions is that a given protein may be modified by all of the aforementioned compounds
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to form a heterogeneous set of advanced glycation end products (10), which may alter the
normal function of a given protein (6, 11-13). For instance, blindness and heart failure
have both linked to AGE formation that occurs on the lens crystallin protein (14) and
vascular collagen protein respectively (15).
Under physiological conditions, human serum albumin (HSA) is modified to form
these products; however, the extent of modification that occurs on HSA has been shown
to be accelerated during diabetes (16). The heterogeneous nature of these compounds
(17) makes it difficult to identify advanced glycation products that occur on HSA because
many peptide and glycation product combinations overlap at mass values that are close to
each other. An example of this overlapping modification pattern is shown in a previous
study (1) where some of the m/z shifts that were identified in commercially glycated
HSA were found to be linked to multiple glycation products. This chapter therefore
investigates techniques that can be used to increase the certainty by which these glycation
products are assigned.
The heterogeneous nature of many post-translational modifications in proteins has
often led researchers to develop their own database search tools or programs based on a
custom set of criteria (1). As an example, tools such as GlycoX (18), GlycoMod (19, 20),
and VEMS (21) are commonly used for determining N- and O-linked glycosylation sites.
However, there are few such tools that have been utilized in previous work to address the
degree of heterogeneity that is present in adducts that result from glycation. The main
objective of this project was to test a method using Matlab for determining the location of
glycation sites on proteins, using human serum albumin (HSA) as a model. This study
was done in collaboration with Dr. Ala Qadi (Department of Computer Science, UNL),
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who generously provided the programs that were used for examining glycation in this
report. Advantages of using Matlab for such work include the fact that it is commonly
used for numerical computations, it is easy to learn, and it has pre-written libraries (i.e., a
bioinformatics package) that can be integrated with other programs for such research.
This report examined the use and several key aspects of a Matlab program that was
designed for use with MALDI-TOF-MS to determine glycation adducts in a protein such
as HSA.
In this report, HSA was first glycated in vitro and then digested using Glu-C,
followed by the use of MALDI-TOF-MS to examine the resulting digest. A control
sample of non-glycated HSA was treated in a similar manner. The mass values obtained
from the glycated sample were compared to the control sample to identify modified
peptides which only occurred in the glycated sample. The mass spectra were then
compared to a theoretical digest and a sample list of modifications (i.e., see Table 3.1)
using an in-house program developed in Matlab. These results were compared to the
locations on HSA that are known from previous studies to be modified to form glycation
products (e.g., lysines 525, 199, 281, 439, and the N-terminus) (22-24). The effects of
mass accuracy and glycation product heterogeneity in this process were considered, as
well as the possible extension of this approach to other glycated proteins.
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3.B. EXPERIMENTAL
3.B.1. Materials. The following items were purchased from Sigma-Aldrich (St. Louis,
MO): HSA (99% pure, essentially fatty acid and globulin free), sequence grade trypsin,
guanidine HCl (99%), dithiothreitol (99%), iodoacetamide (99%), formic acid (96%),
trifluoroacetic acid (98%), 2,3-dihyroxybenzoic acid (98%), α-cyano-4-hydroxycinnamic
acid (99%), D-glucose (99%), potassium phosphate dibasic (99%), potassium phosphate
monobasic (99%), ammonium bicarbonate (99%), sodium azide (99%) and molecular
biology grade water. The glycated serum protein enzymatic assay was purchased from
Diazyme Laboratories (Poway, CA).
3.B.2. Apparatus.

The following items of equipment were obtained from Fisher

Scientific (Pittsburgh, PA): Pierce Slide-A-Lyzer dialysis cassettes (7 kDa MW cutoff,
0.1–0.5 mL and 0.5–3 mL capacity), Bio-Rad 10 DG size exclusion columns (30 x 10
mL) and Millipore µ–C18 ZipTip pipette tips (5.0 µg). The mass spectra were acquired
on a Voyager 6148 MALDI-TOF-MS system (Applied Biosystems, CA). The instrument
settings were as follows: positive-ion delayed extraction reflection mode; delay time, 100
ns; accelerating voltage, 25 kV; guide wire voltage, 0.008% of accelerating voltage; grid
voltage, 77% of accelerating voltage. Mascot Wizard was obtained from the Matrix
Science website (25). Matlab 2009a, including the bioinformatics and statistics toolboxes,
was purchased from Mathworks (Natick, MA). All aqueous solutions were prepared
using water from a Nanopure water system (Barnstead, Dubuque, IA).
3.B.3. Preparation of glycated HSA. Glycated HSA was prepared by dissolving HSA
to a final concentration of 42 g/L in a 3 mL solution that contained 200 mM potassium
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phosphate (pH 7.4), 15 mM D-glucose, and 1 mM sodium azide in water (Note: sodium
azide was added to prohibit bacterial growth; this agent is toxic, and care must be used to
avoid contact of this compound with skin) (9, 26, 27). The concentration of HSA and Dglucose selected for this process represented the physiological concentration of HSA (23)
and a typical blood glucose level found in diabetic patients (i.e., a level of 7 mM when
fasting or a level of 11.1 mM used in the diagnosis of diabetes) (28). This mixture was
incubated at 37 °C for 5 weeks. A control HSA sample was prepared in a similar manner
without the addition of glucose. Following the incubation, the low mass reagents were
removed by using size-exclusion chromatography.

The size-exclusion column was

washed with 20 mL of water and loaded with 3 mL of the HSA/glucose mixture. The
protein was eluted by applying 5 mL of water to the column, with 5 mL fractions being
collected.

Additional purification of the collected protein fraction was obtained by

performing equilibrium dialysis against two 1 L portions of water for 2 h at room
temperature.

An additional dialysis was performed against 1 L of water at 4 °C

overnight. Lyophilization was used to remove water from the HSA for long-term storage.
The resulting glycated HSA samples were stored at 4 °C until later use. The level of
glycation was determined using a commercial fructosamine assay kit from Diazyme.
3.B.4. Sample pretreatment and digestion. Each HSA or glycated HSA sample was
denatured by suspending 3 mg of the protein in a 1 mL solution containing 6 M guanidine
HCl and 100 mM ammonium bicarbonate (pH 8.5). A 1 M dithiothreitol reagent solution
was prepared in pH 8.5, 1 M ammonium bicarbonate buffer. A 15 µL portion of the
dithiothreitol reagent was added to the protein suspension. The protein mixture was
incubated at 37 °C for one hour. A 36 µL aliquot of 1 M iodoacetamide prepared in 1 M
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sodium hydroxide was added to this protein mixture. This mixture was incubated in the
dark for 30 min at room temperature, followed by the addition of 150 µL dithiothreitol
reagent to terminate alkylation. A 0.5 mL portion of this solution was transferred to a
0.5–1 mL dialysis cassette and dialyzed against two 3 L portions of water for 4 h per
cycle. The resulting solution was divided into 50 µL aliquots and brought down to
dryness by using a Speedvac and then stored at -80 ºC.
Glu-C was selected for the enzymatic digestion because it cleaves specifically at
glutamyl residues, and its digestion pattern is less affected by glycation related
modifications than enzymes which cleave at lysine or arginine residues (29, 30). A
working solution of this enzyme was prepared by dissolving Glu-C to a final
concentration of 1 mg/mL in water. A 200 µL volume of 100 mM ammonium
bicarbonate (pH 7.8) was added to a vial of dried HSA. The digestion with this enzyme
was performed by adding 10 µL of this Glu-C solution to the reconstituted HSA or
glycated HSA, followed by incubation of this mixture at 37 °C for 8 h. An additional 5
µL of the 1 mg/mL Glu-C reagent was later added to the protein/Glu-C mixture, and the
solution was incubated for another 18 h. Following these incubation steps, the digestion
was terminated by adding 10 µL of concentrated formic acid. The resulting digest was
separated into 10 µL aliquots and stored at -80 °C until use.
3.B.5. Mass spectrometry. A mixture of α-cyano-4-hydroxycinnamic acid (CHCA)
and 2,3-dihyroxybenzoic acid (DHB) was used as the MALDI matrix. To prepare this
mixture, 20 mg/mL CHCA was prepared by dissolving CHCA in a solution containing
5% formic acid and a 70:30 (v/v) mixture of acetonitrile and water; 20 mg/mL DHB was
similarly prepared by dissolving DHB in a solution containing 0.1% TFA and a 70:30
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(v/v) mixture of acetonitrile and water. These DHB and CHCA solutions were then
mixed in a 50:50 (v/v) ratio. A calibrant solution was also prepared that contained 25
pmol/µL

des-Arg-bradykinin

(904.4681

Da),

32.5

pmol/µL

glu-fibrinopeptide

(1570.6774 Da), and 32.5 pmol/µL angiotensin I (1296.6853 Da) in acetonitrile. A 4 µL
portion of this calibrant mixture was combined with 96 µL of the CHCA and DHB matrix
mixture. This calibrant-spiked matrix solution served two purposes. The first purpose
was to perform external calibration by spotting this calibrant-spiked matrix in MALDI
plate positions that were adjacent to the protein digests. The other purpose was to use the
spiked compounds for internal calibration.
Zip-tip pipettes were used to fractionate the peptides in each digest prior to
obtaining mass spectra. Peptide fractionation was accomplished by wetting a Zip-tip
pipette with two 10 µL portions of 50% acetonitrile and then equilibrated with two 10 µL
portions of 0.1% TFA.

A protein digest sample was loaded into the Zip-tip by

performing ten aspiration and dispensing cycles using a 10 µL portion of the desired
digest. The sample was then desalted by washing the resin with two 10 µL portions of
0.1% TFA solution containing 5% methanol. The peptide fractions were eluted from the
Zip-tip by using 1 µL solutions containing 5, 10, 20, 30, or 50% acetonitrile and 0.1%
TFA in water. Each collected fraction was mixed in a 50:50 (v/v) ratio with thecalibrant-spiked matrix solution and spotted onto a 96-well plate for analysis by MALDITOF-MS. The MALDI plate was first air-dried, and mass spectra were then acquired.
The HSA and glycated HSA samples were first externally calibrated using a
spiked-matrix solution that was adjacent to the respective protein digest on the MALDI
plate. Following external calibration, the mass spectrometry data files were copied and
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placed into a separate computer folder. These new copies were internally calibrated
using the spiked calibrant mass values. A mass accuracy of 50 ppm was typically
obtained with this approach when external calibration was used with the delayed
extraction and reflector mode for mass analysis (1, 31, 32). A mass accuracy of 25 ppm
was typically obtained under the same conditions when internal calibration was used
(33). Based on these results, 25 ppm and 50 ppm error thresholds were used for peptide
mass matching in this work.
3.B.6. Peak extraction and matlab program development.

A diagram that

summarizes the assignment of glycation products based on m/z shifts is summarized in
Figure 1.3. Mascot Wizard (25) is a program that is designed to automatically perform
peptide mass fingerprinting directly from an acquired mass spectra. This peptide mass
assignment is done by comparing a list of peptide masses (that is automatically
generated) to a given database with known proteins. For this current approach, Mascot
Wizard was used to generate a deisotoped mass list from each mass spectrum by first
performing a database search using the raw mass spectrometry data files. Upon
completion of the database search, one of the probability scores was expanded and all of
the observed mass values (including the mass values that were not mapped to any given
protein) were transferred to a tab delimited text file (HSA_raw1.txt). In this file, column
1 contained the mass values and column 2 contained the identity of the respective Zip-tip
fraction (Note: see example in Appendix, Table 3.1a). A theoretical digest table was
generated using PeptideMass, where a maximum of two missed cleavages was allowed.
Carboxyamidomethyl-cysteine (cys-CAM) formation and methionine oxidation were
both assigned as variable modifications during this process (34). This digest table was
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copied directly to a spreadsheet, the formatting and titles were removed, and the resulting
table was rearranged (Note: see example in Appendix, Table 3.2a) and saved as a tabdelimited text file (Digest1.txt).
A third table containing 119 possible early and late stage glycation adducts was
generated in a similar fashion. For this table, a maximum of two modifications was
allowed per peptide, as based on the possible modifications listed in Table 1.1. Each
modification was assigned four integer values based on whether this modification
occurred at one lysine (K1), two lysines (K2), one arginine (R1), two arginines (R2), or
both a lysine and arginine (K and R residues) (see example in Appendix, Table 3.3a).
This file was then saved as a tab-delimited text file (ModSearch1.txt).
Two programs, which were developed by Dr. Ala Qadi (Department of Computer
Science), were used to identify the glycation-modified peptides (see Figure 3.1). The first
program (digestmatch.m) was used to match the detected mass values to the theoretical
digest and generate a theoretical list of modified peptides (see Appendix, Table 3.4a).
The second program (suspect_mod_sites.m) was used to match the extracted mass values
to the list of modified peptides (see Appendix, Table 3.5a). Further details regarding the
development and execution of the script are provided in the Appendix.
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Figure 3.1. Flow chart showing the programs that were used for glycation adduct
identification and the respective input tables that were used with these
programs.

Input Files

Program
digest_match.m

Program
suspect_mod_sites.m

Modsearch1.txt

digestMOD.txt
error_match
(unfiltered)

HSA_raw1.txt

digestmatch_result.txt

Digest1.txt

error_match
(i.e., suspected modification
sites)
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3.C. RESULTS
3.C.1. Sequence coverage and identified modification sites. Using the fructosamine
assay, the glycated HSA sample used in this work was found to contain an average of 1.2
(± 0.1) mol hexose per mol HSA. A total of 77 m/z values were obtained from the
internally-calibrated mass spectra for this sample when using Mascot Wizard. In some
instances, a given peptide could be identified in more than one Zip-tip fraction. When
this occurred, the detected m/z values for a given peptide were averaged prior to running
the Matlab program.

This approach simplified the analysis because the detected

glycation products could be identified in a single run step of the program instead of
running the program multiple times. In addition, averaging these m/z values served a
secondary purpose in that using several individual mass measurements to calculate an
average mass gave a value that was less susceptible to random variations and outliers in
the results.
When the masses of these peptides were matched to a theoretical Glu-C digest at
25 ppm mass threshold, nineteen of these peptides were found to have matches (see Table
3.1), representing peptides from 44% of the primary sequence of HSA (Figure 3.2).
While it is possible to obtain a higher sequence coverage by using multienzyme digestion
(32), the level of coverage that was obtained in this current study was sufficient for
illustrating the factors that may affect the identification of glycation sites. Seventeen of
the 77 peptides that were obtained using Mascot Wizard that were found in the glycated
HSA digest were not present in the control HSA digest.

The program

“suspect_mod_sites.m” was then executed using the masses of these unique peptides and

Table 3.1. Peptides in the internally-calibrated glycated HSA sample that matched the theoretical GluC digest at 25 ppm

a

Residues

Amino Acid Sequence

369-376

CYAKVFDE

496-505
133-141

Modification

MC

Mass (Da)

Error (ppm)

CAM

0

1031.4477

-2

TYVPKEFNAE

1

1197.586

6

TFLKKYLYE

0

1204.647

-12

7-17

VAHRFKDLGEE

0

1300.658

-5

521-531

RQIKKQTALVE

0

1313.772

-14

142-153

IARRHPYFYAPE

0

1519.7815

1

480-492

SLVNRRPCFSALE

CAM

0

1548.79

-3

120-132

VDVMCTAFHDNEE

CAM

0

1566.636

10

466-479

KTPVSDRVTKCCTE

CAM

0

1680.803

-1

154-167

LLFFAKRYKAAFTE

0

1704.937

-6

87-100

MADCCAKQEPERNE

1

1737.7013

1

CAM

CAM and MC are abbreviations for “carboxyamidomethyl-cysteine” and “missed cleavages”, respectively.
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Table 3.1 (continued). Peptides in the internally-calibrated glycated HSA sample that matched the theoretical Glu-C digest at 25 ppm
Residues

Amino Acid Sequence

502-518

FNAETFTFHADICTLSE

426-442

VSRNLGKVGSKCCKHPE

377-393

MC

Mass (Da)

Error (ppm)

1

1945.885

11

CAM

0

1955.9737

-8

FKPLVEEPQNLIKQNCE

CAM

0

2086.071

3

189-208

GKASSAKQRLKCASLQKFGE

CAM

0

2194.146

-14

209-227

RAFKAWAVARLSQRFPKAE

0

2232.23

-9

101-119

CFLQHKDDNPNLPRLVRPE

0

2291.193

9

101-119

CFLQHKDDNPNLPRLVRPE

CAM

0

2348.1945

1

NCDKSLHTLFGDKLCTVATLRE

CAM

0

2578.282

3

61-82

a

Modification

CAM and MC are abbreviations for “carboxyamidomethyl-cysteine” and “missed cleavages”, respectively.
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Figure 3.2. Sequence coverage obtained at a mass accuracy of 25 ppm for an internally
calibrated glycated HSA sample after digestion with Glu-C. The bold letters
represent the sequence coverage that was obtained for the Glu-C digest. The
lower case letters represent the sequence that was not covered.
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the modification search list containing all possible combinations of the glycation products
shown in Table 1.1.

When these modification sites were considered, the sequence

coverage increased to 46% and four peptides were found to be modified to form glycation
products (Note: of the glycated peptides that are identified, a single peptide
corresponding to residues 281-294 on HSA contributed to the noted increase in sequence
coverage). The modification sites were confirmed by a manual examination of the mass
spectra.

An example of a typical result that was obtained through this manual

observation is shown in Figure 3.3(i), where the mass of an unmodified peptide,
encompassing residues 426-442, is shown along with its corresponding modification that
occurs at 2107.99 Da (Figure 3.3(ii)). When the control spectra were examined, the same
modification was barely detectable (Figure 3.3(iii)) and there was no evidence of an
isotopic cluster.
The four suspected modification sites encompass residues 281-294, 426-442, 426442 and 189-208 on HSA, which were being modified in this case to give Nεcarboxyethyl-lysine (CEL) plus fructosyl-lysine (FL-2H2O), pyralline (Pyr) plus Nε-(5hydro-4-imidazolon-2-yl)ornithine (G-H1), CEL plus argpyrimidine (ArgP), and Pyr plus
imadazolone B (IB), respectively (see Table 3.2(i)). Lysines 281 and 286 are the only
lysines within residues 281-294. Peptide modifications that form CEL and FL-2H2O can
only occur on lysine residues, so it appears that K281 and K286 are being modified in the
region 281-294 to form these adducts. The region containing residues 426-442 was
identified as a potential modification site in two instances, leading to the formation of Pyr
+ G-H1 and CEL + ArgP. Lysines 432, 436, and 439 and arginine 428 are found within
residues 426-442. Because there is only a single arginine on this peptide, the arginine-
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Figure 3.3. Several representative mass spectra obtained during the analysis of glycation
adducts in HSA.
(i) The mass spectrum represents a peptide (from residues 426 – 442) that
was found during analysis of the internally-calibrated control HSA sample; a
peptide with the given mass was identified in the same Zip-tip fraction (20%
acetonitrile) using both control and glycated HSA).
(ii)

The mass spectrum represents a peptide from the internally-calibrated

glycated HSA sample that corresponded to residues 426 – 442, with a mass
shift of 152 Da versus non-glycated HSA. These results indicate that the
detected peptide contains CEL and ArgP. This peptide was only identified in
the 30% acetonitrile Zip-tip fraction.
(iii)

The mass spectrum represents the internally-calibrated control HSA

sample and shows that a mass shift of 152 Da on residues 426 – 442 has a
very low intensity. In this case, there is a peak that occurs at 2109 Da,
however, this peak is not associated with an isotope cluster and it is 1 Da
above the expected mass of 2108 Da. This indicates that either there is an
overlapping peptide, or the signal of the modified peptide is too low to be
observed.

ii)

i)

Glycated, 30% ACN
∆ m/z  152 Da
CEL+ArgP

Control, 20% ACN
426 - 442
VSRNLGKVGSKCCKHPE

iii)
Control, 30% ACN
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Table 3.2. Suspected glycation sites that were identified using a 25 ppm and 50 ppm mass accuracya
i) HSA (internal calibration) mass values matched to DigestMOD at 25 ppm
Residues

Amino Acid Sequence

Raw Mass (Da)

∆Mass (Da)

Modifications

Error (ppm)

281-294

KPLLEKSHCIAEVE

1850.9650

198.0528

CEL+FL-2H2O

-24

426-442

VSRNLGKVGSKCCKHPE

1989.9650

148.0160

Pyr+G-H1

-1

426-442

VSRNLGKVGSKCCKHPE

2108.0300

152.0473

CEL+ArgP

4

189-208

GKASSAKQRLKCASLQKFGE

2444.2070

250.0477

Pyr+IB

7

ii) HSA (external calibration) mass values that were modified by glycation at 50 ppm

a

Residues

Amino Acid Sequence

Raw Mass (Da)

∆ Mass (Da)

Modifications

Error (ppm)

267-277

NQDSISSKLKE

1374.7370

126.0317

FL-2H2O

-45

426-442

VSRNLGKVGSKCCKHPE

1990.0300

148.0160

Pyr+G-H1

-34

278-292

CCEKPLLEKSHCIAE

2107.9890

234.0528

FL-2H2O+Pyr

-36

278-292

CCEKPLLEKSHCIAE

2107.9890

234.0739

FL+CEL

-26

426-442

VSRNLGKVGSKCCKHPE

2107.9890

152.0473

CEL+ArgP

23

426-442

VSRNLGKVGSKCCKHPE

2176.1140

220.0583

FL+CML

-30

267-285

NQDSISSKLKECCEKPLLE

2444.2180

166.0266

CML+Pyr

-35

189-208

GKASSAKQRLKCASLQKFGE

2444.2180

250.0477

Pyr+IB

2

Each raw mass value listed is the mass that was obtained using Mascot Wizard. The suspected modifications and their corresponding mass shifts

are also shown. The values in the boxes highlight where a mass value could be assigned to multiple glycation-related modifications. The
italicized values represent glycation-related modifications that were identified in both the internally and externally-calibrated samples.
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specific adducts G-H1 and ArgP can safely be assigned to R428 in this example. It has
been shown previously that the proximity of positively-charged residues and disulfide
bonds to lysine residues increases the reactivity of lysine towards glucose (22). By
looking for lysine residues that are close to positively-charged residues, it was possible to
identify possible reactive sites. Lysine 439 is expected to be more reactive than other
lysines found on this peptide because of its proximity to H440. It is therefore likely that
K439 was being modified by both Pyr and CEL.
Residues 189-208 on HSA have lysines 190, 195, 199, and 205, as well as
arginine 197. R197 is the only arginine present on in this region, so this residue is likely
being modified to give IB based on the results obtained in this study. Lysine 199 is most
likely being modified by Pyr because of its proximity to C200, which places H247 in a
position that is adjacent to K199. The estimated pKa values for the lysine residues can
also be used to indicate the reactivity of a lysine residue to give glycating products, where
lysines with lower pKa values would be expected to be more reactive with glucose or
other sugars at a physiological pH. The pKa values for the lysine residues in HSA were
calculated using PROPKA (35). K199 was estimated to have a relatively low pKa of 7.9
(compared to an average lysine pKa of 10.1 in HSA), which further supports the belief
that this reside should have good reactivity to glucose during glycation.
3.C.2. Effects of mass accuracy and glycation product heterogeneity. The effects of
mass accuracy were examined by comparing the modifications identified in the
internally-calibrated sample (i.e., with a 25 ppm error limit) to the modifications
identified when external calibration was used (i.e., with a 50 ppm error limit) using only
peptides that were found in the glycated HSA samples. The sequence coverage for both
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samples where quite close, where the externally-calibrated sample had 43% coverage and
the internally-calibrated sample had 44% coverage.

This small difference occurred

because three unmodified peptides occurring on residues 521-531, 466-479, and 87-100
that were identified when internal calibration was used were not identified when external
calibration was used. There were also two unmodified peptides occurring on residues
334-354 and 451-465 that were only identified in the externally-calibrated sample. With
the exception of these five peptides, similar peptides were identified when both internal
and external calibration were used.
The heterogeneous nature of glycation products can have a significant effect on
adducts that are assigned at any given level of mass accuracy. An example of this effect
occurred after the program was executed and five glycated peptides were found in the
externally-calibrated sample (see Table 3.2(ii)) compared to three glycated peptides that
were found in the internally-calibrated sample. Of these peptides, only two peptides
(426-442 and 189-208) were identified at both levels of mass accuracy. The CEL and
FL-2H2O modifications that were found on residues 281-294 in the internally-calibrated
sample were not identified when external calibration was used. In addition, there were
five modifications located on three peptides that were identified only when external
calibration was used. These results indicated that using a technique with higher mass
accuracy resulted in increased sequence coverage and reduced the number of assigned
glycation products, thus enhancing the confidence of glycation product assignment.
Mass accuracy considerations can be especially important when a m/z value can
be linked to multiple modifications that have close mass values or when different peptide
masses and modification mass combinations have similar m/z values. For instance, a
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peptide with a m/z value of 2107.99 Da was identified in an externally-calibrated HSA
sample. This mass could be linked to residues 278-292 with either a combination of FL2H2O plus Pyr modifications or FL plus CEL. The resulting difference in mass between
these two combinations is 0.0281 Da, or 13 ppm. The same mass could also be linked to
residues 426-442 on HSA after modification to form CEL plus ArgP adducts. This latter
set of modifications would result in a peptide that has a calculated mass of 2108.038 Da,
representing a 49 - 58 ppm mass shift compared to the modifications occurring on
residues 278-292. When the mass accuracy was increased to 25 ppm, 426-442 was the
only residue which was could be matched to a glycation product, showing that these
potential glycation sites could be better differentiated when a higher mass accuracy is
used.
3.C.3. Effects of peak selection criteria and adduct heterogeneity.

Another effect

that was examined was the effect of peak selection on the amount and types of
modification sites that were identified. The examination of this effect was done by
comparing modifications found in the entire data versus those peptides that were unique
to the glycated HSA. Protein samples that were calibrated internally were used for both
of these comparisons. When the entire data set was considered, a total of fourteen m/z
values (see Table 3.3) were identified as being modified. Of these fourteen identified m/z
values, there were four instances where a given m/z value could be mapped to either a
modified or unmodified peptide. When only the unique peptides were considered, four
peptides were identified as being modified and none of these four peptides overlapped
with the predicted m/z values for unmodified peptides. The peptide overlap pattern
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clearly illustrates that it is advantageous to use unique peptides for the assignment of
modification sites because these sites can be assigned with very little ambiguity.
It is expected that if a greater number of masses are being used to search for
glycation adducts, a larger number of false-hits would occur because of the sheer number
of glycation-modified peptides that may be present. For instance, the theoretical digest
for Glu-C has 204 values and the glycation adduct list has 119 possible values, resulting
in a modified peptide table containing 24,276 values.

This issue would be further

compounded when techniques such as multi-enzyme digestion are used to increase the
sequence coverage. Using the unique peptides in this instance would be useful because
the changes in glycation which occur on HSA can be directly linked to these
modifications, increasing the confidence at which these assignments can be made.

Table 3.3. Modifications detected in internally-calibrated glycated HSA sample at 25 ppm when all peptides were useda

a

Residue

Amino Acid Sequence

Raw Mass (Da)

∆Mass (Da)

Modifications

Error (ppm)

443-450

AKRMPCAE

1031.4477

126.0317

FL-2H2O

17

443-450

AKRMPCAE

1031.4477

126.0317

CEL+MG-H1

17

312-321

SKDVCKNYAE

1552.6660

396.1057

FL-2H2O+AFGP

-19

267-277

NQDSISSKLKE

1680.8030

432.1268

FL+AFGP

-20

572-585

GKKLVAASQAALGL

1704.9370

378.0951

Pyr+AFGP

-19

480-492

SLVNRRPCFSALE

1801.8590

310.0689

G-H1+AFGP

-9

281-294

KPLLEKSHCIAEVE

1850.9650

198.0528

CEL+FL-2H2O

-24

278-292

CCEKPLLEKSHCIAE

1945.8850

72.0211

CEL

-2

The values in boxes indicate where a mass value could be assigned to multiple glycation products. The italicized values represent mass values
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that overlapped with those for some unmodified peptides in the theoretical digest.

Table 3.3 (continued). Modifications detected in internally-calibrated glycated HSA sample at 25 ppm when all peptides were useda

a

Residue

Amino Acid Sequence

Raw Mass (Da)

∆Mass (Da)

Modifications

Error (ppm)

426-442

VSRNLGKVGSKCCKHPE

1989.9650

148.0160

Pyr+G-H1

-1

426-442

VSRNLGKVGSKCCKHPE

2108.0300

152.0473

CEL+ArgP

4

566-585

TCFAEEGKKLVAASQAALGL

2194.1460

130.0266

CEL+CML

-18

480-495

SLVNRRPCFSALEVDE

2216.0210

324.0846

MG-H1+AFGP

-2

359-376

KCCAAADPHECYAKVFDE

2314.9440

144.0423

FL-1H2O

-1

359-376

KCCAAADPHECYAKVFDE

2314.9440

144.0422

CEL*2

-1

228-244

FAEVSKLVTDLTKVHTE

2331.1490

414.1163

FL-1H2O+AFGP

0

566-585

TCFAEEGKKLVAASQAALGL

2331.1490

324.1056

FL*2

6

101-119

CFLQHKDDNPNLPRLVRPE

2331.1490

39.9949

G-H1

7

189-208

GKASSAKQRLKCASLQKFGE

2444.2070

250.0477

Pyr+IB

7

The values in boxes indicate where a mass value could be assigned to multiple glycation products. The italicized values represent mass values

that overlapped with those for some unmodified peptides in the theoretical digest.
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3.D. SUMMARY
This chapter illustrates the use of MALDI-TOF-MS and Matlab for rapidly
identifying potential glycation-related modifications that occur on HSA. By selecting the
unique peptides and using a 25 ppm mass accuracy, residues 281-294, 426-442 (modified
twice) and 189-208 of HSA were clearly shown as being modified to form CEL + FL2H2O, Pyr + G-H1, CEL + ArgP, and Pyr + IB respectively.

The most likely

modification sites based on the structure of HSA, and the proximity of these residues to
positively charged amino acids would be lysines 281, 286, 439, and 199 as well as
arginines 197 and 428.
Three key considerations were described in this chapter which affect the accuracy
and certainty by which glycation adducts can be assigned. The first consideration was
the effect of mass accuracy, where a reduction in mass accuracy was found to result in
peptide modifications being assigned with greater certainty because glycation products
with similar masses could be differentiated. The second consideration examined was the
effect of adduct heterogeneity, where it was found that using an expanded glycation
product search list is necessary for an assignment to be made because many peptide and
glycation product combinations may have similar overlapping masses at a given level of
mass accuracy. The third consideration explored was that some form of peak selection
criteria is necessary for increasing the confidence of assigning glycation products. By
looking at the unique peptides that were present in a glycated HSA sample, it was
possible to link modifications directly to the experimental conditions.
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While the overall level of selectivity for this method is good, in some instances it
is difficult to provide information about the particular amino acid residues that are being
modified in the given protein. In addition, other information, such as the location of
positively-charged residues with respect to glycation sites, can be used to help infer
which amino acids are the most likely sites for the production of glycation adducts (22).
Other information based on pKa values and fractional-accessible surface area for a given
lysine or arginine residue can also be used to aid in these assignments (1, 31). It is also
possible to provide additional selectivity by coupling these techniques with tandem mass
spectrometry (9, 36), fluorescence (37), and quantitative proteomics (29, 31). The mass
accuracy considerations, peak selection criteria, and amino-acid reactivity guidelines that
are outlined in this chapter are not limited to glycation occurring on HSA. As such, other
proteins can be analyzed using the same guidelines.
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3.F. APPENDIX
A detailed description of the programs that were written in Matlab for identifying
glycation sites is given here. Examples of the raw data file, the theoretical digest table,
and the modification search list that were read by the programs are given in Tables 3.1a,
3.2a, and 3.3a respectively. The code for the program “digestmatch.m” is given in Table
3.4a and the code for the program “suspectmodsites.m” is given in Table 3.5a.
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3.F.1. Development and execution of the matlab programs. A flow chart for the
programs “digest_match.m “and “suspect_mod_sites.m” is shown in Figure 3.1. The
code for both of these programs are given in more detail in Tables 4s and 5s. The first of
these programs (digestmatch.m) compared a raw list of masses with mass values that
were predicted for a theoretical HSA digest in order to determine which unmodified
peptides were present in a sample. The first step of this program involved assigning a
matrix containing the number of raw mass values (i.e., i rows) and the number of values
used for the theoretical digest (i.e., j columns) (lines 1-5). The difference between the
raw mass value and the digest mass value were calculated (lines 9-13). Following this, a
new matrix was assigned in a similar fashion to determine the error, in ppm. A table of
results titled “digestmatch_result” was generated with the columns shown in Table 5s
(lines 47-51). A second calculation was performed which added all of the modification
masses to all of the theoretical digest masses. The results from this calculation (Mass2)
were output to a table named “DigestMOD”. Both of these tables were exported to text
files named “digestmatch_result.txt” and “DigestMOD.txt”, respectively.
A second program (suspect_mod_sites.m) was used to read the files
DigestMOD.txt and HSA_Raw1.txt and set up a new matrix with Mass2 by MassHSA
number of cells (lines 1-13). An error value (in ppm) is calculated for all of these mass
values. If this error was less than the desired threshold, the amino acid sequence was
searched with the aacount function (Note: This function is included in the Matlab
bioinformatics toolbox) to determine whether the indicated modification was possible.
When aacount was used, the sequence had to first be converted to characters and the
aacount function had to be assigned (lines 17 and 18). In this case, the function was
assigned to “AA”, where AA.K and AA.R give a count of the total number of lysine and
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arginine residues, respectively, for a given peptide in the theoretical digest. This lysine
and arginine count was compared to the total number of lysine and arginine residues that
were needed for a given modification. To determine the number of lysine or arginine
residues that are present for a given modification, a table was developed where the
number “1” was placed in K1, K2, R1, or R2 if the modification occurs on one lysine,
two lysines, one arginine, or two arginines respectively. “If” statements can then be used
to determine where the modification occurs, and to see if the assigned modification is
possible given the lysine/arginine count. For example, an “if” statement could be used to
determine that a modification was in K1, then AA.K (i.e. the total number of lysines)
could be calculated, where any AA.K value greater than one will be assigned as a
glycation site (lines 20-24). The final result was reported in five tables with the general
name “error_matchn“, in which n can be K1, R1, R2, K2, or KR. These values were then
copied into a spreadsheet and filtered as desired. A separate program was created based
on similar techniques that compared the control HSA digest to the glycated digest to
determine which the m/z values were unique to the glycated HSA digest. Both the
unique peptides and the entire dataset were analyzed.
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Table 3.1a. Example of input for the file “HSA_raw1.txt”
Mass (Da)

Zip-Tip Fractiona

650.0880

5

656.0970

5

760.3660

10

760.8700

10

777.0890

5

855.1110

5

860.4120

5

861.1160

5

912.5440

5

1014.3710

10

1019.5370

10

1031.4030

10

2086.0540

20

2087.0910

30

2176.2360

30

2192.3310

30

2447.3780

50

2523.3570

50

2547.1760

50

2563.4550

50

a

a

The information in the top row of this table should not be included in the HSA_raw1.txt

input file. The “Zip-tip fraction” column indicates the percent of acetonitrile that was
used to elute the indicated peptides from the Zip-tip pipette tips.

Table 3.2a. Example of input for the file “Digest1.txt”a

Residues

MC

Mass (Da)

496-518
543-565
120-141
185-208
133-153
120-141
98-119
245-266
298-321
496-518
185-208
443-465
443-465
298-321
312-333
543-565

2
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1

2720.2548
2718.2571
2711.2367
2707.4307
2705.4238
2695.2418
2690.3579
2684.1207
2670.2425
2663.2333
2650.4093
2647.3040
2631.3091
2629.2160
2627.2520
2620.2091

a

Amino Acid Sequence
TYVPKEFNAETFTFHADICTLSE
QLKAVMDDFAAFVEKCCKADDKE
VDVMCTAFHDNEETFLKKYLYE
LRDEGKASSAKQRLKCASLQKFGE
TFLKKYLYEIARRHPYFYAPE
VDVMCTAFHDNEETFLKKYLYE
RNECFLQHKDDNPNLPRLVRPE
CCHGDLLECADDRADLAKYICE
MPADLPSLAADFVESKDVCKNYAE
TYVPKEFNAETFTFHADICTLSE
LRDEGKASSAKQRLKCASLQKFGE
AKRMPCAEDYLSVVLNQLCVLHE
AKRMPCAEDYLSVVLNQLCVLHE
MPADLPSLAADFVESKDVCKNYAE
SKDVCKNYAEAKDVFLGMFLYE
QLKAVMDDFAAFVEKCCKADDKE

CAM OXa
CAM
CAM
OX
CAM

CAM
CAM

OX
CAM
OX

The information in the top row of this table should not be included in the HSA_raw1.txt input file. “MC”, “CAM”, and “OX” are

used here as abbreviations that stand for “missed cleavages”, “carboxyamidomethyl-cysteine”, and “methionine oxidation”,
respectively.
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Table 3.3a. Example of the input for file “ModSearch1.txt”

Modification

Residues Involved
K1
K2
R1
R2

Mass (Da)a

FL
CEL
CML
FL-1H2O
FL-2H2O
Pyr
AFGP
3-DG-H1
THP
IB
ArgP
MG-H1
G-H1
AFGP
FL*2
CEL*2
CML*2
FL-1H2O*2
FL-2H2O*2
Pyr*2
AFGP*2
FL+CEL
FL+CML
FL+FL-1H2O
FL+FL-2H2O
FL+Pyr
FL+AFGP
CEL+CML
CEL+FL-1H2O
CEL+FL-2H2O

1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

162.0528
72.0211
58.0055
144.0423
126.0317
108.0211
270.0740
144.0423
144.0423
142.0266
80.0262
54.0106
39.9949
270.0740
324.1056
144.0422
116.0110
288.0846
252.0634
216.0422
540.1480
234.0739
220.0583
306.0951
288.0845
270.0739
432.1268
130.0266
216.0634
198.0528

a

0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

0
0
0
0
0
0
0
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

The information in the top row of this table should not be included in the HSA_raw1.txt

input file. The “residues involved” show where the modifications are expected to occur.
A number “1” in positions K1 or K2 rows means that the modification shown occurs on
one or two lysines respectively. The same is true for R1 and R2, which represents one
arginine and two arginines respectively.

Table 3.4a. Code for program “digestmatch.m”
%MData = dlmread('data1.txt',' ')
[Residue,
MC,
MassDig,
Sequence,
Mod,
Mod2] =textread('digest1.txt','%s %f %f %s %s
%s');
[MassHSA
, ZT] =textread('HSA_Raw1.txt','%f %s');
[Gmod, K1,
K2,
R1,
R2,
MassMod] = textread('ModSearch1.txt', '%s %f %f %f %f %f');
sizeHSAMass =size(MassHSA);
sizeDigMass = size(MassDig);
%calcualting the difference
for i=1:1:sizeHSAMass(1);
for j=1:1:sizeDigMass(1);
Difference(i,j) = MassHSA(i) - MassDig(j);
end
end
%calculating the error
sizeDifference=size(Difference);
k=0;
for i=1:1:sizeHSAMass(1);
for j=1:1:sizeDifference(2);
error(i,j) = (Difference(i,j)/MassHSA(i)) * 1e6;
if ((error(i,j) > -50) && (error(i,j) < 50));
k=k+1;
% digestmatch_result(k,:) =
[Residue(j),Sequence(j),Mod(j),Mod2(j),MC(j),MassDig(j),MassHSA(i),ZT(i),error(i,j)];
digestmatch_result(k,:) = [Residue(j) Sequence(j) Mod(j) Mod2(j) MC(j) MassDig(j) MassHSA(i)
ZT(i) error(i,j)];
end
end
end
%This is for generating a list of modified peptides by adding the mass if
%the AGE to the mass of the theoretical digest.
sizeModMass = size(MassMod);
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Table 3.4a, continued. Code for program “digestmatch.m”
for i=1:1:sizeDigMass(1);
for j=1:1:sizeModMass (1);
Mass2(i,j)=MassDig(i)+MassMod(j);
end
end
sizeMass2=size(Mass2);
% Computes a new digest table based by adding the mass of all modifications
% to the mass of the digest. Outputs values as DigestMOD. Use DigestMOD to
% generate a new table (text file) for calculting and filtering error values
h=0;
for i=1:1:sizeDigMass(1);
for j=1:1:sizeMass2(2);
h=h+1;
DigestMOD(h,:)=[Residue(i), MC(i),MassDig(i), Mass2(i,j),Sequence(i), Gmod(j), MassMod(j), K1(j),
K2(j), R1(j), R2(j)];
end
end
outfile = fopen('DigestMod.txt','wt');
sizeDigesMod= size(DigestMOD);
for i=1:1:sizeDigesMod(1)
fprintf(outfile, '%s \t %f\t %f\t %f\t %s\t
1},DigestMOD{i, 2},DigestMOD{i, 3},DigestMOD{i,
7},DigestMOD{i, 8},DigestMOD{i, 9},DigestMOD{i,
% fprintf(outfile, '%s %s %s %s %s %s %s %s
3),DigestMOD(i, 4),DigestMOD(i, 5),DigestMOD(i,
9),DigestMOD(i, 10),DigestMOD(i, 11));
% fprintf(outfile,'%f\n',DigestMOD{i, 2});
end
fclose(outfile);

%s\t %f\t %f\t %f\t %f\t %f\t \n', DigestMOD{i,
4},DigestMOD{i, 5},DigestMOD{i, 6},DigestMOD{i,
10},DigestMOD{i, 11});
%s %s %s \n', DigestMOD(i, 1),DigestMOD(i, 2),DigestMOD(i,
6),DigestMOD(i, 7),DigestMOD(i, 8),DigestMOD(i,
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Table 3.4a, continued. Code for program “digestmatch.m”
outfile = fopen('digestmatch_result.txt','wt');
sizedigestmatch_result=size(digestmatch_result);
for i=1:1:sizedigestmatch_result(1);
fprintf(outfile, '%s\t %s\t %s\t %s\t %f\t %f\t %f\t %s\t %f\t \n',
digestmatch_result{i,1},digestmatch_result{i,2},digestmatch_result{i,3},digestmatch_result{i,4},digestmatch
_result{i,5},digestmatch_result{i,6},
digestmatch_result{i,7},digestmatch_result{i,8},digestmatch_result{i,9});
end
fclose(outfile);
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Table 3.5a. Code for program “suspect_mod_sites.m”
%Mdata=dlmread('data1.txt', ' ')
[Residue, MC, MassDig, Mass2, Sequence, Gmod, MassMod, K1, K2, R1, R2]=textread('digestMOD.txt', '%s %f %f
%f %s %s %f %f %f %f %f');
[MassHSA
, ZT] =textread('HSA_Raw1.txt','%f %s');
sizeHSAMass=size(MassHSA);
sizeMass2=size(Mass2);
%Caluculating error in ppm
h=0;
for i=1:1:sizeHSAMass;
for j=1:1:sizeMass2;
error(i,j)=((Mass2(j)-MassHSA(i))/MassHSA(i))*10^6;
if ((error(i,j)>-50) && (error(i,j)<50));
h=h+1;
char_seq= char(Sequence(j));
AA=aacount(char_seq);
error_match(h,:)=[error(i,j), Residue(j), MC(j), Sequence(j), MassDig(j), MassHSA(i), ZT(i),
Gmod(j), MassMod(j), K1(j), K2(j), R1(j), R2(j)];
if K1(j)==1 && K2(j)==0 && R1(j)==0 && R2(j)==0;
if AA.K >= 1;
error_matchK(h,:)=[error(i,j), Residue(j), MC(j), Sequence(j), MassDig(j), MassHSA(i),
ZT(i), Gmod(j), MassMod(j), K1(j), K2(j), R1(j), R2(j)];
end
end
if R1(j)==1 && K1(j)==0 && K2(j)==0 && R2(j)==0;
if AA.R >= 1;
error_matchR(h,:)=[error(i,j), Residue(j), MC(j), Sequence(j), MassDig(j), MassHSA(i),
ZT(i), Gmod(j), MassMod(j), K1(j), K2(j), R1(j), R2(j)];
end
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Table 3.5a, continued. Code for program “suspect_mod_sites.m”
end
if K2(j)==1 && R1(j)==0 && K1(j)==0 && R2(j)==0;
if AA.K >= 2;
error_matchK2(h,:)=[error(i,j), Residue(j), MC(j), Sequence(j), MassDig(j), MassHSA(i),
ZT(i), Gmod(j), MassMod(j), K1(j), K2(j), R1(j), R2(j)];
end
end
if R2(j)==1 && K2(j)==0 && R1(j)==0 && K1(j)==0;
if AA.R >= 2;
error_matchR2(h,:)=[error(i,j), Residue(j), MC(j), Sequence(j), MassDig(j), MassHSA(i),
ZT(i), Gmod(j), MassMod(j), K1(j), K2(j), R1(j), R2(j)];
end
end
if K1(j) >= 1 && R1(j) >= 1 && K2(j)==0 && R2(j)==0;
if AA.K >= 1 && AA.R >= 1;
error_matchKR(h,:)=[error(i,j), Residue(j), MC(j), Sequence(j), MassDig(j), MassHSA(i),
ZT(i), Gmod(j), MassMod(j), K1(j), K2(j), R1(j), R2(j)];
end
end
end
end
end
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CHAPTER 4

CHARACTERIZATION OF GLYCATION SITES ON IN
VITRO GLYCATED HUMAN SERUM ALBUMIN USING
MASS SPECTROMETRY

4.A. INTRODUCTION
This chapter used the optimized methods for identifying glycation sites that were
developed in Chapter 3, to identify early glycation adducts that occurred on human serum
albumin with varying degrees of glycation. Typically, when external calibration is used, a
maximum allowed error of 50 ppm is used for matching a theoretical digest table to m/z
values within a given mass spectrum. By using internal calibration, a maximum allowed
error of 25 ppm could be used. The increased mass accuracy that was obtained with
internal calibration allowed for increased confidence in the assignment of many modified
residues. Glycation product heterogeneity was also found to be a critical factor for
glycation site assignment, because there were many peptide and glycation product
combinations that overlapped at a very similar mass. In these cases, searching a broad list
of modifications was necessary because it allowed these different combinations to be
taken into account. The higher mass accuracy that was obtained when internal calibration
was used allowed for better differentiation between these glycated peptides. Additionally,
by searching for peptides that were unique to the glycated HSA samples, it was possible
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to assign modification sites that arise from the experimental conditions. By applying the
aforementioned techniques to this current analysis, glycation sites can be assigned to
HSA with greater confidence.
This chapter focuses on early glycation, which occurs on the primary amine
groups on proteins (i.e., lysines or the N-terminus) (1, 2). Early-stage glycation involves
the formation of a Schiff base which forms when free sugars react with these primary
amine groups. The Schiff-base is unstable and subsequently rearranges to form the more
stable Amadori product (3-5). When glucose is used as a reagent, this Amadori product
will take the form of fructosyl-lysine (FL) or dehydrated fructosyl-lysine (i.e., FL-1H2O
or FL-2H2O). While this process is has been well studied in numerous proteins (6-15),
little has been done to characterize these reactions on HSA (2, 16-18). Additionally,
comparisons to see whether glycation of HSA that occurs in vitro is similar to glycation
of HSA that that occurs in vivo has not yet been done. This study therefore provides
preliminary information that can be used for this comparison.
For this study, glycated HSA was prepared in vitro under physiological
conditions. The HSA that was used for this study was collected after two, four, or five
weeks of incubation. These time periods were selected because it should yield HSA that
has similar glycation patterns to HSA that is identified in vivo, given its half life (~ 2 - 4
weeks) (1). Techniques that were previously used to obtain high sequence coverage for
HSA (19) and accurate glycation site assignment (20) were both used in this approach.
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4.B. EXPERIMENTAL
4.B.1. Materials. HSA (99%, essentially fatty acid and globulin free), guanidine-HCl
(99%), ammonium bicarbonate (99%), tris-HCl (99%), potassium phosphate monobasic
(99%), potassium phosphate dibasic (99%), dithiothreitol (99%), iodoacetamide (99%),
D-glucose (99%), sodium azide (99%), trifluoroacetic acid (98%), formic acid (96%),
molecular biology grade water (DNase, RNase, and protease free), methanol (HPLC
grade, 99.9%), and acetonitrile (HPLC grade, 99.9%) were all purchased from SigmaAldrich (St. Louis, MO). The enzymes which were used for this study; sequence grade
trypsin, Glu-C and Lys-C, were also purchased from Sigma-Aldrich. The glycated serum
protein enzymatic assay was purchased from Diazyme Laboratories (Poway, CA).
4.B.2. Apparatus. Siliconized low retention microcentrifuge tubes (0.6 mL and 1.5 mL),
Pierce Slide-A-Lyzer dialysis cassettes (7 kDa MWCO, 0.1 – 0.5 mL and 0.5 – 3 mL),
Millipore µ-C18 Zip-tip pipette tips (0.2 µL bed volume), 0.20 µm nylon filters, and BioRad 10 DG size exclusion columns (10 mL) were all obtained from Fisher Scientific
(Pittsburgh, PA). Mass spectrometry data was collected on a Voyager 6148 MALDITOF-MS system (Applied/Perspective Biosystems, CA). Positive ion delayed extraction
mode was used with an accelerating voltage of 25 kV, a grid wire voltage which was
0.008% of the accelerating voltage, a grid voltage which was 77% of the accelerating
voltage, and a delay time of 100 nanoseconds. Matlab 2009a which included the
bioinformatics toolbox was purchased from Mathworks (Natick, MA). Mascot wizard
was obtained from the matrix science website (21).
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4.B.3. Preparation of glycated HSA. Glycation was initiated by incubating a
physiological concentration of HSA (42 g/L) with a 15 mM glucose solution. The
glucose solution was prepared in pH 7.4, 200 mM phosphate buffer which also contained
1 mM sodium azide (Note: sodium azide was added to prohibit bacterial growth. This
HSA solution was divided into several portions and incubated at 37 °C. HSA samples
containing three different levels of total glycation was examined in this report. To make
these samples, the starting HSA/glucose solution was divided into several portions and
incubated at 37 °C for two or five weeks, which gave the “HSA-2” and “HSA-5” samples
used in this report. A control sample was prepared under identical conditions by using a
solution of 42 g/L HSA dissolved in the same pH 7.4 buffer with sodium azide (but
without the addition of glucose) and that was incubated for five weeks at 37 °C. A third
glycated HSA sample was prepared under these conditions but now using a total added
glucose concentration of 30.7 mM and an incubation time of 4 weeks; these conditions
provided the “HSA-4” sample that was used in this report. A second control sample of
HSA was also prepared under these latter conditions but in the absence of any glucose.
The conditions used here were selected because HSA has a half-life in the body of
approximately 3 weeks (1). The HSA incubated over a 2-week, 4-week, and 5-week
periods were therefore selected because these samples would mimic the maximum
amount of time that HSA spends in the body in vivo.
The HSA was isolated from the reagent solution using a combination of sizeexclusion chromatography (SEC) and equilibrium dialysis. First, a 10 DG size exclusion
column was washed with 20 mL of water followed by loading the column with 3 mL of
the incubated HSA solution. A 5 mL portion of water was then added to the SEC column
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to elute the protein, where this fraction was collected. A 2.5 mL aliquot of this eluent was
then transferred to 0.5 – 3 mL dialysis cassettes, and these samples were dialyzed
extensively against two 1000 mL portions of nanopure water for 2 h at room temperature.
An additional dialysis was then performed overnight at 4 °C. The solution was then
removed from the dialysis cassette, lyophilized, and stored at 4 ºC for later use.
4.B.4 Assay of the extent of glycation. The total amount of glycation in each HSA
sample was determined using a glycated serum protein assay which was obtained from
Diazyme Laboratories (Poway, CA). In this assay, glycated proteins were first cleaved
into glycated peptides using a proteinase K. Fructosaminase was then added to oxidize
these glycated peptides to form glucosone while catalyzing the production of hydrogen
peroxide from oxygen. The amount of hydrogen peroxide produced was measured by
observing the absorbance when hydrogen peroxide reacts with Trinder’s reagent (i.e., a
mixture of N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline sodium and 4-amino1,5-dimethyl-2-phenyl-pyrazol-3-one) in the presence of horse radish peroxidase to form
a colored compound (22, 23). The fructosamine assay kit included two proprietary
reagents (i.e., reagent 1 and reagent 2) and standards containing known amounts of
fructosamine.
To perform this assay, 20 µL of either a saline blank, standards with known
fructosamine concentrations, or HSA dissolved in pH 7.4, 25 mM phosphate buffer
(Note: The concentration of HSA was either 42 or 60 g/L depending on whether the
absorbance fell within the range of the calibration curve) were mixed with 200 µL of
Reagent 1. This mixture was incubated for 5 minutes using a temperature controlled UV
that was set to 37 ºC. At this time, the absorbance at 600 nm (A600) and 700 nm (A700)
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were obtained. A 50 µL aliquot of Reagent 2 was added to the mixture, and the resulting
solution was incubated for another 5 minutes at 37 ºC. The A600 and A700 values were then
obtained. Corrections were made for both light scattering and fructosamine dilution in
this analysis. The correction for light scattering was made by subtracting the A700 from
the A600, and the fructosamine dilution that occurred when Reagent 2 was added to the
mixture was corrected by multiplying the 5 minute absorbance value (Note: this value
was corrected for light scattering) by 0.815. A calibration curve was then developed
using these corrected absorbance values and standard beers law calculations. The extent
of glycation, as given in units of moles of hexose per mol of HSA, was then determined
by dividing the fructosamine concentration by the known HSA concentration.
4.B.5. HSA alkylation and digestion. The glycated HSA samples and corresponding
control samples were all pretreated and digested using the same procedure, equipment
and reagents to minimize any differences in digestion patterns due to changes in the
experimental conditions. Molecular biology grade water was used to prepare ph 8.5, 100
mM ammonium bicarbonate buffer. Solutions containing 6 M guanidine-HCl or 1 M
dithiothreitol were prepared using this ammonium bicarbonate buffer. A solution
containing 1 M iodoacetamide (IAM) and 1 M NaOH was also prepared using nanopure
water. HSA was first reconstituted to a concentration of 3 mg/mL with guanidine-HCl
solution. The resulting solution was gently mixed using a vortex genie mixer. A 15 µL
aliquot of DTT reagent was then added to the HSA solution. This solution was incubated
at 37 °C for 1 hr, after which 36 µL of the IAM/NaOH reagent was added to the HSA
solution. The resulting solution was then incubated in the dark at room temperature for 30
minutes. Following this incubation, an additional 150 µL of DTT reagent was added to

126
the mixture. The HSA solution was then divided into 0.5 mL portions, where each
portion was transferred to 0.1 – 0.5 mL dialysis cassettes. Dialysis was performed on
these portions against three 1000 mL portions of nanopure water, where each dialysis was
performed for 4 h. The dialyzed HSA samples were then divided into 50 µL aliquots,
which contained 100 µg of HSA per aliquot, and placed into low-retention
microcentrifuge tubes. These aliquots were then reduced to dryness by using Speedvac.
The resulting HSA samples (i.e., pretreated HSA) were then stored at -80 °C until later
use. The pretreatment procedure was done on both the control and glycated HSA
samples.
Stock enzyme solutions containing 1 mg/mL of trypsin, Lys-C, or Glu-C were
prepared in nanopure water. A pH 7.8, 100 mM ammonium bicarbonate buffer and a pH
9.0, 75 mM tris-HCl buffer was also prepared. For the trypsin digest, 200 µL of
ammonium bicarbonate buffer was added to vials pretreated HSA or glycated HSA. Each
vial of reconstituted HSA solution was vortexed for 3 – 5 minutes. A 3.3 µL portion of
trypsin stock solution was then added to each reconstituted HSA sample, giving substrate
to enzyme ratios of ~ 30 to 1. These solutions were incubated at 37 °C for 18 h. A 10 µL
aliquot of concentrated formic acid was then added to each HSA solution. The resulting
HSA digests were stored at -80 °C until later use.
For the Glu-C digest, 200 µL of a pH 7.8, 100 mM ammonium bicarbonate buffer
was added to vials of pretreated HSA or glycated HSA. Each vial of reconstituted HSA
solution was vortexed for 3 – 5 minutes. A 10 µL portion of Glu-C was then added to
each reconstituted HSA sample and the solutions were incubated at 37 °C for 8 h.
Another 5 µL portion of Glu-C was added to each HSA sample, giving a final substrate to
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enzyme ratios of 7 to 1, and the resulting solutions were incubated for an additional 18 h.
A 10 µL aliquot of concentrated formic acid was then added to these digests and the
resulting solutions were stored at -80 °C.
For the Lys-C digest, 200 µL of 75 mM tris-HCl buffer (pH 9.0) was added to
vials of pretreated HSA or glycated HSA. Each vial of reconstituted HSA solution was
vortexed for 3–5 minutes.

A 5 µL portion of Lys-C was added to each vial of

reconstituted HSA and the resulting mixtures were incubated at 37 °C for 18 h. The
digestions were terminated by acidifying and freezing the mixture as previously
described.
4.B.6. Collection and analysis of mass spectrometry data. The matrix that was used for
MALDI consisted of a mixture of α-cyano-4-hydroxycinnamic acid (CHCA) and 2,3dihyroxybenzoic acid (DHB). A solution containing 20 mg/mL CHCA and 5% formic
acid was prepared in a 70:30 (v/v) mixture of acetonitrile and nanopure water. Similarly,
a solution containing 20 mg/mL DHB and 0.1% TFA was prepared in a 70:30 (v/v)
mixture of acetonitrile and nanopure water. Both matrix solutions were mixed vigorously
2 – 3 minutes using a vortex-genie mixer and combined in a 50:50 (v/v) ratio. A stock
calibration mixture (calmix), which contained 32.5 pM glu-fibrinopeptide (1570.6774
Da), 25 pM des-Arg-bradykinin (904.4681 Da), and 32.5 pM angiotensin I (1296.6853
Da) was prepared in 100% acetonitrile. A calibrant spiked matrix solution was prepared
by adding 4 µL of the calmix solution to 96 µL of the matrix. This spiked matrix solution
was placed on every adjacent row of a 96-well MALDI plate (i.e., these were placed in
positions that were adjacent to the HSA samples).
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Solutions of 5, 10, 20, 30 and 50 % ACN were prepared in nanopure water.
Concentrated TFA was added to each of these solutions, yielding a final TFA
concentration of 0.1%. A separate wetting solution of 50% ACN was prepared in filtered
nanopure water. An equilibration solution of 0.1% TFA in nanopure water and a wash
solution of 5% methanol and 0.1% TFA in nanopure water were also prepared. A Zip-tip
was wet with two 10 µL portions of the wetting solution, and then equilibrated with two
10 µL portions of the equilibration solution. A 10 µL aliquot of the HSA digest was then
loaded onto the Zip-tip by using 10 aspirate-dispense cycles. The Zip-tip was then
immediately washed with two 10 µL portions of the wash solutions. A 1 µL portion of the
5% ACN solution was then placed into a low retention microcentrifuge tube, and peptide
elution was performed by passing this solution through the Zip-tips with 3 aspiratedispense cycles. The eluted peptides were mixed with 1 µL of the spiked matrix solution
and 0.80 µL of the resulting mixture was spotted onto a 96-well MALDI plate. The Ziptip was washed 3 times with 4 µL of the same ACN solution that was used to elute the
peptides. The elution process was then repeated by using consecutively higher ACN
gradients. All of the mass spectra acquired were first externally calibrated using the
calibration spots on the adjacent rows, then internally calibrated by using the spiked
calibrant masses that were found in the mass spectra for the HSA samples. An evaluation
of unspiked HSA samples shows that there is no overlap in the m/z values for the
calibrants and the HSA-derived peptides. An error of 25 ppm was found to be sufficient
for peptide mass matching when this technique is used (20).
Raw mass values from each mass spectrum were extracted using Mascot Wizard
and these values were compared to an expanded modification list by using a program
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written in Matlab. Details of this program are described in Chapter 3 (20). The glycation
adducts and AGE adducts that were examined are shown in Chapter 3 (Table 3.1). Only
the unique peptides which were found in HSA-2, HSA-4, or HSA-5 samples were
matched to this search list. To determine which peptides were unique, a separate Matlab
program was used to compare the extracted mass list obtained for the glycated HSA
samples to the control HSA samples and match these masses at 50 ppm. The peaks in the
glycated sample that did not match were selected for further analysis, where any modified
residues which matched at 25 ppm were considered to be potential glycation sites (See
Figure 3.4 for an example of this assignment).
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4.C. RESULTS
4.C.1. Fructosamine assay and sequence coverage. The moles of hexose condensed per
moles of HSA increased in a linear fashion over a 3-week period, after which the rate of
glucose incorporation began to slow down (See Figure 4.1). Using this assay, it was
found that the HSA-2 sample had 0.7 (± 0.1) mol hexose/mol HSA, the HSA-4 sample
had 3.4 (± 0.1) mol hexose/mol HSA, and the HSA-5 sample had 1.2 (± 0.1) mol
hexose/mol HSA.
The sequence coverage obtained for the HSA and glycated HSA samples are
summarized in Figure 4.2. For the HSA-C sample, the tryptic, Lys-C and Glu-C digests
covered 78%, 47% and 56% of the primary sequence of HSA respectively. Similarly,
multienzyme digestion of the HSA-2 gave a sequence coverage of 63%, 49% and 44%
and digestion of the HSA-5 sample gave a sequence coverage of 54%, 44% and 49% for
the trypsin, Lys-C, and Glu-C digests respectively. The sequence coverage obtained for
the HSA-4 sample was 69%, 45%, and 55% for the trypsin, Lys-C, and Glu-C digest
respectively. When multienzyme digestion was considered, the total sequence coverage
for the HSA-C, HSA-2, HSA-4, and HSA-5 samples were 90%, 81%, 84%, and 82%
respectively. A decreased coverage for the glycated HSA samples was expected because
glycation induced mass shifts would result in some peptides being undetectable. The
coverage for the HSA-2, HSA-4 and HSA-5 samples all increased to approximately 86%
when the assigned glycated adducts were factored into the sequence coverage calculation.
4.C.2. Mass shifts identified on the HSA samples. Table 4.1 summarizes the peptides
that were identified at all three stages of glycation. There some instances where early-
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Figure 4.1. The extent of glycation that was determined using the enzymatic
fructosamine assay. The results are expressed as the moles of hexose per
moles of HSA as a function of time.
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Figure 4.2. Sequence coverage for the control HSA and the glycated HSA samples. The
sequence coverage obtained when all four HSA samples are considered is
shown in bold. The sequence coverage obtained for the HSA control sample
is shown in CAPS, the coverage obtained for the HSA-2 sample is
underlined, the coverage obtained for the HSA-4 sample is highlighted,
and the coverage obtained for the HSA-5 sample is designated with a line
over the amino acid sequence. Peptides that were linked to modification sites
were factored into the sequence coverage that is shown for the HSA-2,
HSA-4, and HSA-5 samples.
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1 –

dahkSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV

41 –

KLVNEVTEFA Ktcvadesae NCDKSLHTLF GDKLCTVATL

81 –

RETYGEMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV

121 –

DVMCTAFHDN EETFLKKYLY EIARRHPYFY APELLFFAKR

161 –

YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC

201 –

ASLQKFGERA FKAWAVARLS QRFPKAEfae vsklvtdltk

241 –

VHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE

281 –

KPLLEKSHCI AEVENDEMPA DLPSLAADFV ESKdvckNYA

321 –

EAKDVFLGMF LYEYARRHPD YSVVLLLRLA KTYETTLEKC

361 –

CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE

401 –

YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH

441 –

PEAKRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES

481 –

LVNRRPCFSA LEVDETYVPK EFNAETFTFH ADICTLSEKE

521 –

RQIKKQTALV Elvkhkpkat keqlkAVMDD FAAFVEKcck

561 –

ADDKETCFAE EGKKlvaasq aalgl

HSA-5

HSA-2

Table 4.1. Suspect modification sites that were found on glycated HSA. The most likely modification sites are given in bold.
Residues

Lysine

Arginine

Suspect Modification Sitesa

Trypsin

1-10

N+, K4

R10

N+ (FL-1H2O) & R10 (AFGP) or N+ (AFGP) & R10 (3-DG-H1 or THP)

Trypsin

182-195

K190, K195

K186

K190 & K195 (FL & CML)

275-286

K276, K281, K286

n/a

K276 & K286 (FL & FL-1H2O)

539-557 or 542-560

K541, K545, K557, K560

n/a

K545 & K557 (FL-2H2O & FL-2H2O) or (FL-1H2O or Pyr)

565-585

K573, K574

n/a

K573 & K574 (Pyr*2 or CEL & FL-1H2O)

Glu-C

278-292

K281, K286

n/a

K281 & K286 (FL & CEL) or (FL-2H2O & Pyr)

Glu-C

83-100

K93, R98

R98

K93 (FL-2H2O) or K93 (CEL) & R98 (MG-H1)

Lys-C

196-205

K199, K205

R197

K199 & K205 (FL & FL-1H2O) or K199 (FL) & R197 (3-DG-H1 or THP)

Lys-C

414-432

K414, K432

R428

K414 & K432 (FL-1H2O & AFGP) or K414 (AFGP) & R428 (3-DG-H1 or THP)

Trypsin

182-195

K190, K195

R186

K190 & K195 (FL & CML)

275-286

K276, K281, K286

n/a

K276 & K286 (FL & FL-1H2O)

Glu-C

281-294

K281, K286

n/a

K281 & K286 (FL-2H2O & CEL)

Lys-C

5-12

K12

R10

K12 (FL-1H2O) & R10 (MG-H1)

Lys-C

525-534

K525, K534

n/a

K534 (FL-1H2O) or K525 (CEL) & K534 (CEL)

Lys-C

5-20

K12, K20

R10

K12 (FL)

Lys-C

277-286

K281, K286

n/a

K281 & K286 (FL & FL-1H2O)

Lys-C

414-432

K414, K432

R428

K414 & K432 (FL-1H2O & AFGP) or K414 (AFGP) & R428 (3-DG-H1 or THP)

Trypsin
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Digest

Table 4.1 (continued). Suspect modification sites that were found on glycated HSA. The most likely modification sites are given in

HSA-4

bold.

a

Digest

Residues

Lysine

Arginine

Suspect Modification Sites

Trypsin

206-212

K212

R209

K212 (FL-2H2O) or R209 (MG-H1) & K212 (CEL)

Trypsin

1-12

N+, K4, K12

R10

N+ & K12 (CEL & FL-2H2O) or N+ (FL-1H2O) & R10 (MG-H1)

200-212

K205, K212

R209

K205 (CML) & R209 (ArgP)

403-413

K413

R410

K413 or R410 (AFGP), or K413 (FL-2H2O) & R410 (3-DG-H1 or THP)

175-186

K181

R186

K181 (FL-1H2O) & R186 (ArgP)

Trypsin

546-560

K557, K560

n/a

K557 & K560 (CML & FL-1H2O)

Trypsin

258-274

K262, K274

n/a

K274 (FL-1H2O) or K262 (CEL) & K274 (CEL)

160-174

K162, K174

R160

K162 or K174 (FL)

Lys-C

526-536

K534, K536

n/a

K534 & K536 (CML & FL-1H2O)

Lys-C

501-519

K519

n/a

K519 (FL)

Glu-C

557-571

K557, K560, K564

n/a

K557 & K564 (FL & CML)

Glu-C

426-442

K432, K436, K439

R428

K436 (FL)

Glu-C

83-100

K93, R98

R98

K93 (FL-2H2O) or K93 (CEL) & R98 (MG-H1)

– In some instances, a given m/z value could be linked to multiple modifications. The most likely modification sites, which were
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identified based on pKa and FAS data, are given in bold.
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stage glycation products could be assigned to peptides with a high level of certainty. For
example, a m/z value of 1850.97 Da was identified in the HSA-5 sample (Glu-C digest).
This mass was assigned to residues 281-294 on HSA which was modified to form NεCarboxyethyl-lysine (CEL) and dehydrated fructosyl-lysine (FL-2H2O). The only lysines
on this residue that are available for modification are K281 and K286, hence the
formation of FL-2H2O or CEL could occur on either residue. Another example of this
scenario was found on residues 5-12 in the HSA-5 sample. A mass of 1171.591 Da was
detected, which corresponds to residues 5-12 being modified to form FL-1H2O and a Nε(5-Hydro-5-methyl-4-imidazolon-2-yl)ornithine (MG-H1). In this case K12 is being
modified to form FL-1H2O and R10 is being modified to form MG-H1 because these
residues are the only lysine and arginine residues that are found in this peptide. Similar
observations were made in the HSA-4 sample, where early glycation adducts could be
assigned to K93, K557 or K560, and K519.
There were many cases where m/z values could be mapped to different glycation
adducts that resulted in the same m/z shift. For example a raw mass of 2107.95 Da was
identified in the Glu-C digest for the HSA-2 sample, which corresponds to earlyglycation occurring on regions 278-292 on HSA. The first modification involved the
addition of FL and CEL moieties, which would result in a mass shift of 234.07 Da, and
the second modification involved the addition of FL-2H2O and Pyr moieties, which
would result in a mass shift of 234.05 Da. At the assigned mass accuracy of 25 ppm,
these two mass values couldn’t be differentiated, so it is possible that this m/z value could
represent either of the two possibilities. Similarly a peptide encompassing residues 414432 (2466.27 Da) in the Lys-C digest was found to be modified to form FL-1H2O and 1-
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Alkyl-2-formyl-3,4-glycosyl-pyrrole (AFGP). This peptide contains two lysines (K414
and K432) and one arginine (R428) which are able to undergo modification. Since AFGP
is reactive with both lysine and arginine residues, there is one possible scenario where
these modifications are occurring on K414 and K432 and there is another scenario where
FL-1H2O is occurring on either K414 or K432, and AFGP is occurring on R428.
Situations were also present, where different peptides having varying
modifications could also overlap at the same mass, at the given mass accuracy of 25 ppm.
For example, a peptide having a m/z value of 1622.81 Da was detected in the trypsin
digest of the HSA-4 sample. When only early glycation is considered, this mass could
result from residues 1-12, 403-413, and 175-186 being modified to form FL-2H2O and
CEL, FL-2H2O and Nε-[5-(2,3,4-Trihydroxybutyl)-5-hydro-4-imidazolon-2-yl]ornithine
(3-DG-H1) or tetrahydropyrimidine (THP), and FL-1H2O and argpyrimidine (ArgP)
respectively. The HSA-2 and HSA-5 samples also had peptides which showed the same
characteristics. For example, two residue clusters which encompass regions 182-195 and
275-286, or regions 539-560 and 565-585 were identified at the same m/z value on the
HSA-2 sample. Similarly, residues 182-195 and 275-286 were both linked to the same
m/z value in the HSA-5 sample.
When looking at the total number of early-stage glycation products that were
identified in the glycated HSA samples, the HSA-2, HSA-5, and HSA-4 samples were
modified to form 7, 7, or 9 glycated peptides respectively. The assignment of many of
these peptides, however, was not certain because some early-stage and late-stage
glycation adduct combinations overlap at the same mass. If these overlapping peptides
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are not considered, the number of early glycation adducts that were assigned to the HSA2, HSA-5, and HSA-4 sample reduced to 3, 5, and 5 glycated peptides respectively.
4.C.3. Location of the most likely glycation sites based on pKa and FAS data.

It is

clear from the above results that assigning glycation adducts from only the mass shift
data is not adequate for identifying the most likely glycation sites. Information regarding
the glycation-induced mass shifts can be combined with known information about the
pKa and fractional accessible surface area (FAS) of each residue to determine the most
probable source of glycation. The pKa and FAS values for residues that were linked to
m/z shifts are summarized in Table 4.2, where these values were determined using
methods that have been described in the literature (2, 24, 25). It is expected the lysines
having high FAS and low pKa values would facilitate glycation because these lysines are
more exposed to the solvent and because a greater number of lysines would be
deprotonated. The pKa range of lysine residues on HSA is between 6.2 and 11 with an
average pKa of 10.08. The FAS range for lysine residues is between 0.01 – 0.96 with an
average FAS of 0.51.
An example of pKa assignment is shown on residues 1-10 on HSA 2 sample. This
residue contains the N-terminus and K4, both of which are able to interact with the earlyglycation products. This peptide also contains R10 which is able to interact with latestage Maillard products. The pKa of the N-terminus is 7.79 compared to a pKa of 10.53 for
K4, indicating that the N-terminus is the most likely modification site. In situations where
multiple peptides and glycation product combinations overlapped at the same m/z value,
pKa assignment was also used to determine which peptide had the highest chance of
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Table 4.2. Calculated pKa and FAS values for amino-acids which are believed to be

pKa
7.79
10.53
10.43
10.43
10.36
10.43
10.43
10.22
11.92
6.23
10.76
7.47
10.43
10.43
9.64
10.43
9.87
10.29
10.5
10.29
10.5
10.36
10.5
10.43
10.01
7.66
9.92
9.67
10.43

FAS
n/a
0.59
0.32
0.5
0.52
0.43
0.34
0.37
0.42
0.5
0.16
0.58
0.4
0.2
0.66
0.27
0.66
0.52
0.2
0.8
0.8
0.54
0.61
0.23
0.08
0.36
0.51
0.94

Lysine

Residue
N+
4
12
20
93
137
162
174
181
190
195
199
205
212
218
262
274
276
281
286
313
317
323
402
413
414
432
436
439

Arginine

Lysine

glycated.

Residue
444
519
524
525
534
536
541
545
557
560
564
573
574
10
98
144
145
160
186
197
209
218
336
410
428
445
484
521

pKa
10.36
10.43
10.43
15
11.11
10.08
10.5
10.36
10.43
11.63
10.5
10.5
10.5
16.02
11.38
15.69
11.21
13.84
11.75
14.37
12.08
9.64
15.7
12.46
11.29
11.94
10.09
14.01

FAS
0.48
0.72
0.54
0.07
0.12
0.24
0.9
0.56
0.68
0.82
0.93
0.72
0.82
0.13
0.08
0.11
0.21
0.32
0.6
0.13
0.61
0.2
0.07
0.33
0.18
0.21
0.06
0.15
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being glycated. For example, in the tryptic digest of the HSA-5 sample, a m/z value of
1738.82 Da was observed which corresponds to residues 182-195 as well as residues 275286 on HSA. Residues 182-195 were chosen as the most likely glycated peptide because
K190 had favorable pKa and FAS combinations of 6.23 and 0.42 respectively, compared
to K281 and K286 which had pKa values greater than 10.29. In other cases the combined
pKa and FAS data can be used to differentiate the likely glycation sites. For instance a
mass of 2199.80 Da was observed in the Glu-C digest of both the HSA-2 and HSA-4
samples. This mass could have resulted from modifications occurring on residues 83-100
on HSA. This region of HSA contains K93 and R98, where the detected mass shift
corresponded to the formation of either FL-2H2O or CEL and MG-H1. Arginine 98 has a
FAS value of 0.08 which is low compared to the average arginine FAS values on HSA. It
is therefore unlikely that R98 is being modified to form MG-H1. Additionally, K93 has
pKa and FAS values of 10.36 and 0.50 respectively, indicating that this residue is most
likely being modified to form FL-2H2O. Similar assignments are made throughout Table
4.1, where the most likely modification sites are shown.

4.C.4. Semi-quantitative information obtained for the most likely glycation sites and
comparison with previous data. When pKa and FAS sorting were employed, 7 peptides
were identified which could be linked to early-stage glycation products in the HSA-2
digest. Similarly 7 peptides were also identified in the HSA-5 digest and 9 peptides were
identified in the HSA-4 digest. The increase in the amount of detected peptides in the
HSA-4 digest was most likely due to the increased glucose concentration, which would
subsequently increase the concentration of all glycation related products. There were
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several cases in this study in which a given lysine or arginine residue was found to be
modified in multiple samples, such as in different digests of a particular glycated HSA
sample or in HSA samples representing different stages of glycation.. The degree of
overlap is indicative of the reactivity of a particular residue. The data that was obtained
can therefore be sorted based on the degree of overlap, in order to semi-quantitatively
rank these glycation sites. A structure of HSA showing this semi-quantitative assignment
is given in Figure 4.3. When this sorting was done, several residues were identified with
overlapping modification sites in two or more glycated HSA samples. These residues
include the N-terminus and lysines 12, 93, 190, 195, 281, 286, 414, 432, 534 and 557. A
number of lysine residues on region 182-212 on HSA were found to be modified by early
glycation adducts. These residues include K190, K195, K199, K205, and K212, where
K199 was previously identified as having significant amounts of glycation (1, 18). The
low pKa or high FAS values found on these lysines and the fact that these sites were all
assigned as glycation sites, indicate that this region of HSA may be particularly prone to
glycation. The N-terminus and K281, which were identified as modification sites in this
analysis, were also previously reported as being privileged glycation sites (1, 26).
The glycation sites that were identified in this report were compared to sites that
were previously identified using commercially glycated HSA (2, 27). Two comparisons
were made, where the first comparison was performed with mass shifts that were
identified using commercially glycated HSA (2) and the second comparison was
performed with data that was obtained from the quantitative labeling of glycated peptides
(27). The results obtained from this analysis are summarized in Table 4.3, where eight of
the peptides that were identified using this current approach were also found to be
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Figure 4.3. Structure of HSA showing the most likely glycation sites based on semiquantitative data. The most reactive residues are indicated in red followed by
the second most reactive regions indicated in purple.

526-534: K534
83-100: K93, R98

414-432: K414, K432, R428
1-12: N+, R10, K12
278-292: K281, K286
182 – 212: K190, K195, K205
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Table 4.3. Comparison of glycation sites that were found in this study, with glycation sites that were previously found on
commercially glycated HSA.

HSA Sample
HSA-5
HSA-2, HSA-5
HSA-4
HSA-4
HSA-2
HSA-5
HSA-4, HSA-5
HSA-2, HSA-5

Residue 1a
525-534
414-432
206-212
426-442
196-205
281-294
1-12, 5-12
182-195

Residue 2b
520-525
426-442
200-218
426-442
196-209
286-294
7-17
191-205

Residue 3c
525-534
415-439
206-212
415-439
n/a
n/a
n/a
n/a

Overlapping Residues
K525, K534
K432
K212
K436 or K439
K199, K205
K286
K12
K190, K195

Modification
FL, CEL
FL or AFGP
FL or AFGP
FL
FL, FL
FL or CEL
FL
FL, CMLd

a

– Residue 1 represents the region of HSA that was found to be modified by early-stage glycation products in this study.

b

– Residue 2 represents the region of HSA that was found to be modified by early-stage glycation products that was identified for

commercially glycated HSA (2).
c

– Residue 3 represents the region of HSA that was previously found to have significant levels of glycation which were quantified

using 18O-labeling mass spectrometry (27).
d

– Modifications by FL and CML that were identified using this current approach, however, CEL was found to be condensed on this

region of HSA in a previous attempt where commercially glycated HSA was used (2).
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modified in commercially glycated HSA. Of these modifications, five of these
overlapping peptides contain K525, K439, and K199, which are residues that are
expected to contain the largest amount of modification on HSA (1). While these peptides
did overlap with these privileged glycation sites, the pKa and FAS data indicated that
K534 and K436 were the most likely modification sites on their respective peptides.
Additionally, peptides containing the N-terminus and K281 were also identified within
glycated peptides using this current approach. The degree of overlap as well as the pKa
and FAS data, however, indicated that K12 and K286 are the most likely regions of
modification within these peptides. Similar cases are noted by other authors (28, 29),
where the pKa and FAS data do not always agree with the actual glycation pattern. This
disagreement can partially be explained by glycation enhancement that occurs when basic
residues which are located in the vicinity of lysines (26), or conformational changes (1)
that may alter the accessibility and pKa of a given lysine.
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4.D. SUMMARY
When the semi-quantitative sorting and the pKa/FAS trends were considered,
regions 196-205 on HSA was found to be particularly prone to glycation. This region is
also found within a major drug binding pocket on HSA; known as Sudlow site 1 (1, 30).
Lysines 190 and 199, which are found within this highly glycated region of HSA, are
known to be directly involved in the binding of certain of compounds to HSA. Similarly,
F211 and W214 are also directly involved with drug interaction within Sudlow site 1,
where modifications that were found on regions 206-212 overlap with these binding sites.
The overlap of glycation sites with known drug interaction sites on HSA indicates that
glycation may alter the interaction of many site 1 analytes with HSA. Additionally,
residues 182-195 and 281-294, which were found to be glycated in multiple instances
(See Table 4.3), are also found within Sudlow site 1 on HSA. There is also some overlap
between glycation sites and Sudlow site 2 (1, 30) on HSA. Regions 414-432 and 426442, which were identified as having high amounts of glycation in this analysis, overlap
with key drug interaction sites within Sudlow sites 2 on HSA. These interaction sites
include R410, W411, and V433, indicating that glycation would alter drug interaction
that occurs within Sudlow site 2 on HSA. This finding is in agreement with what other
authors have found, where glycation does alter the binding of HSA to various analytes
(31-33).
Several glycated peptides were identified using this current approach. The semiquantitative sorting of these residues and the pKa/FAS data indicated that N-terminus
along with lysines 12, 93, 190, 195, 281, 286, 414, 432, 534 and 557 may all contain
significant amounts of glycation. All of the privileged glycation sites (i.e., N-terminus,
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K199, K281, K439, K525) were found on glycated peptides in this analysis, however, the
pKa and FAS data does not indicate that these residues are the most likely modification
sites. This discrepancy was also noted by other authors (26, 28, 29, 34), where the
predicted pattern which is based on pKa and FAS is not always observed through
experimentation.
Several modification sites were identified in all of the glycated-HSA samples that
were examined in this chapter. Even though a high mass accuracy and unique peptides
were used for this analysis, the data that was obtained for this analysis was quite
complex. To simplify the analysis, information relating to early-stage glycation and latestage glycation were split into two chapters, where information regarding late-stage
glycation is presented given in Chapter 5. Further verification of the proposed
modification sites is given in Chapter 6, where

18

O-labeling mass spectrometry is used

quantify the relative extent of modification occurring on different regions of HSA.
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4.F. APPENDIX
A table showing the m/z shifts that were identified in the glycated HSA samples is
given. This table was generated using the raw output from the program without pKa or
FAS sorting. This table also shows the m/z values of the detected glycated peptides, the
mass of the related peptide when no modifications are present, as well as the shift in these
mass values. Instances where peptides contained both early and advanced glycation
products are also given this table.

Table 4.1a.

Peptides that were modified to form early and advanced glycation products on glycated HSA

HSA-5

HSA-2

Digest Raw Mass (Da)a

Residue

Unmodified Mass (Da)b

Suspect Adduct

∆ Mass (Da)

Trypsin

1563.71

1-10

1149.58

FL-1H2O+AFGP, AFGP+3-DG-H1, AFGP+THP

414.12

Trypsin
Trypsin

1738.83
1738.83

182-195
275-286

1518.78
1432.76

FL+CML
FL+FL-1H2O

220.06
306.10

Trypsin
Trypsin
Trypsin

2409.13
2409.13
2409.13

542-560
539-557
565-585

2175.03
2157.09
2193.12

FL-2H2O+Pyr, FL+CEL
FL-2H2O*2, FL-1H2O+Pyr
Pyr*2, CEL+FL-1H2O

234.05
252.06
216.04

Glu-C

2107.96

278-292

1873.86

FL+CEL, FL-2H2O+Pyr

234.07

Glu-C

2199.81

83-100

2073.83

FL-2H2O, CEL+MG-H1

126.03

Lys-C

1480.76

196-205

1174.67

FL+FL-1H2O, FL+3-DG-H1, FL+THP

306.10

Lys-C

2466.27

414-432

2052.18

FL-1H2O+AFGP, AFGP+3-DG-H1, AFGP+THP

414.12

Trypsin
Trypsin

1738.83
1738.83

182-195
275-286

1518.78
1432.75

FL+CML
FL+FL-1H2O

220.06
306.10

Glu-C

1850.97

281-294

1652.87

CEL+FL-2H2O

198.05

Lys-C

1171.60

5-12

973.52

FL-1H2O+MG-H1

198.05

Lys-C

1272.74

525-534

1128.70

FL-1H2O, CEL*2

144.04

Lys-C

2068.05

5-20

1905.95

FL

162.05

Lys-C

1719.74

277-286

1305.62

FL-1H2O+AFGP

414.12

Lys-C

2466.27

414-432

2052.18

FL-1H2O+AFGP, AFGP+3-DG-H1, AFGP+THP

414.12
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Table 4.1a (continued). Peptides that were modified to form early and advanced glycation products on glycated HSA

HSA-4

Digest Raw Mass (Da) a Residue Unmodified Mass (Da)b

Suspect Adductc

Δ Mass (Da)

Trypsin

980.51

206-212

854.45

FL-2H2O, CEL+MG-H1

126.03

Trypsin
Trypsin
Trypsin
Trypsin

1622.81
1622.81
1622.81
1622.81

1-12
200-212
403-413
175-186

1424.74
1484.77
1352.77
1398.78

CEL+FL-2H2O, FL-1H2O+MG-H1
CEL+ArgP
AFGP, FL-2H2O+3-DG-H1, FL-2H2O+THP
FL-1H2O+ArgP

198.05
138.03
270.07
224.07

Trypsin

1894.76

546-560

1692.74

CML+FL-1H2O

202.05

Trypsin
Trypsin

2028.93
2028.93

160-174
258-274

1704.78
1884.90

FL*2
CEL*2, FL-1H2O

324.11
144.04

Lys-C

1467.81

526-536

1265.76

CML+FL-1H2O

202.05

Lys-C

2365.07

501-519

2203.00

FL

162.05

Glu-C

1939.80

557-571

1719.70

FL+CML

220.06

Glu-C

2118.02

426-442

1955.99

FL, Pyr+MG-H1

162.05

Glu-C

2199.89

83-100

2073.83

FL-2H2O, CEL+MG-H1

126.03

a

– This column shows the detected m/z values that correspond to glycated peptides.

b

– This column shows the corresponding mass of the peptide when no modifications are present.

c

– m/z values where multiple modifications could be assigned at the same mass are shown in bold.
156

157

CHAPTER 5

CHARACTERIZATION OF ADVANCED GLYCATION
END PRODUCTS ON IN VITRO GLYCATED HUMAN
SERUM ALBUMIN USING MASS SPECTROMETRY

5.A. INTRODUCTION
This chapter examines the advanced glycation products that are found on in vitro
glycated human serum albumin (HSA). In Chapter 4, several peptides were identified on
glycated HSA that contained early glycation products (i.e., the Amadori Product and its
dehydrated forms). Based on a semi-quantitative comparison of the data, it appeared that
residues 1-12, 83-100, 182-212, 278-292, 414-432, and 526-534 are being modified. The
data indicated that lysines 93, 281, 286, 190, 195, 205, 534, 414, and 432 as well as the
N-terminus are being modified to form variants of fructosyl-lysine. When the entire data
set including early and late stage glycation were considered, the glycation pattern
obtained was very complex, where a single m/z value could yield multiple peptide and
glycation-product combinations. To simplify the analysis, the data was therefore sorted
using the known pKa and fractional accessible surface area data. Additionally the data
was separated based on whether early or late stage glycation was occurring. The data
presented in this Chapter, therefore focuses on the identification of advanced glycation
end products (AGEs) that occur, at different stages of glycation.

158
Following the initial stages of early glycation (1-5), any glucose in solution is
slowly converted to α-oxaloaldehydes. These compounds, which have been shown to be
significantly more reactive than their glucose counterparts (6-9) lead to the formation of
AGE’s. This study examines AGE’s that result from the interaction of proteins with
glyoxal, methylglyoxal, and 3-deoxyglucosone (10, 11). In some cases, reactions that
occur on the Schiff-base or the Amadori Product can also lead to the formation of AGEs.
In a previous study that looked at the rate of α-oxaloaldehyde formation from a 3
week incubation of glucose (at 37 ºC), it was found that glyoxal had the highest
concentration followed by 3-deoxyglucosone then methylglyoxal (11). From this study,
they found that incubation of a 50 mM D-glucose solution yielded µM concentrations of
α-oxaloaldehydes, where glyoxal had a 20 fold molar excess compared to methylglyoxal,
and 3-deoxyglucosone had a 2.5 fold molar excess compared to methylglyoxal. Even
though there is a large concentration difference between the initial sugar compound and
α-oxaloaldehydes, previous reports indicate that the moles of AGEs found on glycated
proteins is similar to the extent of modification found in early glycation (i.e.,
approximately 1 – 5 moles of modification per mol of HSA) (12, 13). It is therefore
expected that the HSA samples examined in this chapter should have an extent of AGE
modification that is similar to the extent of early glycation. In addition, AGEs that are
derived from glyoxal should be quite abundant, followed by 3-deoxyglucosone and
methylglyoxal derived AGEs (see Table 5.1 for an example of adducts derived from these
α-oxaloaldehyde).

Table 5.1. List of early and advanced-stage glycation products and reactive dicarbonyl compounds that result in there formation

Early-stage glycation
Fructosyl-lysine
Fructosyl-lysine-1H2O
Fructosyl-lysine-2H2O

Abbreviated
FL
FL-1H2O
FL-2H2O

Residue
Lys
Lys
Lys

∆M (Da)
162.05
144.04
126.03

Glyoxal derived adducts
Nε-Carboxymethyl-lysine
Nε-(5-Hydro-4-imidazolon-2-yl)ornithine

Abbrev.
CML
G-H1

Residue
Lys
Arg

∆M (Da)
58.01
39.99

Methylglyoxal derived adducts
Nε-Carboxyethyl-lysine
Nε-(5-Hydro-5-methyl-4-imidazolon-2-yl)ornithine
Tetrahydropyrimidine
Argpyrimidine

Abbrev.
CEL
MG-H1
THP
ArgP

Residue
Lys
Arg
Arg
Arg

∆M (Da)
72.02
54.01
144.04
80.03

3-deoxyglucosone derived adducts
Pyrraline
Nε-[5-(2,3,4-Trihydroxybutyl)-5-hydro-4-imidazolon-2-yl]ornithine
Imadazolone B
1-Alkyl-2-formyl-3,4-glycosyl-pyrrole

Abbrev.
Pyr
3-DG-H1
IB
AFGP

Residue
Lys
Arg
Arg
Arg/Lys

∆M (Da)
108.02
144.04
142.03
270.07
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The same sample preparation and data analysis steps were used for this Chapter and
Chapter 4, therefore a detailed explanation of methods that were used are not given here.
The optimizations that were examined in Chapter 3 are also applied here. In Chapter 4,
emphasis is placed on the identification and location of early-glycation adducts that were
present on glycated HSA, where both peptides that were linked specifically to early-stage
glycation products or a mixture of early and late-stage glycation products were
considered. In contrast, this chapter examines modifications that were identified that were
due to AGEs or peptides where the majority of modifications were mostly AGEs.
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5.B. RESULTS
5.B.1. Frequency of AGE Formation on Glycated HSA. A summary of the AGEs
identified using this approach is given in Table 5.2. When only the peptides that were
modified to form AGEs were considered, 2 AGE modified peptides were found in the
HSA-2 sample, 8 AGE modified peptides were identified in the HSA-5 sample, and 5
AGE modified peptides were identified in the HSA-4 sample. When peptides that include
a mixture of early and late stage glycation products were considered, 7, 6, and 9 peptides
were found to be modified in the HSA-2, HSA-5, and HSA-4 samples respectively.
There does appear to be a trend where the number of peptides that are only
modified by AGEs, increases with increasing glycation periods times. This trend is less
obvious when both early and late-stage glycation is considered. This observation is
consistent with the fact that late-stage Maillard products are formed at a fairly slow rate,
and accumulate on proteins over time (14-16). Interestingly, the HSA-5 sample had more
AGE modification compared to the HSA-4 sample, even though the HSA-4 sample was
incubated in a 2-fold excess of D-glucose compared to the HSA-5 sample. The increased
AGE content of the HSA-5 sample was an unexpected result, considering there was only
a 1 week difference in the incubation period.
The dependence of AGE formation on the total extent of glycation is a pattern that
was generally not observed when looking at the formation of early stage glycation
products (see Chapter 4). The fact that a greatest amount of AGEs were identified in the

Table 5.2.

List of AGEs that were identified in the glycated HSA samples. All three stages of glycation are shown here, which is

HSA-5

HSA-2

represented by the HSA-2, HSA-4, and HSA-5 samples

a

Digest

Residues

Lysine

Arginine

Suspect Modification Sitesa

Trypsin

390-410

K402

R410

K402 (Pyr) & R410 (G-H1)

Lys-C

206-212

K212

R209

K212 (CEL)

Trypsin

520-525

K524, K525

R521

K524 (Pyr) & R521 (G-H1)

Trypsin

210-218

K212

R218

K212 (CEL) & R218 (ArgP)

5-12

K12

R10

K12 (FL-1H2O) & R5 (MG-H1)

Trypsin

187-197

K190, K195

R197

K190 (Pyr) & R197 (ArgP)

Trypsin

137-144

K137

R144

K137 (AFGP) & R144 (ArgP)

Trypsin

324-336

n/a

R336

R336 (G-H1)

Trypsin

318-336

K323

R336

K323 (CEL) & R336 (AFGP)

Glu-C

189-208

K190, K195, K199, K205

R197

K190 or K199 (Pyr) & R197 (IB)

Glu-C

426-442

K432, K436, K439

R428

K436 (Pyr) & R428 (G-H1) or K436 (CEL) & R428 (ArgP)

– The most likely region of modification within a given peptide, as indicated by the pKa and fractional accessible surface area (FAS)
data, is also shown here in bold
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Table 5.2 (continued). List of AGEs that were identified in the glycated HSA samples. All three stages of glycation are shown here,

HSA-4

which is represented by the HSA-2, HSA-4, and HSA-5 samples
Digest

Residues

Lysine

Arginine

Suspect Modification Sitesa

Trypsin

476-484

n/a

R484

R484(IB)

Trypsin

437-445

K439, K444

R445

K439(AFGP), R445(G-H1)

138-145

n/a

R144, R145

R144 & R145 (IB & AFGP)

206-218

K212

R209, R218

K199 (FL-1H2O) & R218 (3-MG-H1) or R209 & R218 (THP & 3-MG-H1)

182-195

K190, K195

R186

K190(Pyr), R186(ArgP)

198-209

K199, K205

R209

K199(AFGP) or K199&K205 (FL & Pyr) or K199&K205 (FL-1H2O & FL-1H2O)

Trypsin

or K199 & R209 (FL-1H2O & 3-DG-H1 or THP)

a

Glu-C

312-321

K313, K317

n/a

K313 & K317 (AFGP)

Glu-C

189-208

K190, K195, K199, K205

R197

K190 (Pyr) & R197 (IB)

– The most likely region of modification within a given peptide, as indicated by the pKa and FAS data, is also shown here in bold

163

164
HSA-5 sample indicated that the amount of AGEs formed was more dependent on the
amount of time used for HSA-glucose incubations than the concentration of D-glucose
that was used. There were some cases where peptides could be assigned to more than one
glycation product. This ambiguity in the assignment of modification sites occurred
because certain m/z values could be linked to multiple peptide/AGE combinations at the
maximum allowed error limit of 25 ppm. The assignment of multiple peptide/AGE
combinations to the same mass value is related to a range of processes including the mass
accuracy (17), level of AGE heterogeneity (18), and the selectivity of this current
approach (see Chapter 3).
5.B.2. AGEs Identified on the glycated HSA samples. There were several cases
where AGE formation could be identified solely based on the mass shift data. This type
of assignment was common in this chapter because only AGE-related compounds were
considered, and repeat assignments (i.e, for m/z values that were linked to both early and
late stage glycation in Chapter 4) were not considered. For instance, a peptide having a
mass of 2690.4 Da was detected in the trypsin digest of the HSA-2 sample. This mass
value indicated that residues 390-410 was being modified to form pyrraline (Pyr) and N_(5-Hydro-4-imidazolon-2-yl)ornithine (G-H1). Since this peptide contained one lysine
and one arginine residue, G-H1 and Pyr were assigned to R410 and K402 respectively.
Similarly a mass of 1280.49 Da was identified in the tryptic digest of the HSA-4 sample.
This m/z value corresponded to a mass shift of 142 Da that occurred on residues 476-484
on HSA. This mass shift indicated that residues 476-484 were being modified to form
imadizolone B (IB), which is specific for arginine residues. Since residues 476-484
contain a single arginine, R428 was being modified to form IB. AGEs could also be
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assigned with little ambiguity to lysine or arginine residues in the HSA-5 sample. For
example, a m/z value of 1679.8 Da was identified in the tryptic digest of the HSA-5
sample. This m/z value corresponded to residues 324-336 on HSA was being modified to
form G-H1. Since there is only a single arginine on this peptide, R336 was found to be
modified to form G-H1. Similar assignments were made on several peptides in the
glycated HSA samples, where AGE assignment on residues 206-212, 137-144, and 318336 were fairly straight forward.
There were several instances where assigning a particular modification site was
difficult, because either multiple modifications overlapped to give the same mass, or
because the modified peptide had multiple lysine or arginine residues that can be
modified. For instance, a mass of 2444.2 Da was identified in the Glu-C digest of the
HSA-5 sample. This mass value corresponded to a mass shift of 250.0 Da that occurred
on residues 198-208 on HSA. The mass shift indicated that residues 198-208 were being
modified to form Pyr and IB. Arginine 197 was found to be modified to form IB because
it is the only arginine residue that’s available for modification. The assignment of Pyr,
which is a lysine specific modification, was not as straightforward because lysines 190,
195, 199, and 205 are all present within regions 189-208 of HSA. An identical
modification was also found in the HSA-4 sample, where a peptide spanning residues
198-208 was found to be modified to form Pyr and IB. An example of a scenario where
multiple AGEs could be assigned to the same m/z value was found on residues 206-218
in the tryptic digest of the HSA-4 sample. A mass shift of 198.1 Da was identified on
these residues, which corresponded to the formation of Nε-(5-Hydro-5-methyl-4imidazolon-2-yl)ornithine (MG-H1) and dehydrated fructosyl-lysine (FL-1H2O) or MG-
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H1 and tetrahydropyrimidine (THP). This indicated that either a combination of K205
and K218 or R209 and R218 are being modified.
There were also cases where a detected m/z shift could be linked to several
peptide/AGE combinations. For instance, a m/z value of 1171.6 Da was identified in the
HSA-2 sample, which could be due to the modification of residues 210-218 or 5-12 on
HSA. In this case, modification of residues 210-218 to form CEL and ArgP, or
modification of residues 5-12 to form FL-1H2O and MG-H1, would have associated mass
shifts of 152.0 Da and 198.1 Da respectively. Two other examples of this ambiguity in
glycation site assignment were identified in the HSA-4 sample, where m/z values of
1495.6 Da and 1706.8 Da were identified as being potential modification sites. The m/z
value of 1495.6 Da resulted from modifications that occurred on regions 437-445 or 138145 on HSA. Similarly, the m/z value of 1706.8 Da corresponded to modifications that
occurred on regions 182-105, 198-209, or 206-218 on HSA.
In cases where multiple modification sites, overlapping glycation products, or
multiple combinations of modified peptides occurred, additional information was used to
determine the most likely modification sites. In Chapter 4, the most likely modification
sites were identified by comparing the suspected modification sites to the pKa and
fractional accessible surface area (FAS) of a given amino-acid residue. Similar
approaches are used in this current chapter, where pKa and FAS data is used to indicate
AGEs on HSA, and the most likely location of these AGEs.
5.B.3. Location of the most likely modification sites based on pKa and FAS data. To
overcome the complexity of AGE assignment, the pKa and the FAS values for AGE-
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linked residues used to select the most likely modification sites. These values were
calculated using tools that are available online, as described in the literature (19, 20). In
general, lysine or arginine sidechains which have higher pKa values are expected to be
less reactive with α-oxoaldehydes because a greater percentage of the amino-sidechains
exists in the protonated state, precluding AGE formation. The FAS on the other hand is a
measure of the accessibility of a given amino acid residue. Residues that have very low
FAS values are therefore expected to be less modified than residues that are more
accessible to the solvent. The detected peptides were sorted first by the respective
sidechain pKa values and then by the respective FAS to determine which AGE and
peptide combination was the most likely to occur at a given m/z value.
The assignment of AGEs on peptides resulting from the HSA-2 digest didn’t
require additional pKa or FAS based sorting because the modifications occurring could
only be linked to specific residues on a given peptide. In the HSA-5 sample, there were 5
peptides where the pKa and FAS data were used to differentiate

the most likely

modification sites. For example, residues 520-525 on HSA-5 sample contained K524 and
K525, where one of these residues is being modified to for Pyr. Lysine 524 has pKa and
FAS values of 10.4 and 0.54 respectively, compared to pKa and FAS values of 15 and
0.07 that were obtained for K525. The pKa/FAS data is strong indicator that K524 was
being modified to form Pyr. Similarly, residues 189-208 was found to be modified on the
HSA-5 sample, where this region of HSA is believed to be modified to form Pyr. This
region of HSA includes K190, K195, K199, and K205, which made it difficult to
pinpoint where this lysine specific modification was occurring. Of these residues, K190
and K199 both had low pKa values of 6.23 and 7.47, indicating that they are both fairly
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reactive with α-oxaloaldehydes. Lysines 190 and 199 also have FAS values of 0.42 and
0.16 respectively. The pKa and FAS data in this case indicated that K190 was being
modified to form Pyr. Similar assignments were made for residues 426-442 and residues
189-208 in the HSA-5 and HSA-4 digests respectively.
In some cases, the pKa and FAS were used to differentiate between multiple
combinations of peptides and AGEs. There were a total of 3 peptides in the HSA-4 and
HSA-5 sample where this type of sorting was used. For the HSA-5 sample, a m/z value of
1171.6 Da was identified which could result from the modification of residues 210-218 or
5-12 on HSA. Residues 210-218 on HSA contained K212 and R218 and residues 5-12
contain R10 and K12. When both lysines are compared, the FAS values for lysines 12
and 212 were 0.59 and 0.40 respectively and the pKa in both cases was 10.43. In
comparison, there was a large difference in the pKa for arginines 10 and 218, where R10
had a pKa of 16.02 and R218 had a pKa of 9.64. The pKa of R218 was well below the
average arginine pKa on HSA, which indicated that the peptide containing residues 5-12
is the most likely modification site. Based on this information, K212 was being modified
to form CEL and R10 was being modified to form ArgP. Similar assignments were made,
where residues 437-445 and 198-209 were both identified as being likely modification
sites, based on the pKa and FAS data. Based on pKa/FAS sorting, K439 and R445 were
found to be modified to form AFGP and G-H1 respectively. Similarly, K199 and R209
were found to be modified to form FL-1H2O and 3-DG-H1 or THP respectively.
As was indicated in Chapter 4, there were situations where the most commonly
identified modification pattern doesn’t match the modification pattern that was
determined based on pKa and FAS data. This was certainly the case for residues 189-208,
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426-442, 437-445, and 520-525 where the most likely modifications are expected to
occur on K199, K439, and K525 respectively. This discrepancy was also noted by other
authors (see Chapter 4 for the relevant references), where the predicted pattern which is
based on pKa and FAS data is not always observed through experimentation.
5.B.4. Semi-quantitative analysis of AGEs. In Chapter 4, the rate of occurrence of
modification sites in the glycated HSA samples was used to estimate the relative extent of
modification that occurred on various parts of HSA. A similar approach was used for
ranking the residues which were modified by AGEs in this chapter. In some cases, a
peptide may be modified by both AGEs and early stage glycation products. When both
types of modification were present, residues that were modified by early stage glycation
products were factored into the analysis. For this classification, the data that is presented
in this chapter and the data that was presented in Chapter 4 (i.e., peptides with amino-acid
residues that could be linked to both early and late stage glycation) are both examined.
When only the data that is presented in this chapter is considered, lysines 190,
199, 212, and 439 as well as arginine 336 were found to have the highest amount of AGE
modifications. Each of the residues listed above were found to be modified in at least 2
peptides. When both early and late stage glycation are considered, K190 and K439 were
found to be modified in at least 3 different peptides, which indicated that extensive
modification was occurring on those residues. Lysines 432, 436, 525 as well as arginine
336 were found to overlap with at most 2 peptides. A diagram summarizing the semiquantitative ranking of AGE-modification sites is summarized in Figure 5.1. The AGEs
that were detected in this study were compared to previous qualitative (21) and
quantitative data (22) that was obtained for commercially glycated HSA (see
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Figure 5.1. Structure of HSA showing the most likely AGE modification sites based on
semi-quantitative data. The most reactive residues are indicated in red (i.e.,
for amino acids that were present in 3 overlapping peptides) followed by the
second most reactive regions shown in purple (i.e., for amino acids that were
present in 2 overlapping peptides).

520-525: K524, K525

426-442: K436 or K439

187-212: K190, K199, K212

324-336: R336
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Table 5.3. Comparison of AGE-modified peptides that were found in this study, with glycation sites that were previously found on
commercially glycated HSA
HSA Sample
HSA-5
HSA-2, HSA-5
HSA-5, HSA-4
HSA-5, HSA-5
HSA-2, HSA-5
HSA-4
HSA-5
HSA-5, HSA-4

Residue 1a
520-525
206-212, 210-218
426-442, 437-445
198-208, 189-208
189-208
476-484
137-144
312-321, 318-336

Residue 2b
520-525
200-218
426-442
196-209
191-205
467-484
133-141
n/a

Residue 3c
525-534
206-212, 213-218
415-439
n/a
n/a
n/a
n/a
318-323

Overlapping Residues
K525
R209
K436, K439, & R428
K199, K205, R197
K190, K195, K199
R484
K137
K313, K317, K323

Modification
Pyr
MG-H1, THP
AFGP, Pyr, CEL, G-H1, ArgP
Pyr, 3-DG-H1, THP
Pyr, IB
G-H1
AFGP
AFGP, CEL

a

– Residue 1 represents the region of HSA that was found to be modified by early-stage glycation products in this study.

b

– Residue 2 represents the region of HSA that was found to be modified by early-stage glycation products that was identified for
commercially glycated HSA (21).

c

– Residue 3 represents the region of HSA that was previously found to have significant levels of glycation which were quantified
using 18O-labeling mass spectrometry (22).
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Table 5.3). Eight peptides that were found to be modified in this current study were also
found to have significant levels of modification in commercially glycated HSA. Four of
these modified peptides contain K199, K439, and K525, which are residues that are
expected to have the largest amount of modification in glycated HSA (23, 24).
Interestingly, these peptides were also found to be linked to early-stage glycation
products in the Chapter 4. Of these residues, K525 and K439 were both previously
identified in our previous qualitative (21) and quantitative studies (see Chapter 2), while
K199 was found to be modified by glycation products in commercially glycated HSA
(21). Several peptides spanning residues 206-218, 476-484, 137-144, and 312-336 were
found to be modified in this current study and in a previous studies using commercially
glycated HSA (21). Of these peptides, the semi-quantitative ranking indicated that
arginines 209 and 484, as well as lysines 137, 313, 317, and 323, are all possible
modification sites.
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5.C. SUMMARY
When pKa and FAS sorting as well as semi-quantitative ranking were used, a
region spanning residues 189-212 on HSA was found to have extensive AGE
modification. The same observation was made in the analysis of glycation sites on in
vitro glycated HSA (see Chapter 4), where several amino acids within residues 196-205
were found to be modified by early glycation products. This finding indicated that a
region on HSA spanning residues 189-212 may be highly modified during glycation. In
addition, K199, which is a commonly identified modification site on HSA, is found
within this same region on HSA. The semi-quantitative comparison also showed that
residues 324-336, 426-442, and 520-525 were also found to have high levels of
modification.
The location of AGEs on HSA was compared to the major drug binding sites on
this protein (i.e., Sudlow sites I and II) (25, 26). In this comparison, several modified
peptides were found within both Sudlow sites. Of the residues that were semiquantitatively ranked, residues 189-212 is found within Sudlow site I. The proximity of
AGE-modified residues (i.e., K190 or K199 and R197), to Sudlow site 1 is a strong
indicator that AGE formation on these residues may interfere with Site 1 ligand
interaction. Similarly K212 and R218, which were being modified to form AGEs, are
also located within Sudlow site 1 of HSA. The proximity of K212 to Y211, which is a
known drug interaction site, indicates that drug binding may be altered in this region of
HSA during glycation. The AGE modification that occurred on R218 may also affect
HSA-drug interaction, because this residue is also a known drug binding site on HSA.
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Several modified peptides were also found in the vicinity of Sudlow site II on
HSA. For instance, residues 426-442, which has a high level of AGE modification, was
found in Sudlow site II. K436 or K439 are believed to be involved in AGE formation,
where this modification may interfere with drug interaction that occurs at V433 or Cys438 on HSA. Similarly, peptides spanning residues 390-410, 437-445, and 476-484 are
all found within this region of HSA, where lysines 402 and 484 as well as arginines 410,
428, 445, and 484 are believed to have been modified to form AGEs. Arginine 410 is a
known drug interaction site on HSA; therefore AGE formation on this residue would
directly interfere with drug interaction at this site. The remaining AGE modified peptides
are located in close proximity to residues Y411, L430, A449, and R485, indicating that
AGE formation may alter the drug interaction that occur at these key drug binding sites.
The results indicate that AGE modification is indeed occurring in both Sudlow
sites on HSA. The modifications that occur on HSA appear to be heterogeneous in nature,
where a large number of both early and advanced stage glycation products are found
within both drug interaction sites. Many regions of HSA that were found to have high
levels of modification in this study were also identified in previous studies that examined
commercially glycated HSA. When this comparison was done, peptides containing K525,
R209, K439, and K199 were consistently identified as being modification sites. This
finding is consistent with the most commonly reported glycation sites in the literature
(23, 24, 27) and the results that were obtained in Chapter 4.
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5.E. APPENDIX
A table showing the AGE-related m/z shifts that were identified in the glycated HSA
samples is given. This table was generated using the raw output from the program
without pKa or FAS sorting. This table provides data that is complements the data
provided in Table 4.1a. Instances where peptides are modified to form mixtures of
overlapping early and advanced glycation products are given in Table 4.1a. Table 5.1a
provides information for peptides that only contained AGEs.

HSA-5

HSA-2

Table 5.1a

Peptides that were modified to form AGEs in the glycated HSA samples

Digest

Raw Mass (Da)a

Residue

Unmodified Mass (Da)b

Suspect Adductc

∆ Mass (Da)

Trypsin

2690.35

390-410

2542.28

Pyr+G-H1

148.02

Glu-C

2547.21

566-585

2007.06

AFGP*2

540.15

Glu-C

2547.21

168-188

2305.10

FL+ArgP

242.08

Lys-C

926.46

206-212

854.45

CEL

72.021

Trypsin

949.49

520-525

801.49

Pyr+G-H1

148.02

Trypsin

1171.60

5-12

973.52

FL-1H2O+MG-H1

198.05

Trypsin

1171.60

210-218

1019.58

CEL+ArgP

152.05

Trypsin

1364.65

187-197

1176.60

Pyr+ArgP

188.05

Trypsin

1405.72

137-144

1055.59

AFGP+ArgP

350.10

Trypsin

1679.75

324-336

1639.78

G-H1

39.99

Trypsin

2658.16

318-336

2316.10

CEL+AFGP

342.10

Glu-C

1989.97

426-442

1841.95

Pyr+G-H1

148.01

Glu-C

2108.03

426-442

1955.99

CEL+ArgP

152.05

Glu-C

2444.21

189-208

2194.18

Pyr+IB

250.05
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HSA-4

Table 5.1a (continued) Peptides that were modified to form AGEs in the glycated HSA samples

Digest

Raw Mass (Da)a

Residue

Unmodified Mass (Da)b

Suspect Adductc

∆ Mass (Da)

Trypsin

1280.49

476-484

1138.50

IB

142.03

Trypsin

1495.67

437-445

1185.56

AFGP+G-H1

310.07

Trypsin

1495.67

138-145

1083.59

IB+AFGP

412.10

Trypsin

1706.83

182-195

1518.78

188.05

Trypsin

1706.83

198-209

1436.77

Pyr+ArgP
FL+Pyr, AFGP, FL-1H2O+FL-2H2O, FL1H2O+FL-2H2O

Trypsin

1706.83

198-209

1436.77

270.07

Trypsin

1706.83

206-218

1508.81

FL-2H2O+3-DG-H1, FL-2H2O+THP, AFGP
FL-1H2O+MG-H1, 3-DG-H1+MG-H1,
THP+MG-H1

Glu-C

1753.71

312-321

1213.55

AFGP*2

540.15

Glu-C

2444.24

189-208

2194.18

Pyr+IB

250.05

a

– This column shows the detected m/z values that correspond to glycated peptides.

b

– This column shows the corresponding mass of the peptide when no modifications are present.

c

– m/z values where multiple modifications could be assigned at the same mass are shown in bold.

270.07

198.05

182

183

CHAPTER 6

QUANTITATIVE ANALYSIS OF GLYCATION SITES ON
IN VITRO GLYCATED HUMAN SERUM ALBUMIN

6.A. INTRODUCTION
The glycation of various proteins in the body has been linked to many of the
chronic complications that are commonly diagnosed in diabetes, including nephropathy
(1), macro-vascular complications (2), and cataract formation (3). Glycation that occurs
on human serum albumin (HSA) has been shown to alter the structure, function, and
binding capabilities of this protein (4, 5); however, there is little quantitative information
about the regions on HSA that are most prone to modification (5, 6). The objective of this
study is to obtain quantitative information about the levels of glycation that occur on
glycated human serum albumin (HSA) and link this information to the glycation products
that were previously identified on HSA (see Chapters 4 and 5). This information can be
used to model the expected glycation pattern on HSA that is glycated in vivo.
The same HSA and glycated HSA samples that were previously used for
qualitative studies (see Chapters 4 and 5) were used to obtain quantitative data in this
analysis. This quantification was performed using 18O-labeling (7, 8) and matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) (9). The
HSA samples were glycated under physiological conditions for either two weeks or five
weeks to yield glycated HSA that contained 0.72 (± 0.1) and 1.23 (± 0.1) mol hexose/mol
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HSA respectively, as determined by an enzyme-based fructosamine assay (10, 11). This
level of modification represents the expected amount of HSA glycation that on occurs
during pre-diabetes (~0.5 - 1 mol hexose per mol HSA) and diabetes (~ 1-3 mol hexose
per mol HSA) respectively (12, 13). This level of glycation is consistent with the 2-3 fold
increase in the concentration of glycated peptides that is typically observed in diabetes
(1).
To quantify the modification sites, the glycated HSA samples were digested in
18

O-labeled water and the control HSA samples were digested in 16O-labeled water. The

resulting peptides were then mixed in a 50:50 (v/v) ratio. Mass spectra for the 16O digest,
18

O digest, and mixed digest were then acquired and the 16O/18O ratios were determined.

The control sample was also digested in

18

O water, and this sample was used to obtain

reference 16O/18O values for control HSA versus itself.
The coupling of

16

O/18O-labeling and MALDI-TOF-MS is advantageous for this

analysis because the peptides can be labeled in a single step, reducing the chance of
encountering systematic labeling errors (7). The use of MALDI-TOF-MS is also
advantageous because it limits the amount of interaction that 18O-labeled peptides would
have with aqueous solvents containing regular water, such as solvents that are used for
LC-MS systems. In a previous attempt at quantifying immobilization sites (9), there was
significant peptide-to-peptide variability for the reference

16

O/18O ratios (i.e.,

16

O/18O

ratios that were obtained when a control HSA sample was compared to itself), which
indicated that the absolute

16

O/18O ratios should not be used for quantifying the small

amount of glycation that would occur on peptides. The wide variation in reference
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16

O/18O ratios was confirmed in our previous attempt at measuring

16

O/18O ratios for

minimally glycated HSA, where there was some ambiguity in quantifying the glycation
sites because few peptides had 16O/18O ratios that were above the assigned cutoff value.
This effect had also been observed by other authors, where the peptide-to-peptide
labeling efficiency was found to be influenced by the size of the peptide, resulting in
inefficient enzyme-peptide interaction (8). This difference in enzyme-peptide substrate
formation has been shown to significantly impact the amount of
incorporated during digestion (7).

Quantitation by

18

18

O label that gets

O labeling is also sensitive to

variations in volume size, ion intensity, unresolved peptides, and differential sample loss
(7, 14).
To counter the effects of variations in peptide-to-peptide labeling, the calculated
16

O/18O ratios for the glycated HSA samples were compared directly to the 16O/18O ratios

obtained for a control HSA sample (containing no glycation). An f-test (15) was used to
determine whether the variance for both 16O/18O ratios were the same or not followed by
the appropriate Student’s t-test (15) to see whether the 16O/18O ratios were different at the
90% confidence level. The 16O/18O ratios in the glycated HSA sample that were higher at
the 90% confidence level were assumed to be glycated. These values were subsequently
ranked by the relative difference in their 16O/18O ratios for the glycated HSA and control
HSA digests. By using this approach, it was possible to quantify the relative extent of
modification occurring on different regions of HSA and assign glycation products to
HSA with a high level of certainty.
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Variations in volume differences and sample loss were avoided by performing
both the

16

O and

18

O digests side-by-side and by preparing samples with the same

apparatus and reagents. The use of similar reagents was particularly important for the
enzyme addition step where the use of separate vials of enzymes (even if they are from
the same lot) has been shown to cause drastic changes in the

16

O/18O ratios. This

difference is clearly illustrated in Figures 6.1 (i) and 6.1 (ii).
Low retention micro-centrifuge tubes were used to reduce the degree of
adsorption-based sample loss that can occur when the protein is being dried under
vacuum. The MALDI laser intensity was manually adjusted to ensure that the majority of
detected ions were of sufficient intensity for quantitation (i.e., a selected signal-to-noise
ratio of 25) and that detector saturation was not occurring (i.e., the detector response was
not allowed to go above 20,000 counts). By using the described adjustments, several
peptides were identified as having significant levels of modification which could be
linked to large increases in the 16O/18O ratios with respect to the reference 16O/18O ratios
that were obtained for the control sample. All of the key glycation sites could be
quantified and ranked in this analysis.
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Figure 6.1. (i) Mass spectrum showing the isotopic distribution of a peptide when two
different vials of trypsin are used to produce 16O- and 18O- labeled digests.
(ii) Mass spectrum obtained when an identical method to (i) is performed
where the same vial of trypsin is being used for both the 16O and 18O labeled
digest.
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(i)

(ii)
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6.B. EXPERIMENTAL
6.B.1. Materials. The following chemicals were purchased for Sigma-Aldrich (St.
Louis, MO): Des-Arg-bradykinin (97% pure), glu-fibrinopeptide (97%), angiotensin I
(97%, acetate salt), 2,3-dihyroxybenzoic acid (98%), α-cyano-4-hydroxycinnamic acid
(99%), HSA (99%, essentially fatty acid and globulin free), trypsin (sequence grade),
Glu-C (sequence grade), Lys-C (sequence grade), guanidine-HCl (99%), dithiothreitol
(99%), D-glucose (99%), iodoacetamide (99%), triflouroacetic acid (98%), sodium azide
(99%), formic acid (96%), molecular biology grade water (DNase, RNase, and protease
free), methanol (HPLC grade, 99.9%),

18

O-enriched water (97%),

16

O-enriched water

(99.99%), molecular biology grade water, and acetonitrile (HPLC grade, 99.9%).
6.B.2. Apparatus. Siliconized low retention microcentrifuge tubes (0.6 mL and 1.5 mL)
and 0.20 µm nylon filters were obtained from Fisher Scientific (Pittsburgh, PA). Slide-ALyzer dialysis cassettes (7000 Da MW cutoff, 0.1-0.5 mL and 0.5-3 mL) were obtained
from Pierce (Rockford, IL), and Zip-tip pipette tips (µ-C18 bed, 0.2 µL bed) were
obtained from Millipore (Billerica, MA). Mass spectra were collected on a Voyager
6148 MALDI-TOF-MS system (Applied/Perspective Biosystems, CA). The instrument
settings were as follows: positive-ion delayed extraction reflection mode; delay time, 100
ns; accelerating voltage, 25 kV; guide wire voltage, 0.008% of accelerating voltage; grid
voltage, 77% of accelerating voltage. Matlab 2009a, which included the bioinformatics
toolbox, was purchased from Mathworks (Natick, MA). Mascot Wizard was obtained
from the Matrix Science website (16).
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6.B.3 Digestion and labeling of HSA samples. The same HSA and glycated HSA
samples that were used previously for the identification of glycation-related
modifications in Chapters 4 and 5 were also used for this analysis. The pretreatment of
HSA (i.e., denaturation, reduction, and alkylation) was performed as described in Chapter
4. Following pretreatment, the HSA samples were placed into 0.1 – 0.5 mL dialysis
cassettes, and dialysis was performed on the HSA samples versus 3, 1000 mL portions of
water for 4 hours each. The resulting control and glycated HSA solutions were adjusted
to the same volume. A 40 µL aliquot of each HSA solution was placed into several low
retention microcentrifuge tubes and these samples were brought down to dryness using a
Speedvac (unheated). These vials, which contained approximately 80 µg of either control
HSA or glycated HSA, were stored at -80 °C until later use.
The tryptic digest was performed by first reconstituting a vial of control HSA in
200 µL of 0.1 M, pH 7.8 ammonium bicarbonate buffer that was prepared in 16O-enriched
water. The glycated HSA samples were reconstituted in a similar manner, where
enriched water was used in place of

16

18

O-

O-enriched water. A 3.33 µL aliquot of 1 µg/µL

trypsin solution (prepared in Nanopure water) was then added to the reconstituted HSA
samples. The HSA solutions were incubated at 37 °C for 18 h. Following this incubation,
the digestions were terminated by adding 10 µL of formic acid to the HSA solutions.
These digests were stored at -80 °C until later use.
The Glu-C digest was performed by reconstituting a vial of control HSA in 200
µL of 0.1 M, pH 7.8 ammonium bicarbonate buffer that was prepared in

16

O-enriched

water. The glycated HSA samples were reconstituted in a similar manner, where

18

O-
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enriched water was used in place of 16O-enriched water. A 10 µL aliquot of 1 µg/µL GluC solution (prepared in Nanopure water) was then added to the control HSA and glycated
HSA samples and the samples were incubated for 8 h at 37 °C. An additional 5 µL of
Glu-C was then added to the mixtures and the incubation was continued for an additional
18 h. Following this incubation, the digestions were terminated by adding 10 µL of
formic acid and the samples were stored at -80 °C.
The Lys-C digest was performed by first reconstituting a vial of control HSA in
200 µL of pH 9.0 tris buffer (75 mM) that was prepared in

16

O-enriched water. The

glycated HSA samples were reconstituted in a similar manner, where 18O-enriched water
was used in place of

16

O-enriched water. A 5 µL aliquot of a 1 µg/µL Lys-C solution

(prepared in Nanopure water) was then added to the reconstituted HSA samples. The
mixtures were incubated for 18 h at 37 °C. Following this incubation, 10 µL of formic
acid was added to terminate the digestion and the samples were stored at -80 °C (Note:
the endoproteinase Lys-C that was obtained from Sigma-Aldrich was only available in 5
µg quantities, therefore, several of these vials were reconstituted individually and pooled
prior to this analysis to ensure that the same solution was being used for each sample).
6.B.4. MALDI-TOF-MS data collection. The MALDI matrix consisted of a mixture of
2,3-dihyroxybenzoic acid (DHB) and α-cyano-4-hydroxycinnamic acid (CHCA). In
previous studies, this mixture has been shown to enhance the sequence coverage and that
is obtained for HSA (9). To make this matrix, 20 mg/mL solutions of CHCA and DHB
were prepared in a 70:30 (v/v) mixture of acetonitrile and water. A 1 mL aliquot of the
CHCA solution was spiked with 50 µL of formic acid and a 1 mL aliquot of the DHB
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solution was spiked with 1 µL of trifluoroacetic acid. Both matrices were then mixed in a
50:50 (v/v) fashion, where the resulting mixture was used as the matrix solution for the
remainder of this analysis. To calibrate the mass spectrometer, 96 µL of the mixed matrix
was added to 4 µL of a standard calibrant solution that contained 32.5 pM glufibrinopeptide (1570.6774 Da), 25 pM des-arg-bradykinin (904.4681 Da), and 32.5 pM
angiotensin I (1296.6853 Da) that was prepared in acetonitrile. The resulting solution was
placed in positions on the MALDI plate that were adjacent to the HSA samples, where
each calibrant spot was used to calibrate the mass spectrometer for each adjacent HSA
sample. The HSA digests were fractionated by loading 10 µL of the HSA digest on Ziptip pipette tips. These peptides were eluted with 1 µL of 5, 10, 20, 30, or 50% of
acetonitrile in water, as previously described (9, 17, 18). The eluted fractions were then
mixed with 1 µL of the mixed MALDI matrix and the resulting mixture was slowly
vortexed for 15 seconds. A 0.75 µL portion of the resulting mixture was then
immediately spotted on the MALDI plate.
6.B.5. Peak selection using Matlab and data analysis techniques. The mass spectra
that were acquired represented the average of six individual spectra, where each spectrum
represented the summation of 200 laser shots. Peptide mapping for the control HSA
digest was performed by using Mascot Wizard with the default settings and a 50 ppm
threshold. This analysis was limited to 2 missed cleavages, and carbamidomethylcysteine (fixed) and methionine oxidation (variable) were selected as possible
modifications. The raw mass values that were obtained using Mascot Wizard were
transferred to a tab delimited text file. After processing the data with Mascot Wizard,
peptide masses that were identified in different Zip-tip fractions (i.e., for m/z values that
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belonged to the same peptide) were averaged, and these averaged values were used to
create a master list of mass values that were linked to peptides. Two programs were
developed in Matlab that obtained areas for the M+0 to M+4 peaks from the raw data
(see Figure 6.2 for a flow chart that represents both programs). The program that was
developed by Dr. Ala Qadi (Department of Computer Science, UNL) was used as a
template (see Chapter 2) for the development of program in this project.
The first program (see Figure 6.2) read two input files, where the first file
contained the peptides that were obtained using Mascot wizard (list 1) and the second file
contained the raw data (i.e., mass values and their corresponding area values) that was
obtained from the mass spectra. In the first step, the mass values that were present in both
lists were compared, to determine which mass values matched at a maximum allowed
error of 50 ppm.
error(ppm) =

(mass(list1) − mass(list 2) ) *10 6
mass(list 2)

(1)

For the peptides that matched, the mass values corresponding to the M+0 through M+4
peaks were assigned by adding 0, 1, 2, 3, and 4 to the masses that were present in list 1.
The identified M+0  M+4 values were exported to a separate text file (result.txt). This
text file was then compared to the raw data to obtain area values for each mass within a
given isotopic cluster (i.e., for the M+0  M+4 peaks) (Note: A 100 ppm maximum
allowed error was used for this comparison). Two programs are shown in the Appendix
for obtaining the M+0  M+4 values for the 16O-labeled digest (Tables 6.1a (i)) and the
18

O-labeled digest (Table 6.1a (ii)).
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Ufuk Nalbantoğlu, a graduate student in Electrical Engineering at UNL,
generously provided an addition to this program that was used to combine these five
tables into a single table that was sorted by mass. The code that was used to develop this
program is beyond the scope of this project; hence it is not shown here. This method was
used to identify areas for the M+0 to M+4 peaks in the 16O- and mixed-O labeled digests,
respectively. A similar approach was used for the

18

O-labeled digests, where 4 Da was

added to the mass values in list 1, and these adjusted mass values were used to search for
peptides that were labeled with two

18

O- atoms. Once these values were assigned, the

M+0 to M+4 values were identified by subtracting 4, 3, 2, 1, and 0 from the matched
mass values. All other steps for determining the peak area values were identical to the
method that was used for the 16O-labeled digest.
The 16O/18O ratios were then determined as shown below (in Equation1). The
16
18

I' 0
O
=
O (I"0 + I"2 ( c ) + I"4 ( c ) )

terms I’ and I” in the above equation represents the contribution from the

(1)
16

O and

18

O

digests respectively. The subscripts 0, 2, and 4 show whether the contribution comes
from peptides that contain zero (M+0 peak), one (M+2 peak), or two (M+4 peak)
labels respectively. This equation is described in more detail elsewhere (9).

18

O
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Figure 6.2. Flow chart showing the steps that were taken to extract the isotope peak
areas for the mixed and

16

O-labeled digests. The first four steps were

performed using a single program (a_16_iso_select.m). A separate program
(sort_mass.m) was used to sort the resulting table.
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mascotmatch16.txt
(i.e., list 1)

rawdata.txt
(i.e., list 2)

1. Match to 50 ppm
2. Calculate expected mass for M+0  M+4
3. Output results to a text file

result.txt
(i.e., Mass (Da) corresponding to
M+0, M+1, M+2 ...)

4. Match M+0  M+4 (with a maximum error of 100 ppm)
Table
Mass Area
M+0
------ ---------- ---------- ----M+1 …

Sorted Table
Mass 1: M+0 area
Mass 2: M+0 area

M+1 area M+2 area
M+1 area M+2 area
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Each

16

O/18O ratio that was obtained for glycated HSA was compared to its

corresponding reference

16

O/18O ratio to determine whether the glycated sample had

significant amounts of modification (at the 90% confidence level). This comparison was
done using a student’s t-test (15). Prior to performing the student’s t-test, an F-test was
used to determine whether the variance of the

16

O/18O ratio for a given peptide is the

same at the 95% confidence level (15). If the

16

O/18O ratio that was obtained for the

glycated sample was significantly higher (at the 90% confidence level) than the 16O/18O
ratio obtained for the control sample, the peptide corresponding to that ratio was
considered to be a significant glycation site. A 90% confidence level was found to be
more suitable than a 95% confidence level for assigning glycation sites with this
approach because of the large variances that were associated with some of the

16

O/18O

ratios, especially in cases where the S/N ratio for the corresponding peptides was low.
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6.C. RESULTS
6.C.1. Detected peptides and sequence coverage. The usable sequence coverage (i.e.,
the coverage representing the number of amino acid residues for which

16

O/18O ratios

could be determined) obtained for the control HSA sample digested with trypsin, Lys-C,
or Glu-C was 76%, 62%, or 61%, respectively. When all of the digests were considered, a
total of 106 peptides were detected which covered 91% of the amino acids in HSA (See
Figures 6.3). There was however, a slight decrease in the usable sequence coverage once
the calculated

16

O/18O ratios was factored in, because some of the peptides that were

identified in the control digest were not found in the glycated HSA digests. The resulting
usable sequence coverage for the HSA-2, HSA-5, and control HSA samples (see Figure
6.1a) were reduced to 82%, 86%, and 86% respectively.
In the control and HSA-5 samples, the useable sequence coverage represented all
regions of HSA except residues 52-60, 175-181 (K181), 228-240 (K233 and K240), 314323 (K317 and K323), 349-359 (K351 and K359), 443-444 (K444), 532-545, 558-560
(K560), and 575-585. In addition to the above residues, residues 287-313 (K313) were
not part of the useable sequence coverage for HSA-2 sample. The useable sequence
coverage included 100% of the arginine residues and 84 – 85% of the lysine residues that
were present on HSA. The lack of coverage in these regions was of little consequence to
this study because the residues that are expected to have the highest amounts of
modification (e.g., Lysines 525, 439, 281, 199 and the N-terminus) are not found in these
regions of HSA (6, 19).

6.C.2. Calculated 16O/18O ratios for the HSA samples. The calculated 16O/18O ratios
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Figure 6.3. The usable sequence coverage that was obtained for the control HSA
digest is shown in bold and caps. The lower case letters represents
the remainder of the sequence in HSA, where no
calculations were made.

16

O/18O ratio
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1-

DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV

41-

KLVNEVTEFA Ktcvadesae NCDKSLHTLF GDKLCTVATL

81-

RETYGEMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV

121-

DVMCTAFHDN EETFLKKYLY EIARRHPYFY APELLFFAKR

161-

YKAAFTECCQ AADKaacllp kLDELRDEGK ASSAKQRLKC

201-

ASLQKFGERA FKAWAVARLS QRFPKAEfae vsklvtdltk

241-

VHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE

281-

KPLLEKSHCI AEVENDEMPA DLPSLAADFV ESKDVCKNYA

321-

EAKDVFLGMF LYEYARRHPD YSVVLLLRLA KTYETTLEKC

361-

CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE

401-

YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH

441-

PEAKRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES

481-

LVNRRPCFSA LEVDETYVPK EFNAETFTFH ADICTLSEKE

521-

RQIKKQTALV Elvkhkpkat keqlkAVMDD FAAFVEKCCK

561-

ADDKETCFAE EGKKlvaasq aalgl
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for the tryptic HSA digest are given in Tables 6.1 (i) and (ii). From the tryptic digest
table, it can be seen that the

16

O/18O ratios were calculated for 31 peptides in both the

control HSA and HSA-5 samples. In the HSA-2 sample, the 16O/18O ratio for the peptide
corresponding to a mass of 2974.31 Da (representing residues 287-313) was not
calculated because a sufficient signal was not detected in mixed digest that could be used
for quantitation. The calculated

16

O/18O ratios for the trypsin digest ranged from 0.59-

1.79 with an average of 1.43 (Figure 6.4).
Similarly, the

16

O/18O ratios for the Glu-C digest of HSA (see Appendix, Table

6.2a) were calculated at different stages of glycation. In this analysis, the 16O/18O ratios
for 18 peptides were calculated for both the control HSA and HSA-5 digest, compared to
17 peptides that were found in the HSA-2 sample. The peptide that had a calculated
16

O/18O ratio in the control HSA sample that did not have a calculated 16O/18O ratio in the

HSA-2 sample had a mass of 1801.92 Da, which could be mapped to residues 451-465 on
HSA. A ratio for this peptide could not be obtained due to the intensity of the same
peptide in the mixed digest for the HSA-2 sample. The distribution of the calculated
16

O/18O ratios are shown in Figure 6.2a (i). From this data set, it was determined that the

16

O/18O ratio for the control HSA samples ranged anywhere from 0.12-2.57, with an

average of 1.19.
Using similar approaches, the

16

O/18O ratios for the peptides found in the Lys-C

digest were arranged and compared (see Appendix, Table 6.3a). Using this format, the
ratio for 20 peptides were calculated in the control HSA digest, compared to 19 peptides
which were identified in the HSA-2 and HSA-5 samples, respectively. The reduction in

Table 6.1 (i). Calculated 16O/18O ratios for the tryptic digests.
Control
a

Mass (Da) Error (ppm)
927.50
2
960.57
6
1055.59
-1
1074.53
-16
1149.60
-10
1226.60
-5
1342.62
-11
1371.56
-5
1434.53
-6
1443.64
-4
1467.82
-17
1546.80
2
1552.60
-2
1623.80
5
1627.73
0
1639.94
0

a
b

Residue
138-144
403-410
137-144
182-190
1-10 or 42-51
11-20
546-557
163-174
82-93
263-274
337-348
275-286
360-372
324-336
561-574
414-428

Amino Acid Sequence
YLYEIAR
FQNALLVR
KYLYEIAR
LDELRDEGK
DAHKSEVAHR
FKDLGEENFK
AVMDDFAAFVEK
AAFTECCQAADK
ETYGEMADCCAK
YICENQDSISSK
RHPDYSVVLLLR
LKECCEKPLLEK
CCAAADPHECYAK
DVFLGMFLYEYAR
ADDKETCFAEEGKK
KVPQVSTPTLVEVSR

16

18

O/ O
1.66
1.51
1.34
1.67
1.99
1.56
0.72
1.21
1.10
1.81
2.01
1.37
1.46
1.85
1.52
1.31

HSA-2
b

SD
0.24
0.31
0.39
0.93
0.81
0.71
0.13
0.30
0.17
0.46
0.43
0.51
0.47
0.06
0.28
0.20

16

18

O/ O
1.94
1.30
1.59
2.55
1.57
1.19
0.46
1.48
1.36
2.07
2.01
2.02
2.33
2.43
1.10
1.69

HSA-5
b

SD
0.41
0.18
0.55
0.44
0.81
0.45
0.12
0.22
0.77
1.32
1.01
0.58
0.67
0.36
0.34
0.46

16

O/18O
2.02
1.53
1.55
2.02
3.20
1.34
1.03
0.95
1.89
2.42
2.43
1.49
1.86
3.05
1.32
1.38

SDb
0.41
0.25
0.20
1.58
1.69
0.32
0.20
0.33
0.93
0.90
0.70
0.80
0.20
0.38
0.39
0.19

– “Error” represents the mass accuracy of the assigned peptide. For simplicity, the control HSA digest was used for peptide mass fingerprinting.
– “SD” designates the standard deviation that was calculated for the given 16O/18O ratios. The value represents the square root of the sum of the

standard deviations squared that were obtained across different Zip-tip fractions.
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Table 6.1 (ii). Calculated 16O/18O ratios for the trypsin digest.
Control
a

Mass (Da) Error (ppm)
1657.72
-21
1714.80
0
1742.88
-9
1899.01
7
1910.92
-5
2045.10
0
2086.80
-19
2260.08
27
2490.28
-2
2518.20
-5
2585.11
-4
2650.30
15
2674.31
-1
2778.43
25
2974.31
-10

a
b

Residue
390-402
94-106
146-159
146-160
485-500
373-389
241-257
501-519
21-41
352-372
241-262
115-136
445-466
115-137
287-313

Amino Acid Sequence
QNCELFEQLGEYK
QEPERNECFLQHK
HPYFYAPELLFFAK
HPYFYAPELLFFAKR
RPCFSALEVDETYVPK
VFDEFKPLVEEPQNLIK
VHTECCHGDLLECADDR
EFNAETFTFHADICTLSEK
ALVLIAFAQYLQQCPFEDHVK
MPCAEDYLSVVLNQLCVLHEK
VHTECCHGDLLECADDRADLAK
LVRPEVDVMCTAFHDNEETFLK
RMPCAEDYLSVVLNQLCVLHEK
LVRPEVDVMCTAFHDNEETFLKK
SHCIAEVENDEMPADLPSLAADFVESK

16

18

O/ O
1.21
1.46
1.55
1.48
1.46
1.43
1.27
1.73
1.71
1.82
0.92
1.21
0.99
1.01
1.05

HSA-2
b

SD
0.58
0.21
0.15
0.33
0.24
0.08
0.20
0.47
0.18
0.30
0.06
0.03
0.06
0.02
0.05

16

18

HSA-5
b

O/ O SD
1.11
0.29
1.59
0.16
1.85
0.35
2.38
0.97
1.31
0.17
1.68
0.08
1.66
0.29
1.37
0.47
1.92
0.34
1.23
0.53
0.81
0.04
1.24
0.12
0.78
0.09
0.92
0.04
none detected

16

O/18O
1.33
1.86
2.59
2.47
1.45
1.95
1.65
0.75
3.50
1.43
0.84
1.11
0.93
1.09
1.21

SDb
0.42
0.33
0.74
0.60
0.15
0.41
0.25
0.24
0.73
0.68
0.15
0.02
0.36
0.08
0.70

– “Error” represents the mass accuracy of the assigned peptide. For simplicity, the control HSA digest was used for peptide mass fingerprinting.
– “SD” designates the standard deviation that was calculated for the given 16O/18O ratios. The value represents the square root of the sum of the
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standard deviations squared that were obtained across different Zip-tip fractions.
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Figure 6.4. Reference 16O/18O ratios that were obtained for the tryptic digest. The error
bars represents the calculated standard deviation of a given
The central dashed line represents the average
dashed lines represents the range of

16

16

16

O/18O ratio.

O/18O ratio and outer

O/18O ratios that were obtained.

Figure 6.4
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the number of detected peptides was due to a peptide with a m/z value of 2259.99 Da
(residues 21-41) that was detected in the control digest but not in the HSA-2 or HSA-5
digests. The reference 16O/18O ratios in the Lys-C digest ranged anywhere from -0.04 to
2.11, with an average 16O/18O ratio of 1.13 (see Appendix, Figure 6.2a (ii)). The average
16

O/18O ratios for the trypsin, Lys-C, and Glu-C control digests showed little deviation

and varied from only 1.13-1.43; however, the individual

16

O/18O ratios for the control

digests did show significant variability.

6.C.3. Peptides with high 16O/18O ratio peptides in the HSA-2 sample. When
reference

16

O/18O ratios were compared to the

the

16

O/18O ratios that were obtained for

glycated HSA, numerous peptides were identified in both glycated samples with high
16

O/18O ratios. The

16

O/18O ratios that were obtained for the glycated HSA samples are

summarized in Table 6.2. In total, 17 peptides were identified in the HSA-2 sample that
had significantly higher
respective reference

16

O/18O ratios (at the 90% confidence level) compared to their

16

O/18O ratios. These peptides had a relative increase in

16

O/18O

ratios that ranged anywhere from 6% to 77%.
The highest change in 16O/18O ratios were found on residues 101-119, 1-10 or 4251, 360-372, 521-537, and 275-286 on HSA, which had corresponding relative increases
in16O/18O ratios of 77%, 63%, 60%, 57%, and 48%, respectively versus normal HSA.
The N-terminus, K525, and K281, which are believed to be the most likely glycation sites
(5, 6, 19), were all located on residues that had the most significant levels of modification
in this analysis. In addition to these sites, a peptide corresponding to residues 426-442 on
HSA was also identified as having a relative change in

16

O/18O ratio of 19%, which

represented a significant increase at the 90% confidence level. This increase in 16O/18O

Table 6.2. Peptides in the HSA-2 sample with significantly higher 16O/18O ratios at the 90% confidence level.
Most Likely Location of Modified Residuesc
Digest
Glu-C
Lys-C
Tryptic
Glu-C
Tryptic
Tryptic
Tryptic
Lys-C
Tryptic
Glu-C
Glu-C
Glu-C
Glu-C
Glu-C

Mass (Da)
2348.094
1149.619
1552.595
1313.796
1546.800
1623.795
2086.798
1552.592
1639.938
1519.783
1945.862
2578.264
1704.910
1955.975

Residuea
101-119
42-51/1-10
360-372
521-537
275-286
324-336
241-257
360-372
414-428
142-153
502-518
61-82
154-167
426-442

Relative Diff.b
77%
63%
60%
57%
48%
31%
31%
30%
29%
29%
28%
24%
22%
19%

Lysine
106
N+ ,4 (FL)
372
524, 525, 536, 538 (Pyr, FL, or CEL)
276, 281, 286 (FL, CEL, Pyr)
n/a
n/a
372
414 (FL, AFGP)
n/a
n/a
64, 73
159
432, 436, 439 (Pyr, CEL, FL,
or AFGP)

Arginine
114, 117
10 (AFGP, 3-DG-H1, or THP)
n/a
521 (G-H1)
n/a
336
257
n/a
428 (AFGP, 3-DG-H1, THP)
144
n/a
81
160
428 (G-H1, ArgP, AFGP,
3DG-H1, or THP)

Trypsin
Glu-C
Lys-C

2045.096
2232.208
1714.785

373-389
209-227
94-106

17%
16%
6%

378, 389
212, 225 (CEL)
106

n/a
209, 218, 222 (ArgP)
98

a

– Residues that have been previously identified by other authors are shown in bold.

b

– This value represents the percent relative difference of the 16O/18O ratio for the glycated HSA sample and the control HSA sample.

c

- The most likely modification sites are underlined. The suspected modification; based on the data in previous chapters, is also shown.
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ratio is on the lower end of increased 16O/18O ratio values that correspond to significant
modification; however, this site was also previously identified as being one of the likely
modification sites of in vivo glycated HSA (6). A peptide corresponding to residues 189208 was also identified in the Glu-C digest, with a 24% increase in
compared to its reference

16

O/18O ratio

16

O/18O ratio (i.e., 0.93 +/- 0.11). This peptide contains K199

which has previously been identified as one of the likely glycation sites on HSA (6).
While an increase in the average 16O/18O ratio for this peptide was noted, the increase in
the 16O/18O ratio for this peptide was not significant at the 90% confidence level because
of the large variance in the

16

O/18O ratio that was obtained for the HSA-2 sample (i.e.,

1.16 +/- 0.99).
The regions of HSA that contained significant amounts of modification in this
analysis were compared to the relative extent of modification that was found on
commercially glycated HSA (see Chapter 2). When this comparison was done, 7 of the
11 peptides that were previously identified as having high amounts of modification in
commercially glycated HSA were also found to have high amounts of modification in
this current analysis. For instance, residues 107-114 was previously found to have the
highest measurable 16O/18O ratio and thus contained the largest amount of modification in
the commercially glycated HSA sample. This finding is consistent with the findings in
this study, where a similar peptide (i.e., residues 101-119) was found to have the largest
relative change in 16O/18O ratio. Other overlapping and likely modification sites included
regions 521-537, 324-336, 414-428, 61-82, 426-442, and 209-227 on HSA. Some of the
sites that were previously thought to have excessive amounts of modification (i.e., K233,
K439, and K525) based on a qualitative analysis (see Chapter 2) were also found to have
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large levels of modification in this current analysis. For instance, residues 521-537
(which contains K525) had the fourth largest increase in 16O/18O ratio and residues 426442 (which contains K439) was found to have a moderate increase in

16

O/18O ratio. A

moderate change in 16O/18O ratio was also observed on residues 426-442 for the HSA-5
sample. Lysine 233, which was previously thought to have significant levels of
modification based on a qualitative comparison (see Chapter 2), was not identified in
either stage of glycation in this study as having significant levels of modification. These
combined factors indicate that K525 and K439 may indeed contain high levels of
modification. The difference in the ranked modification sites that were obtained in the
previous study using commercially glycated HSA (see Chapter 2) and this current
approach can be attributed to experimental design. By using low retention apparatus, the
concentration of peptides in the HSA digests were increased, allowing for an improved
estimation of 16O/18O ratios. The strength of the techniques used in this current chapter, is
that changes in the 16O/18O ratio that are related to increased levels of modification can be
distinguished from changes in 16O/18O ratios that are due to peptide labeling efficiency.

6.C.4. Peptides with high 16O/18O ratios in the HSA-5 sample. The peptides which
were found to be significantly glycated in the HSA-5 sample are ranked and sorted in
Table 6.3. In total, 21 peptides were found to have significant increases in 16O/18O ratio
(compared to their respective reference 16O/18O ratio) at the 90% confidence level. These
peptides had a relative increase in the
104%.

16

O/18O ratios that ranged anywhere from 7% to

Table 6.3. Peptides in the HSA-5 sample with high 16O/18O ratios identified at the 90% confidence level.
Most Likely Location of Modified Residuesc
Digest
Trypsin
LysC
GluC

Mass (Da)
2490.280
1149.619
1313.796

Residuea
21-41
42-51/1-10
521-531

Differenceb
104%
98%
75%

Lysine
41
51/N+
524, 525 (Pyr, FL, or CEL)

Arginine
n/a
n/a
521 (G-H1)

Trypsin

1434.525

82-93

72%

93

n/a

Trypsin
Trypsin
Trypsin
GluC
GluC
Trypsin
Trypsin

1899.009
1149.604
1342.620
1737.692
2194.152
2045.096
2086.798

146-160
1-10
546-557
87-100
189-208
373-389
241-257

67%
61%
44%
42%
40%
36%
30%

159
4/N+
557
93
190, 195, 199, 205 (Pyr, FL, or CML)
378, 389
n/a

160
10 (MG-H1)
n/a
98
197 (ArgP, or IB)
n/a
257

a

– Residues that have been previously identified by other authors are shown in bold.

b

– This value represents the percent relative difference of the 16O/18O ratio for the glycated HSA sample and the control HSA sample.

c

– The most likely modification sites are underlined. The suspected modifications (based on the data in previous chapters) are also
210

shown in parenthesis.

Table 6.3 (continued). Peptides in the HSA-5 sample with high 16O/18O ratios identified at the 90% confidence level.
Most Likely Location of Modified Residuesc
Digest
Trypsin
Trypsin
GluC

Mass (Da)
1714.796
1552.595
1955.975

Residuea
94-106
360-372
426-442

Differenceb
27%
27%
26%

Lysine
106
372
432, 436, 439 (Pyr, CEL,
FL, or AFGP)

Arginine
98
n/a
428 (G-H1, ArgP, AFGP,
3DG-H1, or THP)

GluC
GluC
Trypsin
GluC
LysC
GluC
LysC

1519.783
2348.094
927.495
2578.264
2348.988
2232.103
1552.592

142-153
101-119
138-144
61-82
74-93
209-227
360-372

26%
22%
22%
17%
15%
10%
7%

n/a
106
n/a
64, 73
93
212, 225 (CEL)
372

144 (ArgP), 145
114, 117
144 (ArgP)
81
81
209, 218, 222 (ArgP)
n/a

a

– Residues that have been previously identified by other authors are shown in bold.

b

– This value represents the percent relative difference of the 16O/18O ratio for the glycated HSA sample and the control HSA sample.

c

– The most likely modification sites are underlined.
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The largest relative changes in 16O/18O ratios occurred for residues 21-41, 1-10 or
42-51, 521-531, 82-93, and 146-160 on HSA, where the 16O/18O ratios for these residues
increased by 104%, 98%, 75%, 72%, and 67%, respectively. Of these residues, the Nterminus and lysine 525 were both found on peptides that had the most significant levels
of modification in this analysis. In addition, K199 and K439 were also found on peptides
that had significantly increased 16O/18O ratios at the 90% confidence level; however, the
extent of modification that was found on these residues was moderate. The ranking of the
relative change in 16O/18O ratio for the HSA-5 digest was similar to the relative change in
16

O/18O ratios that was obtained for the HSA-2 sample, where a peptide containing the N-

terminus was found to have the highest amount of modification followed by lysines 525,
199 and 439 in the HSA-5 sample. Lysine 281, which was previously identified as one of
the more likely glycation sites on HSA, was found on a peptide which had an associated
relative increase in its 16O/18O ratio of 8% when compared to its reference 16O/18O ratio
(i.e., 1.37 +/- 0.51). This amount of increase; however, did not represent a significant
increase at the 90% confidence level because of the small difference in the average
16

O/18O ratios and the large variance that was associated with the

16

O/18O ratio

measurement in the HSA-5 sample (1.49 +/- 0.80). This result was unexpected because
this same peptide was identified with a 48% increase in

16

O/18O ratio in the HSA-2

sample. A possible explanation for this result is that peptides found within residues 275286 of HSA may be more susceptible to early glycation than later modification by
advanced glycation end products. This finding also indicated that any early-stage
glycation products that were present on this residue in the HSA-2 sample may have
degraded after 3-weeks of incubation.

213
When this data was compared to the data that was previously obtained for
commercially glycated HSA (see Chapter 2), six of the eleven peptides that were
previously identified as having high amounts of modification in commercially glycated
HSA were also found to have high amounts of modification in this current analysis. The
previously identified regions of significant glycation overlap with residues 521-531, 146160, 426-442, 101-119, 61-93, and 209-227, which were found to have relative increases
in their 16O/18O ratios of 75%, 67%, 26%, 22%, 15-17%, and 10%, respectively. Lysine
525, which is found in residues 521-531 of HSA, gave a relative increase in the 16O/18O
ratio of 75% using this current approach, where this increase was the third highest
relative increase in 16O/18O ratio obtained of all the 16O/18O ratios of peptides found in the
HSA-5 digest. This result is consistent with the findings for the HSA-2 sample, where a
large relative increase in the 16O/18O ratio was also found for residue 521-531. The data
presented here for the HSA-5 sample does not indicate that extensive modification is
occurring on lysines 233 or 439.

6.C.5. Determination of the most likely modification sites on glycated HSA. To
determine the most likely modification sites, peptides that were found to have high
16

O/18O ratios in this current analysis were compared to modifications that were

previously identified in the glycated HSA samples (see Chapters 4 and 5) as well as
known information about localized acid-base catalysis. The pKa and fractional accessible
surface (FAS) area for a given amino acid were previously used to identify the most
likely early or late stage glycation products. There is however little consensus amongst
other researchers as to whether the pKa values and the accessibility of these residues can
be reliably used to assign glycation sites (6, 20, 21). An attempt was therefore made to
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assign the most likely regions of modification based on the empirical

16

O/18O data and

compare this data with the previous assignments based on pKa and FAS data.
When the

18

O-labeling data was factored into the identification of modified

residues in the HSA-2 sample, several early and late stage glycation products could be
linked to peptides with large changes in

16

O/18O ratio values. A summary of these

peptides is given in Table 6.4, where eight peptides were found to be modified by either
early or late stage glycation products based on their mass shifts. The majority of
modifications that were identified using

16

O/18O ratio assignments were similar to

peptides that were identified using pKa and FAS based assignment; however,
modifications that occurred on residues 168-188 and 275-286 were both unique to this
study. For example, a m/z value of 2547.21 Da indicated that residues 168-188 or 566585 were being modified to form fructose-lysine (FL) plus argpyrimidine (ArgP) or 1alkyl-2-formyl-3,4-glycosyl-pyrrole (AFGP) respectively. Since the mass value of the
peptide/modification combination in both cases was the same, the most likely
modification could not be differentiated based solely on mass accuracy. When pKa and
FAS sorting was used, the later peptide (residues 566-585) was found to be the most
likely modification region, however, when the

18

O-labeling data was used, the peptide

corresponding to residues 168-188 was found to be the most likely modification site. This
finding is in agreement with a previous study where it was found that pKa and FAS trends
do not always agree with the experimental data (6). A similar assignment was made for
the HSA-5 sample, where peptides that were found to have high

16

O/18O ratios in this

analysis were compared to modifications that were previously identified in the glycated

Table 6.4. Identification of early and late stage glycation on the HSA-2 sample based on the change in 16O/18O ratios of a control
sample versus a glycated sample.
Digest

Raw Mass (Da)

Δ Mass (Da)

Residue

Suspected Modificationa

Trypsin

1563.709
1738.826

414.116
306.0951

1-10
275-286

FL+AFGP, AFGP+(3-DG-H1or THP)
FL*2

2107.961
2199.812
2547.209

234.074
126.032
242.079

278-292
83-100
168-188

FL+CEL, FL+Pyr
FL, CEL+MG-H1
FL+ArgP

926.455
1480.763
2466.271

72.021
306.095
414.116

206-212
196-205
414-428

CEL
FL+FL, FL+3-DG-H1, FL+THP
FL+AFGP, AFGP+3-DG-H1, AFGP+THP

b

Glu-C
b

Lys-C

a

– Due to the complexity and size of this dataset, all of the early stage glycation products (i.e., FL, FL-1H2O, FL-2H2O) are

summarized as FL.
b

– Multiple peptide assignment was possible due to overlapping m/z values resulting from peptides with different types of

modification. The 16O/18O ratios were used to deduce the most likely combinations in these cases.
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Table 6.5. Identification of early and late stage glycation in the HSA-5 sample based on the change in 16O/18O ratios of control HSA
versus glycated HSA.
Digest

Raw Mass (Da)

Δ Mass (Da)

Residue

Suspected Modificationa

Trypsin

949.492
1171.6
1405.715
1738.829
2658.159

148.016
198.0529
350.1002
220.0583
342.0951

520-525
5-12
137-144
182-195
318-336

Pyr+G-H1

Glu-C

1989.965
2108.03
2444.207

148.016
152.0473
250.0477

426-442
426-442
189-208

Pyr+G-H1
CEL+ArgP
Pyr+IB

Lys-C

1171.591
1272.743

198.0529
144.0423

5-12
525-534

2466.27

414.1163

414-432

FL-1H2O+MG-H1
FL-1H2O, CEL+CEL
AFGP+FL-1H2O, AFGP+3-DG-H1, or
AFGP+THP

b

b

a

FL-1H2O+MG-H1
AFGP+ArgP
FL+CML
CEL+AFGP

– Due to the complexity and size of this dataset, all of the early stage glycation products (i.e., FL, FL-1H2O, FL-2H2O) are

summarized as FL.
b

– Multiple peptide assignment was possible due to overlapping m/z values resulting from peptides with different types of

modification. The 16O/18O ratios were used to deduce the most likely combinations in these cases.
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HSA samples (see Table 6.5). All of the modifications that were determined by 16O/18O
ratio assignment were also found when the pKa and FAS values were factored in.
There were many situations in this current study where particular regions of HSA
that had high

16

O/18O ratios, contained many potential sites of modification. In these

cases the location of a given lysine or arginine residue in relation to a positively charged
residue (i.e., histidine and lysine residues) was used to help identify the most reactive
regions on HSA. The distance between amino acids was calculated from a pdb file (22)
using Visual Molecular Dynamics (23). If no basic residues were in the vicinity (i.e.,
within 20 Å) of the suspected modified residues, the pKa and FAS data were then used to
further differentiate which amino acid residue was most likely to be modified. The results
for this analysis are shown in Tables 6.2 and 6.3. For example, a peptide encompassing
residues 189-208 on HSA was found to have a high 16O/18O ratio in the HSA-5 sample.
This region of HSA contains four lysine and one arginine residue and was modified to
form ArgP or imidazolone B (IB), which are arginine specific, and pyrraline (Pyr), FL, or

Nε-carboxymethyl-lysine (CML), which are lysine specific. Since there is only one
arginine residue in this peptide, the assignment of ArgP or IB to R197 is straight-forward;
however, the assignment of the lysine specific modifications was less obvious. The αcarbon of K199 is located 15 Å away from the α-carbon of H257, which is a basic residue
at physiological pH. In addition, K199 has a low pKa of 7.47 versus an average pKa of
10.08 for all lysines on HSA. These factors strongly indicate that K199 was the most
likely modification site in this region of HSA. The previously obtained m/z shift data (see
Chapter 5); however, indicated that some modification was also occurring within regions
187-197 on HSA to form Pyr and ArgP adducts (see Table 6.5). This region contains
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K190 and K195, where K190 has a pKa of 6.23 and K195 has a pKa of 10.76. The fact
that K190 would be mostly deprotonated at a physiological pH indicates that this residue
is more reactive than K195. The data, therefore, indicated that modifications that
occurred on K190, K199, and R197 all contributed to the increased

16

O/18O ratio that

corresponded to residues 189-208 in the HSA-5 sample. Similar assignments were made
in both the HSA-2 and HSA-5 samples, where the most likely modification sites are
indicated in Tables 6.2 and 6.3
The glycated HSA samples were also compared to see whether there were any
major differences in the total number of suspected early or late stage glycation products
that were identified in these samples. For simplicity, a total count of the potential early or
late stage glycation products was performed using the data presented in Tables 6.4 and
6.5. A total of twelve early stage glycation products were identified in the HSA-2
compared to five early stage glycation adducts in the HSA-5 sample. In addition, 16 late
stage glycation adducts were found in the HSA-2 sample versus a total of 21 late stage
glycation adducts identified in the HSA-5 sample. The total number of modifications was
consistent at both stages of glycation, where a total of 28 and 26 modifications were
identified in the HSA-2 and HSA-5 samples respectively. These trends are in line with
the expectation that when proteins are glycated for extended periods of time, the
concentration of late-stage glycation products should increase relative to the
concentration of early stage glycation products. This trend also explains the results from
the enzymatic glycation assay (see Chapter 4), where the concentration of fructosamine
initially increased at a fairly steady rate (i.e., for a 0 to 3 week glycation period) followed
by a decrease in the rate of fructosamine formation after a 3 week period of glycation.
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6.D. SUMMARY
This chapter quantified the relative extent of modification that occurred on
different regions of HSA. The major difference with this current approach, as compared
to the previous attempt (Chapter 2), was that reference 16O/18O ratios were factored into
the determination of modification sites. By obtaining a set of reference 16O/18O ratios, it
was possible to do a direct comparison of these reference ratios to the 16O/18O ratios that
were obtained for glycated HSA. These ratios were then ranked according to relative
increase in 16O/18O ratio and used to determine the most likely regions of modification on
HSA that contained varying amounts of total glycation. The data strongly indicated that
the degree of modification that occurs of HSA during glycation is more widespread than
was previously thought.
A summary of the largest changes in

16

O/18O ratios at both sampled stages of

glycation is given in Figure 6.5 (i) and (ii). It was determined that significant amounts of
modification were taking place at or near both Sudlow sites 1 and 2 (i.e., the major
binding sites on HSA) where Sudlow site 1 has a larger degree of modification in both
tested HSA samples. For the HSA-2 sample, five significantly modified residues were
found within Sudlow site 1, where the relative increase in 16O/18O ratio ranged anywhere
from 16% - 48%. A lower degree of modification was found within Sudlow site 2 in the
HSA-2 sample, where three significantly modified peptides were identified with relative
increases in

16

O/18O ratios that ranged between 17% and 29%. Similarly, a greater

amount of modification was found in Sudlow site 1 for the HSA-5 sample, where three
modification sites were identified with relative 16O/18O ratio increases of 30% and 67%,
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Figure 6.5

(i) A structure of HSA that shows the regions with the highest relative
increases in

16

O/18O ratios for the HSA-2 sample versus normal HSA.

Several residues were identified as being highly glycated at both
Sudlow sites of HSA. This structure was generating a pdb file and
VMD (23).
(ii) A structure of HSA that shows the regions with the highest relative
increases in

16

O/18O ratios for the HSA-5 sample versus normal HSA.

As was the case for the HSA-2 sample, several residues were identified
as being highly glycated at both Sudlow sites of HSA (i.e., both major
binding sites). There were also some differences in the ranking of these
highly glycated regions, indicating that the length glycation alters the
glycation pattern.
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(i)

521-531 (K52/R521, 57%)

101-119 (K106/R117, 77%)

426-442 (K439/R428, 19%)

42-51 (K51, 63%)

1-10 (N+/R10, 63%)

275-286 (K281, 48%)

324-336 (R336, 31%)

360-372 (K372, 60%)
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(ii)

521-531 (R521/K525, 75%)
82-93 (K93, 72%)
21-41 (K41, 104%)

42-51 (N+, 98%/61%)

546-557 (K557, 44%)
1-10 (N+, 98%/61%)

146-160 (K159/R160, 67%)

189-208 (K190/K199/R197, 40%)
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respectively. Only one modification site was found in Sudlow site 2 for the HSA-5
sample, which had a relative 16O/18O ratio increase of 36%. The largest observed change
in

16

O/18O ratios in the HSA-2 sample were found for residues 101-119, 1-10 or 42-51,

360-372, 521-537, and 275-286. These findings are consistent with the glycation pattern
seen previously, where K525, K281, and the N-terminus were found to have significant
levels of glycation (5). These 16O/18O ratios indicated that the N-terminus or K51, K372,
K525, and K281 and arginines 117, 10, 521 were being modified. Glycation products
were found on the N-terminus, lysines 525 and 281, as well as arginines 10 and 521.
For the HSA-5 sample, the highest amount of modification occurred on residues
21-41, 1-10 or 42-51, 521-531, 82-93, and 146-160 on HSA. Of these residues, the high
16

O/18O ratio obtained for residues 1-10 and 521-531 are consistent with the expectation

that the N-terminus and K525 should have significant amounts of glycation. In addition,
lysine 199, which is also a suspected glycation site (5), was also found to have significant
levels of modification in this analysis. Lysine 281 was also identified as a glycation site
with a relative 16O/18O ratio increase in the HSA-5 sample. The increase associated with
this residue, however, was not significant at the 90% confidence level. Based on the m/z
shift data that were sorted by

16

O/18O ratios, the N-terminus/K51, and lysines 525, 199,

and 378 as well as arginines 521, 10, and 197, could all be linked to residues that were
modified to form glycation-related products.
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6.F. APPENDIX
Table 6.1a shows the Matlab programs that were used to obtain area values for the
M+0 to M+4 peaks within a given isotopic cluster. Two separate programs were
developed for the
16

16

O-labeled digest (i) and the

18

O labeled digest (ii) respectively. The

O/18O ratios that were obtained for the Glu-C digest (Table 6.2a) and the Lys-C digest

(Table 6.3a) are also given. The useable sequence coverage (i.e. the percentage of amino
acids that correspond to calculated

16

O/18O ratios) is also given in Figure 6.1a for the

HSA-2 (i) and HSA-5 (ii) samples. Figure 6.2 summarizes the reference range of 16O/18O
ratios that were obtained for the Glu-C (i) and Lys-C (ii) samples respectively.
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Table 6.1a (i). Program used for obtaining the area values for the isotopes of a given
peptide in the 16O digest or mixed digest
[massa]=textread('mascotmatch16.txt', '%f');
[massb, area]=textread('rawdata.txt', '%f %f');
sizemassa=size(massa);
sizemassb=size(massb);
k=0;
h=0;
for i=1:1:sizemassa(1);
for j=1:1:sizemassb(1);
acc(i,j)=((massa(i)-massb(j))/massb(j))*10^6;
if ((acc(i,j)>-70)&& (acc(i,j)<70));
k=k+1;
h=h+1;
massb0(k,:)=(massb(j)+0);
massb1(k,:)=(massb(j)+1);
massb2(k,:)=(massb(j)+2);
massb3(k,:)=(massb(j)+3);
massb4(k,:)=(massb(j)+4);
result(h,:)= [massb0(k,:), massb1(k,:), massb2(k,:),
massb3(k,:), massb4(k,:)];
end;
end;
end;

outfile=fopen('result.txt', 'wt');
sizeresult=size(result);
for i=1:1:sizeresult(1);
fprintf(outfile, '%f\t %f\t %f\t %f\t %f\t \n', result(i,1),
result(i,2), result(i,3), result(i,4), result(i,5));
end
fclose(outfile);
clear all
[massb0, massb1, massb2, massb3, massb4]=textread('result.txt', '%f %f
%f %f %f');
[massa, area]=textread('rawdata.txt', '%f %f');
sizemassa=size(massa);
sizemassb0=size(massb0);
sizemassb1=size(massb1);
sizemassb2=size(massb2);
sizemassb3=size(massb3);
sizemassb4=size(massb4);
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Table 6.1a (i), continued. Program used for obtaining the area values for the isotopes of a
given peptide in the 16O digest or mixed digest
k=0;
h=0;
m=0;
n=0;
o=0;
for i=1:1:sizemassa(1);
for j=1:1:sizemassb0(1);
acc0(i,j)=(((massa(i)-massb0(j))/massb0(j))*10^6);
if ((acc0(i,j)>-100)&& (acc0(i,j)<100));
k=k+1;
a0(k,:)=[massa(i), area(i)];
end;
end;
end;
for i=1:1:sizemassa(1);
for j=1:1:sizemassb1(1);
acc1(i,j)=(((massa(i)-massb1(j))/massb1(j))*10^6);
if ((acc1(i,j)>-100)&& (acc1(i,j)<100));
h=h+1;
a1(h,:)=[massa(i), area(i)];
end;
end;
end;
for i=1:1:sizemassa(1);
for j=1:1:sizemassb2(1);
acc2(i,j)=(((massa(i)-massb2(j))/massb2(j))*10^6);
if ((acc2(i,j)>-100)&& (acc2(i,j)<100));
m=m+1;
a2(m,:)=[massa(i), area(i)];
end;
end;
end;
for i=1:1:sizemassa(1);
for j=1:1:sizemassb3(1);
acc3(i,j)=(((massa(i)-massb3(j))/massb3(j))*10^6);
if ((acc3(i,j)>-100)&& (acc3(i,j)<100));
n=n+1;
a3(n,:)=[massa(i), area(i)];
end;
end;
end;
for i=1:1:sizemassa(1);
for j=1:1:sizemassb4(1);
acc4(i,j)=(((massa(i)-massb4(j))/massb4(j))*10^6);
if ((acc4(i,j)>-100)&& (acc4(i,j)<100));
o=o+1;
a4(o,:)=[massa(i), area(i)];
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Table 6.1a (i), continued. Program used for obtaining the area values for the isotopes of a
given peptide in the 16O digest or mixed digest
end;
end;
end;
%The a0 through a4 values should represent the distribution for the
oxygen
%16 digests. b0 through b4 are being used as random variables, not
linked to any distribution.
sort_mass
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Table 6.1a (ii). Program used for obtaining the area values for the isotopes of a given
peptide in the 18O digest
[massc]=textread('mascotmatch16.txt', '%f');
[massb, area]=textread('rawdata.txt', '%f %f');
massa=massc+4;
sizemassa=size(massa);
sizemassb=size(massb);
sizemassc=size(massc);
k=0;
h=0;
%modified massa to represent the b4 peak
for i=1:1:sizemassa(1);
for j=1:1:sizemassb(1);
acc(i,j)=((massa(i)-massb(j))/massb(j))*10^6;
if ((acc(i,j)>-60)&& (acc(i,j)<60));
k=k+1;
h=h+1;
massb0(k,:)=(massb(j)-4);
massb1(k,:)=(massb(j)-3);
massb2(k,:)=(massb(j)-2);
massb3(k,:)=(massb(j)-1);
massb4(k,:)=(massb(j)-0);
result(h,:)= [massb0(k,:), massb1(k,:), massb2(k,:),
massb3(k,:), massb4(k,:)];
end;
end;
end;
outfile=fopen('result.txt', 'wt');
sizeresult=size(result);
for i=1:1:sizeresult(1);
fprintf(outfile, '%f\t %f\t %f\t %f\t %f\t \n', result(i,1),
result(i,2), result(i,3), result(i,4), result(i,5));
end
fclose(outfile);
clear all
[massb0, massb1, massb2, massb3, massb4]=textread('result.txt', '%f %f
%f %f %f');
[massa, area]=textread('rawdata.txt', '%f %f');
sizemassa=size(massa);
sizemassb0=size(massb0);
sizemassb1=size(massb1);
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Table 6.1a (ii), continued. Program used for obtaining the area values for the isotopes of
a given peptide in the 18O digest
sizemassb2=size(massb2);
sizemassb3=size(massb3);
sizemassb4=size(massb4);
k=0;
h=0;
m=0;
n=0;
o=0;
for i=1:1:sizemassa(1);
for j=1:1:sizemassb0(1);
acc0(i,j)=(((massa(i)-massb0(j))/massb0(j))*10^6);
if ((acc0(i,j)>-100)&& (acc0(i,j)<100));
k=k+1;
b0(k,:)=[massa(i), area(i)];
end;
end;
end;
for i=1:1:sizemassa(1);
for j=1:1:sizemassb1(1);
acc1(i,j)=(((massa(i)-massb1(j))/massb1(j))*10^6);
if ((acc1(i,j)>-100)&& (acc1(i,j)<100));
h=h+1;
b1(h,:)=[massa(i), area(i)];
end;
end;
end;
for i=1:1:sizemassa(1);
for j=1:1:sizemassb2(1);
acc2(i,j)=(((massa(i)-massb2(j))/massb2(j))*10^6);
if ((acc2(i,j)>-100)&& (acc2(i,j)<100));
m=m+1;
b2(m,:)=[massa(i), area(i)];
end;
end;
end;
for i=1:1:sizemassa(1);
for j=1:1:sizemassb3(1);
acc3(i,j)=(((massa(i)-massb3(j))/massb3(j))*10^6);
if ((acc3(i,j)>-100)&& (acc3(i,j)<100));
n=n+1;
b3(n,:)=[massa(i), area(i)];
end;
end;
end;
for i=1:1:sizemassa(1);
for j=1:1:sizemassb4(1);
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Table 6.1a (ii), continued. Program used for obtaining the area values for the isotopes of a
given peptide in the 18O digest
acc4(i,j)=(((massa(i)-massb4(j))/massb4(j))*10^6);
if ((acc4(i,j)>-100)&& (acc4(i,j)<100));
o=o+1;
b4(o,:)=[massa(i), area(i)];
end;
end;
end;
%The b0 through b4 values should represent the distribution for the
oxygen
%16 digests. b0 through b4 are being used as random variables, not
linked
%to any distribution.

Table 6.2a.

16

O/18O ratios that were obtained for the Glu-C digest
Control

Mass (Da)
1031.453
1197.571
1300.674
1313.796
1519.783
1541.749
1548.770
1680.796
1704.910
1737.692
1801.915
1945.862
1955.975
2085.985
2194.152
2232.208
2348.094
2578.264
a

a

Error (ppm)
3
-6
7
4
2
36
-16
-5
-22
-4
0
-1
-8
-38
-11
-19
-42
-4

Residue
369-376
496-505
7-17
521-531
142-153
506-518
480-492
466-479
154-167
87-100
451-465
502-518
426-442
377-393
189-208
209-227
101-119
61-82

Amino Acid Sequence
CYAKVFDE
TYVPKEFNAE
VAHRFKDLGEE
RQIKKQTALVE
IARRHPYFYAPE
TFTFHADICTLSE
SLVNRRPCFSALE
KTPVSDRVTKCCTE
LLFFAKRYKAAFTE
MADCCAKQEPERNE
DYLSVVLNQLCVLHE
FNAETFTFHADICTLSE
VSRNLGKVGSKCCKHPE
FKPLVEEPQNLIKQNCE
GKASSAKQRLKCASLQKFGE
RAFKAWAVARLSQRFPKAE
CFLQHKDDNPNLPRLVRPE
NCDKSLHTLFGDKLCTVATLRE

16

18

O/ O
1.92
0.96
1.57
1.15
1.40
1.42
1.29
1.15
1.63
1.19
0.49
1.16
1.15
1.22
0.93
1.12
0.99
0.68

HSA-2
b

SD
0.65
0.83
0.43
0.30
0.30
0.52
0.22
0.18
0.26
0.31
0.00
0.03
0.08
0.25
0.11
0.09
0.05
0.01

16

18

HSA-5
b

O/ O SD
1.44
0.79
0.46
0.07
2.00
1.00
1.80
1.13
1.80
0.78
1.41
0.68
1.40
0.16
1.33
0.55
1.98
0.08
1.76
0.70
none detected
1.48
0.07
1.38
0.12
1.46
0.28
1.16
0.99
1.30
0.23
1.75
1.11
0.84
0.05

16

O/18O
1.43
1.20
1.87
2.00
1.76
1.66
1.36
1.40
1.84
1.70
2.23
1.19
1.46
1.43
1.29
1.24
1.21
0.80

SDb
0.51
0.47
0.59
0.79
0.19
0.16
0.28
0.65
0.35
0.49
0.00
0.34
0.11
0.34
0.54
0.07
0.08
0.14

– “Error” represents the mass accuracy of the assigned peptide. For simplicity, the control HSA digest was used for peptide mass

fingerprinting.
b

– “SD” designates the standard deviation that was calculated for the given 16O/18O ratios. The value represents the square root of the

sum of the standard deviations squared that were obtained across different Zip-tip fractions.
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Table 6.3a.

16

O/18O ratios that were obtained for the Lys-C digest
Control

Mass (Da)
854.457
973.520
1149.619
1342.628
1352.764
1371.553
1443.630
1529.860
1552.592
1657.738
1714.785
1924.053
2045.051
2052.147
2259.987
2348.988
2490.244
2585.088
2674.285

Error (ppm)
6
-1
4
-5
-3
-10
-8
-7
-4
-9
-7
-17
-22
-17
-16
-20
-17
-11
-11

2807.453
a

-6

a

Residue
206-212
5-12
42-51
546-557
403-413
163-174
263-274
213-225
360-372
390-402
94-106
415-432
373-389
414-432
21-41
74-93
21-41
241-262
445-466

Amino Acid Sequence
FGERAFK
SEVAHRFK
LVNEVTEFAK
AVMDDFAAFVEK
FQNALLVRYTK
AAFTECCQAADK
YICENQDSISSK
AWAVARLSQRFPK
CCAAADPHECYAK
QNCELFEQLGEYK
QEPERNECFLQHK
VPQVSTPTLVEVSRNLGK
VFDEFKPLVEEPQNLIK
KVPQVSTPTLVEVSRNLGK
EFNAETFTFHADICTLSEK
LCTVATLRETYGEMADCCAK
ALVLIAFAQYLQQCPFEDHVK
VHTECCHGDLLECADDRADLAK
RMPCAEDYLSVVLNQLCVLHEK

138-159

YLYEIARRHPYFYAPELLFFAK

16

18

HSA-2
b

O/ O
0.51
1.13
1.00
1.48
1.29
1.44
1.37
1.27
1.31
1.54
1.17
0.73
1.28
1.26
1.53
0.83
0.79
0.93
0.88

SD
0.54
0.32
0.23
0.30
0.14
0.44
0.48
0.07
0.09
0.53
0.06
0.22
0.06
0.15
0.57
0.01
0.10
0.21
0.04

0.84

0.01

16

18

O/ O
1.40
0.93
1.64
1.10
1.09
1.43
1.36
1.26
1.71
1.48
1.25
0.52
1.17
1.01
0.80
0.65
0.88
0.86
0.84

HSA-5
b

SD
O/18O
0.58
1.76
0.07
1.04
0.77
1.99
0.20
1.07
0.23
1.32
0.35
1.23
0.12
1.28
0.07
1.21
0.13
1.40
0.71
1.34
0.04
1.17
0.01
0.39
0.05
1.30
0.15
1.15
none detected
0.25
0.95
0.12
0.98
0.04
0.92
0.09
0.70
0.07

16

0.75

SDb
1.11
0.15
0.64
0.16
0.76
0.23
0.28
0.08
0.06
0.56
0.08
0.12
0.08
0.08
0.25
0.13
0.04
0.09
0.03

– “Error” represents the mass accuracy of the assigned peptide. For simplicity, the control HSA digest was used for peptide mass

fingerprinting.
b

– “SD” designates the standard deviation that was calculated for the given 16O/18O ratios. The value represents the square root of the

sum of the standard deviations squared that were obtained across different zip-tip fractions.
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FIGURE LEGEND
Figure 6.1a

(i) Usable sequence coverage obtained for the HSA-2 sample when the
calculated 16O/18O ratios were considered. A 12% reduction in coverage
was observed for this sample compared to the control HSA digest.
(ii) Usable sequence coverage obtained for the HSA-5 sample when the
calculated

16

O/18O ratios were considered. A 5% reduction in sequence

coverage was observed for this sample compared to the control HSA
digest.

Figure 6.2a

(i) Reference

16

O/18O ratios for the Glu-C digest. The central dashed

line represents the average

16

O/18O ratio and the outer dashed lines

represent the range of 16O/18O ratios that were obtained.
(ii) Reference

16

O/18O ratios for the Lys-C digest. The central dashed

line represents the average

16

O/18O ratio and the outer dashed lines

represent the range of 16O/18O ratios that were obtained.
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(i)

Sequence coverage obtained for the HSA-2 digest

14181121161201241281321361400441481521561-

(ii)

DAHKSEVAHR
KLVNEVTEFA
RETYGEMADC
DVMCTAFHDN
YKAAFTECCQ
aslqkFGERA
VHTECCHGDL
KPLLEKshci
eakDVFLGMF
CAAADPHECY
YKFQNALLVR
PEakRMPCAE
LVNRRPCFSA
RQIKKQTALV
ADDKETCFAE

FKDLGEENFK
Ktcvadesae
CAKQEPERNE
EETFLKKYLY
AADKaacllp
FKAWAVARLS
LECADDRADL
aevendempa
LYEYARRHPD
AKVFDEFKPL
YTKKVPQVST
DYLSVVLNQL
LEVDETYVPK
Elvkhkpkat
EGKKlvaasq

ALVLIAFAQY
NCDKSLHTLF
CFLQHKDDNP
EIARRHPYFY
kLDELRDEGK
QRFPKAEfae
AKYICENQDS
dlpslaadfv
YSVVLLLRla
VEEPQNLIKQ
PTLVEVSRNL
CVLHEKTPVS
EFNAETFTFH
keqlkAVMDD
aalgl

LQQCPFEDHV
GDKLCTVATL
NLPRLVRPEV
APELLFFAKR
assakqrlkc
vsklvtdltk
ISSKLKECCE
eskdvcknya
ktyettlekC
NCELFEQLGE
GKVGSKCCKH
DRVTKCCTES
ADICTLSEKe
FAAFVEKcck

Sequence coverage obtained for the HSA-5 digest

14181121161201241281321361401441481521561-

DAHKSEVAHR
KLVNEVTEFA
RETYGEMADC
DVMCTAFHDN
YKAAFTECCQ
ASLQKFGERA
VHTECCHGDL
KPLLEKSHCI
eakDVFLGMF
CAAADPHECY
YKFQNALLVR
PEakRMPCAE
LVNRRPCFSA
RQIKKQTALV
ADDKETCFAE

FKDLGEENFK
Ktcvadesae
CAKQEPERNE
EETFLKKYLY
AADKaacllp
FKAWAVARLS
LECADDRADL
AEVENDEMPA
LYEYARRHPD
AKVFDEFKPL
YTKKVPQVST
DYLSVVLNQL
LEVDETYVPK
Elvkhkpkat
EGKKlvaasq

ALVLIAFAQY
NCDKSLHTLF
CFLQHKDDNP
EIARRHPYFY
kLDELRDEGK
QRFPKAEfae
AKYICENQDS
DLPSLAADFV
YSVVLLLRla
VEEPQNLIKQ
PTLVEVSRNL
CVLHEKTPVS
EFNAETFTFH
keqlkAVMDD
aalgl

LQQCPFEDHV
GDKLCTVATL
NLPRLVRPEV
APELLFFAKR
ASSAKQRLKC
vsklvtdltk
ISSKLKECCE
ESKdvcknya
ktyettlekC
NCELFEQLGE
GKVGSKCCKH
DRVTKCCTES
ADICTLSEKe
FAAFVEKcck
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(i)

(ii)

Figure 6.2a
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CHAPTER 7
CONCLUSIONS AND FUTURE TRENDS
7.A. SUMMARY
The objective of the work presented in this dissertation was to provide qualitative
and quantitative information about the modifications that occur on glycated human serum
albumin (HSA). Techniques based on matrix-assisted laser desorption/ionization mass
spectrometry (MALDI-TOF MS) and 18O-labeling were used for these studies.
The first chapter in this dissertation gave a brief introduction to protein glycation
and techniques that are typically used for qualitatively and quantitatively characterizing
glycation products. A discussion of the techniques that were examined in this dissertation
was also provided here. The second chapter of this dissertation examined the use of 18Olabeling combined with MALDI-TOF MS as a means of determining the relative extent
of modification that occurs on different regions of glycated HSA. This examination was
done by digesting a HSA sample in

16

O-labeled water and digesting a glycated HSA

sample in 18O-labeled water, mixing these samples, and determining the 16O/18O ratio for
each detected peptide. Under this regime, peptides that were glycated displayed an
increase in their

16

O/18O ratio. Several residues were identified in this study as having

high levels of glycation. A qualitative comparison of the glycation sites indicated that
K525, K439, and K233 may have significant levels of glycation. In addition, eight
peptides were found to have high 16O/18O ratios, including R14, R81, R218, K413, K432,
K159, K212, and K323. An observation was made in this study that the increases in

16

242
O/ O ratios were small compared to the typical observed range (~0.5 - 3.0) of O/18O
18

16

ratios in control samples, therefore the use of reference 16O/18O ratios were needed.
The third chapter examined techniques that could be used for improving the
assignment of glycation products on HSA. This chapter examined several variables,
including the effects of mass accuracy, glycation product heterogeneity, and peptide
selectivity, on the assignment of glycation sites. In this examination, it was found that
increasing the mass accuracy by using internal calibration, using an expanded
modification search list, and selecting the peptides that were only due to glycation could
be used to reduce the complexity and improve the assignment of glycation sites. When
these approaches were applied, lysines 281, 439, and 199 were found to be modified in
glycated HSA.
Chapters 4 and 5 examined the locations and types of modifications that occur on
glycated HSA. Chapter 4 focused on the identification of early-stage glycation products
and Chapter 5 focused on the analysis of advanced glycation endproducts. HSA samples
that contained three different levels of glycation were examined to see whether the
modifications were consistent at different levels of total glycation. These samples were
also used to semi-quantitatively rank the frequency of modification for a given peptide
and compare this information to qualitative and quantitative data that was previously
obtained for commercially glycated HSA. In the analysis of early-stage glycation that
occurred on glycated HSA, regions 83-100, 1-12, 182-212, 278-292, 414-432, and 526534 were found to have a high amount of modification. Similarly, regions 187-212, 324336, 426-442, and 520-525, were found to have a high amount of modification when latestage glycation was considered. This indicated that a region spanning residues 187-212
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could have extensive modification during glycation. In addition, when all of the
modification sites were compared to the quantitative and qualitative information obtained
for commercially glycated HSA, lysines 199 or 205, 436 or 439, and 525 were
consistently identified as modification sites.
In Chapter 6, 18O-labeling and MALDI-TOF MS were used to quantify the extent
of modification that occurred on different regions of HSA at different stages of glycation.
This attempt was different from prior attempts (Chapter 2) in that a relative comparison
with a set of reference 16O/18O ratios was performed, and a t-test was used to determine
whether these modifications were significantly different or not. When this was done,
significant increases in the 16O/18O ratios were clearly evident at both stages of glycation
with larger increases being seen for glycated HSA that was incubated with D-glucose for
five weeks. All of the previously identified glycation sites were quantified using this
approach. Of these previously identified sites, the N-terminus was consistently found to
have found to have the largest amount of modification followed by lysines 525 and 439.
The relative amount of modifications that occurred on lysine 281 and 199 seemed to
fluctuate based on the total degree of glycation. This was an unexpected result, because
K525 is commonly identified as having the highest amount of glycation on HSA. This
strongly indicated that AGE modification plays an important role in the modification of
HSA.

Several arginine residues were also found to contain significant amounts of

modification. The quantitative data obtained in Chapter 6 was used to select the most
likely modified peptides, as identified in Chapters 4 and 5, where a decrease in the total
number of early glycation products and an increase in the total number of advanced
glycation endproducts were found as the total level of glycation for HSA was increased.
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7.B. FUTURE DIRECTION
There is no clear consensus as to whether HSA glycation that is performed in
vitro is a good representation of HSA glycation that occurs in the human body during
diabetes. The next step for this project would be to apply the same techniques that were
used for characterizing modifications on in vitro glycated HSA to the analysis of glycated
HSA obtained from the serum of diabetic patients. The total level of glycation in these
patient samples can be obtained using the fructosamine assay, as described earlier, and
the location of these modification sites can be determined by looking at the m/z shifts that
are induced by glycation.

18

O-Labeling can also be used to obtain data that can be used

for a direct comparison with the HSA samples examined in this dissertation. The analysis
of in vivo glycated HSA may be complicated, however, by the fact that there may be
variations in the sequence of HSA based on ethnic and regional differences. The selection
of a suitable control for qualitative and quantitative comparison would therefore need to
be examined.
Differences in the modification pattern of in vitro versus in vivo glycated HSA
would most likely be due to the presence of multiple analytes in vivo. Future work should
therefore examine the effects of these analytes on the glycation of HSA. For instance,
HSA plays a major role in the binding and transport of fatty acids throughout the body.
The glycation of HSA can therefore be examined in the presence of fatty acids to see how
the glycation pattern is altered, and whether the degree of modification that occurs on in
vitro glycated HSA approaches the degree of modification that is found on HSA that is
obtained from diabetics. This study can be expanded to include the effects of
physiological concentrations of α-oxaloaldehydes on the glycation of HSA and methods
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that can be used to stabilize the concentrations of glucose/α-oxaloaldehydes during HSA
glycation. Another interesting approach based on the above principles would be to
perform HSA-glucose incubations in the presence of certain drugs to see how the relative
extent of modification is affected. This type of study would provide direct information
about how the glycation of HSA may affect its drug binding properties.
The efficient examination of mixed modes of HSA glycation, as described in the
paragraph above, will require improved sample throughput and data analysis techniques.
The sample throughput can be improved by using on-line digestion and performing online peptide fraction. For the studies examined in this dissertation, HSA was incubated
with a given enzyme (in solution phase) for 18 – 24 hours. The major advantage of using
on-line digestion/fractionation is that complete proteolysis and fraction of HSA can be
achieved in less than 30 minutes. Isobaric tags for relative and absolute quantitation
(iTRAQ) can also be used to improve the sample throughput. This tag can be used to
modify the N-terminal region of peptides from a proteolytic digest. The major advantage
of using this technique is that multiple mass tags are available, allowing for the
quantification of peptides from multiple glycated HSA samples. The other advantage of
using iTRAQ is that the fragmentation pattern of the tag can be used to perform SRM
based quantitation.
Data analysis can be improved by modifying the glycation product identification
program (as described in Chapter 3) to include data about the pKa of a given amino-acid
sidechain and include data about local acid-base catalysis on a given lysine residue. The
modification search list can be expanded to include other AGEs such as 5methylimidazol-4-one, C2-imines, 3,4-dihydroxy-2-imidazoline, and various protein
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cross-links. By including these AGEs, it would be possible to track the progress of the
Maillard reaction at different stages of glycation. Tandem LC-MS/MS combined with 2D
affinity enrichment could also be used to improve the quality of glycation product
assignment. For instance, a whole serum digestion could be performed followed by the
affinity enrichment of modified peptides. The enrichment can be achieved by using
antibodies that specifically interact with certain classes of AGEs (i.e., glyoxal,
methylglyoxal, or 3-deoxyglucosone based AGEs) or by using phenylboronic acid
chromatography. The modified peptides could then be trapped on a RPLC column
followed by LC-MS/MS detection.

